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Abstract 
    Ultraviolet (UV) B therapy can induce complete clearance of psoriasis and 
often leads to prolonged remission following a treatment period. UVB 
phototherapy is a commonly used, highly effective treatment modality, but 
despite this its mechanism of action remains poorly understood.  This thesis 
investigates the importance of keratinocyte apoptosis in UVB-induced 
clearance of psoriasis using a novel approach, and employs a mathematical 
model to explore the effects of this on epidermal homeostasis.   
    The in vivo effects of two wavelengths of UVB were compared, one of which 
is clinically effective in clearing psoriasis (311nm), and one which is ineffective 
(290nm) even at high doses. This allowed investigation of which effects of UVB 
are relevant to plaque clearance; eliminating „bystander‟ effects such as 
erythema. The study showed significant keratinocyte apoptosis in lesional 
psoriatic epidermis following 311nm UVB compared to 290nm UVB; peaking 
16-24h post irradiation. To determine clinical significance, a computational 
model of psoriatic epidermis was created utilising histological and kinetic 
parameters. The model predicted that apoptosis should occur in both stem and 
TA cells to account for plaque remodelling. This was confirmed and quantified 
experimentally, with real-time assays determining the rate of keratinocyte 
apoptosis. These data were fed back into the model and demonstrated that the 
observed level of keratinocyte apoptosis was sufficient to account for complete 
remodelling of psoriatic plaques in response to therapeutic UVB.   
    The data was supported by gene array studies, which showed differential 
regulation of apoptotic genes at early time-points following 311nm rather than 
290nm UVB. Finally, the wavelength dependence of UVB-induced apoptosis 
was examined, and only wavelengths which can clear psoriasis (i.e. greater 
than 300nm & less than 320nm UVB) induced significant epidermal apoptosis. 
    In summary, this thesis demonstrates that keratinocyte apoptosis is a key 
mechanism of psoriatic clearance in response to UVB.  
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1. Introduction 
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Psoriasis is a common disorder with an estimated lifetime prevalence of 1.5-
2.2% in the adult population in the Western world (Stern, Nijsten et al. 2004; 
Gelfand, Weinstein et al. 2005), with 75% of patients presenting before age 40 
(Barker, Palmer et al. 2006). The term is derived from the Greek word „psora‟ 
meaning itch or rash, and was first formally described in 1808 (Plumbe 1824).  
    Psoriasis can manifest in different clinical forms, including plaque, guttate, 
pustular and erythrodermic. Chronic plaque psoriasis is the most common form, 
and is characterised by thick, erythematous, scaly plaques which can appear at 
any site on the skin. It causes symptoms ranging from itching and bleeding to 
loss of limb function, with significant social morbidity and occupational disability 
(Smith and Barker 2006). It is also a major economic burden, and in the US has 
been estimated to cost $1500 per patient/ year, with work loss accounting for 
40% of this (Fowler, Duh et al. 2008). 
    Current treatment options are relatively limited. Patients with mild-to-
moderate disease may be adequately treated with topical therapies. However, 
these are time consuming, can be messy, smelly and stain skin or clothing, and 
have limited efficacy in many patients. Patients with moderate to severe 
psoriasis often require potentially toxic treatments to control their disease, 
including ciclosporin, methotrexate, and anti-TNFα-therapies.  In contrast, UVB 
(ultraviolet B) phototherapy is a relatively safe (Young 1995) and effective 
treatment option  for many patients. The efficacy of the most commonly used 
systemic treatments (Pearce, Nelson et al. 2006) is shown in Figure 1-1, 
however it should be noted that these results are drawn from separate studies 
which will not have been carried out using identical methodologies.  Moreover, 
current measurement of treatment success (e.g. Psoriasis Area and Severity 
Index scoring (PASI) see appendix C) doesn‟t distinguish remodelling of 
existing plaques back to normal from switching off active disease (i.e. the ability 
for psoriasis to flare up again). As psoriasis may flare during a course of 
treatment due to external effects (e.g. concurrent infection) the improvement in 
disease may be underestimated as measured by the current scoring systems, 
making it more difficult to compare efficacy of different treatments as this 
cannot be controlled for. 
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Figure 1-1. Comparison of the efficacy of psoriatic therapies. Data show a 
meta-analysis of the percentage of patients achieving improvement in PASI 
score by at least 75% over a 12 week period. The studies will have had 
different protocols and this should be considered when interpreting the results. 
Adapted from (Pearce, Nelson et al. 2006). 
     
    Systemic treatments can be highly effective in many patients, although side-
effects and dosage regimes can limit their usefulness. At present there are no 
known indicators to suggest which patients are likely to respond to which 
treatment, and a trial and error approach is often employed. Phototherapy with 
UVB is a safer approach to treatment, and is generally very well tolerated. UVB 
wavelengths of around 311nm are highly effective in clearing psoriasis (Coven, 
Burack et al. 1997; Gordon, Diffey et al. 1999; Kirke, Lowder et al. 2007), but 
wavelengths just 20nm lower, around 290nm, are ineffective (Parrish and 
Jaenicke 1981). This thesis describes a novel approach to examine the 
mechanism of action of UVB in the clearance of psoriasis in vivo by comparing 
the cellular effects of clinically effective (311nm) and ineffective (290nm) 
wavelengths of UVB. Thus, changes specific to the therapeutic wavelength can 
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be detected whilst eliminating non-specific effects of UVB. An overview of the 
use of UVB in psoriasis is presented, and the possible mechanisms by which it 
may work are discussed. Understanding the mechanisms by which UV acts to 
clears psoriasis, may provide insight into the pathology that drives the disease, 
and help with development of treatments which are more targeted, leading to 
greater efficacy and less side-effects. 
    
 
1.1. The Epidermis 
    The skin is the largest organ in the body, exceeding 2m2 in the average adult, 
yet at the majority of sites are no more than 2.5mm in thickness. Structurally, it 
is principally divided into two layers: the epidermis which is 75-150µm thick, but 
may be up to 600µm on palms and soles; and dermis which is usually less than 
2mm, but may be up to 4.5mm on sites such as on the back (Tobin 2006). The 
skin is the primary barrier to exogenous insults such as UV radiation, chemical 
exposure, mechanical stresses and infection. It also has important homeostatic 
functions including maintenance of temperature and fluid balance, providing 
sensory input, and plays an important role in psychosexual communication.  
    The epidermis forms a continuous sheet of stratifying keratinizing epithelium, 
of which keratinocytes are the principal cell type (approximately 80%) (Savill 
2003). Other cell types include melanocytes, T cells, Langerhans‟ cells and 
monocytes. The epidermis is conventionally divided into four layers (Figure 
1-2). 
1. The stratum corneum which comprises anucleated differentiated squames 
which are eventually exfoliated 
2. The stratum granulosum which contains the majority of differentiating cells 
3. The stratum spinosum which includes proliferating cells, but these will be 
committed to differentiation (transit amplifying cells) 
4. The basal layer which contains the keratinocyte stem cell population 
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Figure 1-2. Histology of normal and psoriatic skin. In psoriasis (right) there 
is elongation of the rete ridges, with thinning above the dermal papillae and an 
increase in dermal vasculature. The number of epidermal keratinocytes is 
markedly increased and the stratum corneum is thickened. Adapted from 
Hunter (Hunter 1995). 
 
    In psoriasis the epidermis becomes hyperkeratotic, with elongation of the 
rete ridges and marked thickening of the stratum corneum and stratum 
spinosum (Figure 1-2). Epidermal stem cells are found within the basal layer, 
and have been shown to be of greatest density adjacent to the tips of the 
dermal papillae (Jones, Harper et al. 1995; Ghali, Wong et al. 2004). Stem cells 
are also located in the bulge region of the hair follicle, however evidence 
suggests that these have a transient role in regenerating epidermis in response 
to wound healing, rather than having a role in epidermal homeostasis (Ito, Liu et 
al. 2005). Stem cells divide within the basal layer, therefore an increase in their 
activity may explain the elongation of the rete ridges classically found within 
psoriasis. Other changes in psoriatic epidermis include a reduced or absent 
stratum granulosum in proliferating plaques, and significant growth of superficial 
capillaries within plaques leading to tortuous elongated capillaries in the dermal 
papillae. The latter is thought to be due to release of mediators such as 
vascular endothelial growth factor and platelet derived growth factor from 
keratinocytes (Liu, Krueger et al. 2007). 
  
s.corneum 
s.granulosum 
Dermal papillae 
s.spinosum 
s.basale 
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1.2. Pathogenesis of psoriasis 
    Traditionally psoriasis was considered to be caused by a primary abnormality 
of keratinocyte hyperproliferation and reduced turnover time. However, with the 
realisation that ciclosporin cleared psoriasis, and that plaques contained large 
numbers of T cells which „disappeared‟ as plaques resolved, it became widely 
accepted that psoriasis could be due to a primary abnormality within the T cell 
compartment.  In normal skin, T cells are not present in the epidermis at all.  
However in psoriasis, T cells (predominantly CD8+ cells) can be found in high 
numbers throughout the epidermis, and T cells are increased within the dermis 
(predominantly CD4+ cells). There is also an increase in the number of CD11c+ 
dendritic cells within the lower epidermis, and Langerhans‟ cells (which are 
usually present uniformly within the epidermis) migrate up to the stratum 
spinosum (Liu, Krueger et al. 2007). More recently evidence has once again 
challenged dogma suggesting that primary abnormalities may also exist within 
the keratinocyte compartment (Section 1.2.3).  Although the primary 
abnormality in psoriasis is still debated, what is clear is that psoriasis 
represents a complex interplay between the innate and adaptive immune 
system, environmental triggers and susceptibility genes. The evidence for these 
is examined below. 
 
1.2.1.1. Genetics of psoriasis 
    The incidence of psoriasis varies considerably between both geographical 
location and race, and is quoted as approximately 2% in Caucasians and 0.1% 
in the Chinese population (Sun, Li et al. 2007).  The genetic basis for psoriasis 
is generally accepted, although it is complicated by the fact that the penetrance 
of genes associated with psoriasis is so variable, and environmental triggers 
are required to stimulate phenotypic changes. Overall, a family history of 
psoriasis is only found in a third of patients (Elder, Nair et al. 2001). The 
concordance of psoriasis in monozygotic twins is estimated at 65-72%, and 15-
30% in dizygotic twins (Bowcock and Cookson 2004).  
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    Two peaks in age at presentation have been described: the first is in 
individuals aged 20-30 years (individuals presenting below the age of 40 are 
defined as having type 1 psoriasis) and a second smaller peak at 50-60 years 
(type 2 psoriasis). It is postulated that these two peaks may have differing 
aetiologies, and indeed evidence for genetic association is stronger in the group 
with earlier age of presentation. Epidemiological studies have suggested that 
the relative risk of developing psoriasis in a first degree relative of an affected 
individual with type 1 disease is 10, with the risk falling to 2 in relatives of type 2 
disease (Elder, Nair et al. 2001). 
    The genetics of psoriasis are multifactorial, and linkage studies examining 
the genetics of psoriasis have often yielded inconsistent results (Nair, Henseler 
et al. 1997; Trembath, Clough et al. 1997; Samuelsson, Enlund et al. 1999; 
Lee, Ruschendorf et al. 2000) . Psoriasis susceptibility 1 (PSORS1) is an 
exception to this, and is the most extensively studied locus. It is located in the 
major histocompatibility complex (HLA) class1 region, on the short arm of 
chromosome 6. The HLA-Cw6 allele is thought to be the most likely candidate 
within this, and is carried by two thirds of psoriatic patients, although 10% of 
unaffected individuals also express this (Elder, Nair et al. 2001). Elucidation of 
the genetics of psoriasis and other complex genetic disorders are confounded 
by the high population frequency of disease alleles (Risch and Merikangas 
1996), but the development of HapMap has made large-scale genome wide 
association studies (GWAS) possible . These allow typing of 100,000 to 
100,000,000 SNPs in thousands of individuals to identify susceptibility loci, 
which can be consistently reproduced between studies. The major association 
loci identified by GWAS to date include SNPs located within 19 regions 
including: HLA-C, IL12B, IL23R, IL23A, IL4/IL13, TNFAIP3, TNIP1, LCE3B, 
LCE3C, ZNF313, PTPN22, CDKAL1 (Cargill, Schrodi et al. 2007; Capon, 
Bijlmakers et al. 2008; Liu, Helms et al. 2008; Nair, Duffin et al. 2009; Zhang, 
Huang et al. 2009), and seven of these have been consistently replicated 
between studies (IL23R, IL13, TNIP1, IL12B, HLA-c, TNFAIP3 and IL23A) 
(Elder, Bruce et al. 2010). 
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    IL23R, a gene identified by GWAS, encodes the IL-23 receptor gene (a 
newly defined cytokine which induces IFN-γ) (Cargill, Schrodi et al. 2007). IL-23 
comprises two subunits, p19 and p40, and possesses structural similarity to IL-
12.  Human keratinocytes produce both the IL-12 and IL-23 subunits (Piskin, 
Sylva-Steenland et al. 2006), and can thereby promote the type 1 response. 
Lesional psoriatic keratinocytes express an enhanced level of IL-12 and IL-23 
mRNA and protein compared to non-lesional or normal skin (Yawalkar, Karlen 
et al. 1998; Piskin, Sylva-Steenland et al. 2006; Cargill, Schrodi et al. 2007), 
which can then directly modulate T cell IFN-γ secretion by T cells. Enhanced IL-
23 expression has also been shown in macrophages, dermal dendritic cells and 
Langerhans‟ cells (Piskin, Sylva-Steenland et al. 2006). Recently Th17 cells 
have been described and these have been strongly implicated in psoriasis (Di 
Cesare, Di Meglio et al. 2009). IL23 stimulates proliferation and survival of Th17 
cells, which produce IL-17 and IL-22 (Haider, Lowes et al. 2008), this enhances 
the expression of keratinocyte antimicrobial peptides, and promote the psoriatic 
phenotype. Therapeutic treatment options such as narrowband UVB have been 
shown to suppress lesional psoriatic IL-23 down to levels seen in normal and 
non-lesional skin (Piskin, Tursen et al. 2004).  
    Drugs which target monoclonal antibodies against TNFα such as Infliximab 
can clear psoriasis. Polymorphisms in the genes whose products work 
downstream of TNFα to regulate NFκB (TNFAIP3 and TNIP1), have been 
identified as possible psoriasis susceptibility loci (Nair, Duffin et al. 2009). 
TNFAIP3 encodes a protein (A20) which inhibits NFκB and temporarily limits 
immune responses. In a mouse model, the region containing TNFAIP3 has 
been shown to promote psoriasis through TNFα (Wang, Kess et al. 2008), and 
interestingly the same region of the gene is associated with an increased risk of 
atherosclerosis (Idel, Dansky et al. 2003); a co-morbidity with a higher 
prevalence in patients with psoriasis (Gelfand, Neimann et al. 2006). However, 
common polymorphisms in this region have also been associated with 
rheumatoid arthritis and systemic lupus erythematosis in other studies (Plenge, 
Cotsapas et al. 2007; Graham, Cotsapas et al. 2008; Musone, Taylor et al. 
2008). 
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    Further genes of interest identified by GWAS include the late cornified 
envelope genes LCE3B and LCE3C.  Homozygous deletion of these are 
associated with an increased risk of psoriasis, and the LCE genes are strongly 
up-regulated in psoriasis (de Cid, Riveira-Munoz et al. 2009; Coto, Santos-
Juanes et al. 2010; Huffmeier, Bergboer et al. 2010). This supports the 
evidence described in section 1.2.3, that psoriatic keratinocytes are abnormal. 
 
 
1.2.2. Role of T cells in psoriasis 
    T cells play an important role in the pathogenesis of psoriasis (Abrams, 
Lebwohl et al. 1999; Bos and De Rie 1999). This is illustrated in animal models 
where engrafted non-lesional human psoriatic skin develops into psoriasis, but 
is preventable by inhibition of T cells proliferation (Boyman, Hefti et al. 2004). 
Clinical observation also supports the role of T cells in psoriasis, for example, 
bacterial superantigens exacerbate or unmask psoriasis (Valdimarsson, Baker 
et al. 1995), bone marrow transplantation from psoriatic donors has been 
reported to trigger psoriasis in recipients who have not previously had psoriasis 
(Gardembas-Pain, Ifrah et al. 1990), T cell targeted therapies can treat 
psoriasis (Chaudhari, Romano et al. 2001; Lebwohl, Tyring et al. 2003; 
Leonardi, Powers et al. 2003) and cytokine-based treatments can exacerbate 
psoriasis (Asnis and Gaspari 1995).  
    There has been much interest in studying the depletion of T cells following 
psoriatic treatments including UVB (Krueger, Wolfe et al. 1995; Ozawa, 
Ferenczi et al. 1999), although whether these clear as a cause or effect 
phenomenon is unclear. Psoriasis is sometimes labelled as an autoimmune 
disease although no potential antigen has ever been discovered. Perhaps the 
most convincing evidence for T cells as the primary abnormality in psoriasis 
comes from a study in which superantigen-activated psoriatic immunocytes 
were injected into uninvolved psoriatic human skin grafted onto severe 
combined immunodeficient (SCID) mice (Wrone-Smith and Nickoloff 1996). 
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This resulted in the „symptomless‟ skin changing into a psoriatic phenotype. A 
caveat to this study is that activation with non-antigenic substances, such as 
nerve growth factor (NGF), have been shown to cause a similar phenotypic 
change in engrafted normal skin (Nickoloff, Schroder et al. 2000). This suggests 
that local factors within the skin may also activate lesional T cells, inducing the 
observed phenotypic changes.  
    The T cell model of psoriasis fails to explain several features of psoriasis. In 
particular, the symmetrical nature of psoriasis, the Koebner phenomenon, and 
the resolution of psoriasis at sites of anaesthesia (Farber, Lanigan et al. 1990; 
Raychaudhuri and Farber 1993). The latter has been linked with up-regulation 
of NGF (which is expressed by keratinocytes) and its receptor (NGF-R) in 
lesional and non-lesional psoriasis (Fantini, Magnoni et al. 1995). NGF 
activates T cells, recruits inflammatory cells, promotes proliferation of 
keratinocytes and protects keratinocytes from apoptosis (Farber and 
Raychaudhuri 1999). It has been hypothesised that NGF has a role in wound 
healing, and its up-regulation may drive an inflammatory response and 
keratinocyte proliferation, possibly explaining why the Koebner phenomenon 
occurs in psoriasis (Nickoloff, Schroder et al. 2000). Moreover, it is now realised 
that drugs which have immunosuppressive effects on T cells, e.g. ciclosporin 
and tacrolimus, also exert direct independent effects on both neutrophils and 
keratinocytes (Fisher, Duell et al. 1988; Reynolds, Voorhees et al. 1998; Al-
Daraji, Grant et al. 2002). Furthermore, psoriasis often relapses almost 
immediately after these drugs are stopped, suggesting that they are 
suppressing the disease rather than inducing remission. 
 
 
1.2.3. Role of keratinocytes in psoriasis 
    Non-lesional psoriatic keratinocytes differ from normal keratinocytes as 
evidenced by abnormally increased rate of proliferation (Weinstein, McCullough 
et al. 1984) and an abnormal intracellular calcium signal in response to 
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physiological agonists (Karvonen, Korkiamaki et al. 2000; Ross 2005). 
Moreover they have altered intracellular signalling pathways including activated 
STAT3 (Pasparakis, Courtois et al. 2002; McKenzie and Sabin 2003; Sano, 
Chan et al. 2005; Arthur and Darragh 2006). Transgenic mice with constitutively 
active STAT3 develop a psoriatic phenotype, but require activated T cells to be 
present for this to occur (Sano, Chan et al. 2005). Similarly when non-lesional 
psoriatic skin is grafted onto SCID mice, the psoriatic phenotype develops only 
when activated T cells are introduced (Wrone-Smith and Nickoloff 1996; Gilhar, 
Yaniv et al. 2006).  
    An inducible JunB double-knockout mouse model has been described by 
Zenz et al (Zenz, Eferl et al. 2005). JunB is located in the PSORS6 psoriasis 
susceptibility region and is involved in regulation of cell proliferation, 
differentiation and cytokine expression. Deletion of JunB and c-jun from 
epidermal keratinocytes resulted in mice with the psoriatic phenotype and 
arthritic lesions. The authors concluded that changes in keratinocytes were 
sufficient to initiate psoriasis-like skin changes. However, conflicting data exists 
about whether JunB is reduced or increased in psoriatic plaques (Zenz, Eferl et 
al. 2005; Haider, Duculan et al. 2006). 
    LL37 is an antimicrobial peptide which can be transiently expressed by 
keratinocytes following skin injury (Dorschner, Pestonjamasp et al. 2001; 
Heilborn, Nilsson et al. 2003). In psoriasis LL37 expression has been shown to 
be persistently high (Frohm, Agerberth et al. 1997), and can bind to self-DNA 
(Lande, Gregorio et al. 2007). This activates plasmacytoid dendritic cells and 
triggers TLR9, producing IFN-α (Lande, Gregorio et al. 2007). LL37 has been 
shown to be the principal trigger for IFN-α production, which is central to the 
development of psoriasis (Nestle, Conrad et al. 2005). In this way, T cells are 
further stimulated and a positive feedback loop is initiated (Nickoloff and 
Griffiths 1990). However unlike in normal skin, this effect is maintained long 
after the initial stimulus is withdrawn. 
    Further evidence in support of keratinocytes being the primary abnormality in 
psoriasis includes the fact that psoriasis can occur linearly within Blaschko lines 
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(migratory patterns of epidermis) which suggests that the responsible genetic 
defect lies within this compartment (Moss 1999). Finally, proliferation of stem 
cells from non-lesional psoriasis can be stimulated using supernatant and T 
cells derived from psoriatic plaques. However, T cells do not stimulate 
proliferation of stem cells derived from non-psoriatic patients (Bata-Csorgo, 
Hammerberg et al. 1995).  
 
Figure 1-3. Pathogenesis of psoriasis. T cells, keratinocytes and antigen 
presenting cells (APCs) secrete proinflammatory cytokines which can act in a 
positive feedback loop, augmenting the development of psoriasis. Th17 cells 
and APC secrete IL22 which up regulates STAT3 and induces antimicrobial 
peptide production by keratinocytes which contribute to the psoriatic phenotype. 
Whether the primary abnormality lies with keratinocytes or T cells is unknown. 
 
 
    If keratinocytes represent a primary abnormality in psoriasis, then T cells are 
pivotal in amplifying abnormal cytokine production to drive and maintain plaque 
formation. Psoriatic keratinocytes secrete higher levels of chemo-attractant 
factors such as interleukin 1 and TNFα which induce epidermal T cells 
migration and activation. Once activated, a positive feedback loop can exist 
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whereby T cells will induce hyperproliferation of keratinocytes through release 
of stimulating cytokines including GM-CSF and IFN-γ (Bata-Csorgo, 
Hammerberg et al. 1995) (Figure 1-3). TNFα production stimulates further 
TNFα releasing cytokines from keratinocytes, dendritic cells, T cells, 
neutrophils, monocytes, macrophages and NK T cells; making it difficult to 
identify the primary trigger. 
 
 
1.2.4. Role of dendritic cells in psoriasis 
    Dendritic cells (DCs) are involved in tolerance and generate specific T cell 
activation in response to environmental signals. Normal skin comprises 
Langerhans‟ cells and dermal dendritic cells. The latter are increased in 
psoriasis, and two other DC subsets are also present: plasmacytoid DCs and 
inflammatory dendritic epidermal cells. Interestingly, dermal DCs are activated 
in both lesional and non-lesional psoriasis (Zhou, Krueger et al. 2003), and 
produce TNFα (Nickoloff, Karabin et al. 1991). When activated, DCs transform 
into stimulatory APCs, but under conditions of steady-state they present 
peptides with insufficient stimulation leading to the development of T cell anergy 
or regulatory T cell production. It has been postulated that psoriasis can be 
triggered when this balance of immune reactivity versus tolerance is disturbed 
(Bos, de Rie et al. 2005).  
    Plasmacytoid dendritic cells (PDC) secrete IFNα, and are key effector cells in 
the innate immune system in response to viruses, and in doing so provide a link 
between the innate and adaptive immune system. IFNα therapy can exacerbate 
psoriasis (Downs and Dunnill 2000), and the IFNα signalling pathway has been 
shown to be activated in psoriasis (van der Fits, van der Wel et al. 2004). A 
study by Nestle et al demonstrated that IFNα derived from PDCs had an 
essential role in the local activation and expansion of T cells in grafted psoriatic 
plaques on AGR-/- mice, and suggested that these are key cells in driving 
psoriasis development (Nestle, Conrad et al. 2005).  
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1.3. Ultraviolet radiation 
    UV radiation is part of the electromagnetic spectrum, lying between the 
visible and x-ray region, and can be divided into three regions according to its 
wavelength (Figure 1-4) although the accepted waveband definitions do differ 
slightly between countries: 
UVA: 320- 400 nm; 
UVB: 290- 320 nm; 
UVC: 200- 290 nm. 
    Approximately 5% of terrestrial summer solar radiation comprises energy 
within the UV spectrum, with the majority of this being UVA, and a small 
proportion (approximately 6%) being UVB. UVA alone is not effective in clearing 
psoriasis, although can be very effective when combined with a psoralen 
(PUVA). The increased risk of burning and skin cancers associated with this 
treatment modality, limits the number of exposures to PUVA therapy that any 
patient can safely be given (Slaper, Schothorst et al. 1986; McKenna, Patterson 
et al. 1996). 
    There is a wide variation in biological effects of UV, dependent on 
wavelength. Longer wavelengths (UVA) penetrate deeper into the skin, and 
may cause effects within the dermis, whereas shorter wavelengths show less 
penetration. Average transmission of UV through skin on the lower back follows 
an exponential curve, with maximal change between 275 and 290nm. In normal 
forearm skin, wavelengths of 290nm have been shown to penetrate into the 
lower epidermis approximately 14 times less than 314nm (Meinhardt, Krebs et 
al. 2009). UVB and UVC have both been shown to induce apoptosis of normal 
keratinocytes in vitro. However, UVC appears to cause significantly more (6-4) 
photoproducts and cyclobutane pyrimidine dimers than UVB in cultured 
keratinocytes (Takasawa, Nakamura et al. 2005). The authors of this study also 
found a greater release of mitochrondrial apoptotic pathway factors (such as 
cytochrome C) with UVC rather than UVB, but UVB achieved equal rates of 
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apoptosis through activation of the extrinsic pathway (see appendix A). This 
suggests that effects of UV on keratinocytes are wavelength specific, 
irrespective of differences in penetration. 
 
Figure 1-4. Diagrammatic illustration of the UV spectrum showing the 
proportion of UV reaching the Earth’s surface. The ultraviolet spectrum 
comprises 5% of solar radiation with the majority of terrestrial UV radiation 
being UVA (94%). UVB comprises just 6%. 
 
    The mechanism of action of UVB in the clearance of psoriasis is unknown. 
However, even in normal skin it causes a plethora of cellular effects within the 
epidermis, including apoptosis (Kulms and Schwarz 2000), DNA damage 
(Ichihashi, Ueda et al. 2003; Cadet, Sage et al. 2005), cell cycle arrest (Athar, 
Kim et al. 2000; Pavey, Russell et al. 2001), immunosuppression (Schwarz 
2002), cellular proliferation (Del Bino, Vioux et al. 2004) and cytokine release 
(Schwarz and Luger 1989).  
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    Apoptosis (programmed cell death) is a highly regulated, conserved, energy 
requiring process that eliminates damaged, infected or superfluous cells. In 
normal skin, keratinocytes can undergo apoptosis following UV irradiation at 
doses of around or greater than the minimal erythemal dose (Murphy, Young et 
al. 2001). These cells have a characteristic morphology consisting of shrunken 
eosinophilic cytoplasm, membrane blebbing, chromatin condensation and DNA 
fragmentation, leading to formation of pyknotic nuclei and apoptotic bodies 
(Claerhout, Van Laethem et al. 2006). The mechanism of „sunburn cell‟ 
formation is dependent on the degree of cellular DNA damage, and is controlled 
by the tumour suppressor gene p53, which triggers the intrinsic apoptotic 
pathway. DNA is a chromophore within the epidermis, directly absorbing UVB 
which leads to formation of cyclobutane dimers and (6-4) photoproducts. UVA 
can produce mutations indirectly, through mechanisms such as oxidative stress 
and photosensitisation reactions (Ichihashi, Ueda et al. 2003), but can also 
generate UVB-type photoproducts (Douki, Reynaud-Angelin et al. 2003). There 
is evidence that UV may also trigger apoptosis through the extrinsic pathway by 
directly activating the death receptors or inducing release of their ligands 
(Murphy, Young et al. 2001) (for an overview of apoptotic pathway see 
appendix A). Apoptosis of these cells is an important regulatory mechanism to 
reduce the associated risk of malignant transformation.  
    Interestingly, cumulative UV-induced mutations secondary to chronic sun 
exposure leads to a reduced apoptotic response (Claerhout, Van Laethem et al. 
2006). This implies either a down-regulation in pro-apoptotic stimulus, or an 
overactive anti-apoptotic pathway, e.g. survivin over-expression (Aziz, Ghotra 
et al. 2004). 
    UV dose can be expressed either as MEDs (minimal erythemal dose) or 
SEDs (standard erythemal dose). An MED is a visible indicator of individual 
biological response, and is defined as the lowest amount of radiation required 
to achieve just perceptible reddening of the skin 24h after irradiation. This 
measure is widely used in clinical practice, although it will be greatly affected by 
many variables. These include the wavelength of the UV source, the irradiated 
field size, intrinsic characteristics of the skin (such as pigmentation and 
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anatomical location) and observational factors such as the ambient light used to 
read the measurement etc. An SED is a standardised measure of 
erythemogenic UV exposure, with one SED being equal to an erythemal 
effective exposure of 100 J/m2 (Diffey 2002). This erythemally weighted quantity 
is useful when describing an administered dose, but does not take into account 
an individual‟s erythemal sensitivity. 
 
 
1.3.1. UVB as a treatment for psoriasis 
    For years it has been well recognised that exposure to sunlight can improve 
psoriasis in some patients. Accordingly, UV lamps have been developed 
commercially, which are effective in clearing psoriasis in approximately 70% of 
patients (Coven, Burack et al. 1997; Gordon, Diffey et al. 1999; Kirke, Lowder 
et al. 2007), often with prolonged remission (Markham, Rogers et al. 2003). 
Patients attend for treatment 2-3 times per week for approximately 6-8 weeks, 
with an average starting dose of 0.7 times their MED. However, some patients 
don‟t respond at all, and others relapse immediately after completion of therapy. 
Presently, we are unable to predict who is likely to respond well to treatment, 
and do not know why it is so effective for some patients, but others remain less 
susceptible to its effects.  
    Different wavebands of UVB have been used to clear psoriasis. Most 
commonly used is narrowband UVB and less so broadband UVB (280-315nm). 
Evidence for the efficacy of specific wavelengths is based on work by Parrish 
and Jaenicke (Parrish and Jaenicke 1981) in which four patients with psoriasis 
were irradiated with seven different UV wavelengths, from 254nm to 313nm. 
They showed that wavelengths below 296nm cause erythema but are not 
effective in clearing psoriasis, even when used at in multiples of up to 28 times 
the minimal erythema dose; however, wavelengths from 300 to 313nm were 
effective. Monochromatic excimer lasers (308nm) are now also used as a 
treatment for localised psoriasis (Asawanonda, Anderson et al. 2000; Bianchi, 
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Campolmi et al. 2003; Gerber, Arheilger et al. 2003; Kollner, Wimmershoff et al. 
2005) and have been demonstrated to be as effective as 311nm in clearing 
psoriasis (Kollner, Wimmershoff et al. 2005). 
    In response to Parrish and Jaenicke‟s work which suggested that 
wavelengths around 313nm were more effective at clearing psoriasis than the 
nearest tested wavelength of 304nm (Parrish and Jaenicke 1981), fluorescent 
lamps (narrowband UVB) were developed commercially. The phosphor coating 
on these bulbs produces a peak emission of 311nm, and have also found to be 
highly effective for clearing psoriasis. The efficacy of 311nm UVB in clearing 
psoriasis has not been directly compared to 313nm. 
    It has been hypothesised that UVR induces apoptosis of lymphocytes in vivo. 
In part this is because epidermal T cells deplete as psoriasis improves with UV 
treatment. Studies have examined skin biopsies from patients before treatment 
and after resolution of psoriasis at a non-disclosed time interval from the last 
dose of radiation (Krueger, Wolfe et al. 1995; Ozawa, Ferenczi et al. 1999). We 
know from previous work that keratinocyte apoptosis in normal skin appears 
around 8-12h, peaks 24-48h after UV exposure, and will not be detected after 
60-72h (Woodcock and Magnus 1976; Murphy, Mabruk et al. 2002; Mass, 
Hoffmann et al. 2003), although the former study was performed in mice. If 
psoriasis has virtually resolved, it is arguably too late to know which cells have 
been important in causing this to occur and which cells are altered as a 
bystander effect of psoriatic resolution. 
    The mechanism of UVB-induced clearance of psoriasis has been the focus of 
numerous studies. However, previous work has looked for changes occurring 
following therapeutic UVB (Bianchi, Campolmi et al. 2003; Abou El-Ela, Nagui 
et al. 2010; Johnson-Huang, Suarez-Farinas et al. 2010). No previous studies 
have compared the direct effects of therapeutic versus ineffective wavelengths 
of UVB, which would allow identification important contributors to psoriasis 
clearance rather than bystander effects. 
    UV-induced T cell apoptosis has been demonstrated with the TUNEL 
(terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labelling) 
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technique (Krueger, Wolfe et al. 1995; Bianchi, Campolmi et al. 2003). 
However, studies have shown that TUNEL gives false positive results in 
psoriatic epidermis because of an increased number of DNA nicks, caused by 
the high rate of DNA replication (Wrone-Smith, Mitra et al. 1997). This 
technique is therefore unreliable, and there is no other direct evidence to 
suggest that large numbers of T cells undergo apoptosis within treated psoriatic 
epidermis. In vitro data from four UVR sources demonstrated peripheral T cells 
apoptosis with UV wavelengths ranging from 290- 311nm (Novak, Berces et al. 
2004). However, in support of the theory that T cells may not be the principal 
target cells in effective UV treatment, they demonstrated that 290nm is three 
times more effective at inducing T cell apoptosis than 311nm. The fact that 
290nm is known to be clinically ineffective in clearing psoriasis suggests that T 
cells may not be as important in the mechanism of action of this particular 
therapeutic modality.  
 
 
 
1.4. Apoptosis 
    Apoptosis is a key physiological event in both developmental biology and 
tissue homeostasis, and is a normal physiological response in reaction to 
stimuli such as irreparable DNA damage. The physical characteristics of 
apoptotic cells described above (section 1.3) are well characterised, although 
the pathways involved are more complicated. Apoptosis can occur through the 
intrinsic (mitochondrial) pathway or extrinsic (death receptor) pathway (see 
appendix A). The former can be triggered by DNA damage or cytotoxic drugs, 
and is mediated by the bcl-2 family of proteins. The extrinsic pathway is initiated 
by the recruitment of Fas-associated death domain to the death domain 
receptors of the TNF Superfamily, leading to downstream activation of caspase 
8 (Wallach, Boldin et al. 1997). The „caspase cascade‟ is usually common to 
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both pathways (see below), and consists of the executioner caspases 3, 6 and 
7, which are activated by proteolytic cleavage. These caspases are key 
mediators of DNA fragmentation via cleavage of a wide range of cytoplasmic 
and nuclear proteins (Duncan, Turowec et al. 2010). In particular, cleaved 
caspase-3 translocates to the nucleus, where it cleaves substances including 
the DNA repair enzymes ICAD (inhibitor of caspase-activated DNAse) and 
PARP (poly (ADP-ribose) polymerase), leading to DNA fragmentation. A 
caspase independent pathway has also been shown to exist following 
mitochondrial release of EndoG (endonuclease G) and AIF (apoptosis inducing 
factor), which can directly translocate to the nucleus and induce DNA 
fragmentation independently (Bajt, Cover et al. 2006). 
 
 
1.4.1. Methods of apoptosis detection  
Apoptosis is a dynamic process which is often measured by end-point assays, 
such as immunohistochemistry and flow cytometry. Morphological changes 
including DNA-fragmentation and cytoplasmic shrinkage (as opposed to 
swelling of the cell associated with necrosis) can be observed following nuclear 
staining and examination by light/ electron microscopy. Techniques based on 
detection of DNA fragmentation (e.g. TUNEL (see section 1.3.1), in situ nick 
translation, in situ hybridisation and PARP detection) are not specific for 
apoptosis, and therefore need to be interpreted cautiously (Stadelmann and 
Lassmann 2000). Annexin V is used to detect early apoptosis by flow cytometry 
as it precedes DNA fragmentation (Martin, Reutelingsperger et al. 1995), but 
cannot be used for in vivo detection as it binds to phosphatidylserine 
transposed to the outer membrane during apoptosis (van Engeland, Nieland et 
al. 1998) and these are disrupted during processing (van den Eijnde, 
Luijsterburg et al. 1997).  
    Antibodies against various members of the apoptotic pathways exist. 
However, detection of early proteins such as p53, cytochrome C and the Bcl-2 
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family do not imply that the apoptotic pathway will complete, and cells 
expressing these markers may recover completely. In contrast, antibodies to 
caspase-3 are sensitive and specific for apoptosis in vivo and in vitro, and once 
activated the cell is destined to undergo apoptosis (Stadelmann and Lassmann 
2000; Huerta, Goulet et al. 2007). A caspase-3 substrate is available for real 
time imaging, and can be used in primary cells (Cen, Mao et al. 2008) (see 
section 2.2.2) and techniques such as FRET (fluorescence-resonance energy 
transfer) can be a useful for measuring the rate of apoptosis, but can only be 
applied to transfected cells (Tyas, Brophy et al. 2000).      
 
 
1.4.2. Apoptosis in psoriasis 
    Wrone-Smith et al studied the effects of incubating cultured psoriatic and 
non-psoriatic keratinocytes in a semisolid medium (methylcellulose) for up to 
24h and found significantly less apoptosis in the psoriatic keratinocytes. They 
surmised that psoriatic keratinocytes had an increased capacity to resist 
apoptosis (Wrone-Smith, Mitra et al. 1997), and this is often quoted as evidence 
that psoriatic keratinocytes are generally resistant to apoptosis. Apoptosis as a 
mechanism of plaque clearance has since been largely overlooked. However, a 
few studies have indicated that apoptosis may be a relevant mechanism of 
plaque clearance. 
    Low dose methotrexate has been shown to induce apoptosis of keratinocytes 
using epidermal explants comprising normal human keratinocytes, and the 
authors suggested that this may explain the reduction in epidermal hyperplasia 
in psoriasis treated with methotrexate (Heenen, Laporte et al. 1998). Dithranol 
(anthralin) is another effective treatment for psoriasis, and has also been shown 
to induce apoptosis in normal keratinocytes (McGill, Frank et al. 2005). 
Moreover, ongoing work in our laboratory has shown that keratinocyte 
apoptosis can be detected in vivo following routine dithranol treatment to 
psoriatic plaques (Leech et al, unpublished). Apoptosis of psoriatic 
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keratinocytes has also been shown in vivo following treatment with infliximab 
(Markham, Mathews et al. 2006; Raho, Vena et al. 2010), although the 
importance of this in plaque clearance has not yet been demonstrated. 
 
 
 
1.5. Mathematical modelling 
    Mathematical modelling allows prediction of how a biological system will 
behave based on available evidence, without the need for time-consuming and 
sometimes impossible experiments (Diffey 2004). It also allows further 
understanding of the possible mechanisms of specific processes. Modelling 
does not replace the need for laboratory based experimentation, but 
complements it by focusing on what is likely to be important, and which 
mechanisms or pathways fit best with the known evidence. 
    A model is a simplification of the in vivo process, and can be used to 
examine the relationship between cause and effect; for example the effects of 
UVB on the keratinocyte compartment of psoriatic skin. This requires temporary 
exclusion of the non-essential details, and by striping the model down to 
essential components only, it is possible to examine whether the process under 
investigation acts directly on the compartment under examination. If a direct 
relationship is not found, this suggests that other factors are likely to be of 
greater importance and should also be considered. Furthermore modelling 
highlights gaps in knowledge, which may lead the researcher to go back „to the 
bench‟ and design further relevant experiments which may be fundamental to 
understanding the system under investigation. Finally, modelling allows a more 
predictive approach which can then be tested, allowing for considerable savings 
in time and money (Kirkwood, Boys et al. 2003). 
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    Predominantly two types of computational models exist: stochastic and 
deterministic. Stochastic models are useful when random events may occur 
and may have important influences on the behaviour of the system. Each run of 
the model will give a different result, and for this reason numerous stimulations 
are required. The advantage of stochastic models is that they allow the user to 
test a range of possibilities which fall within and outside the expected range of 
probability, and can be used to determine whether the model assumptions hold 
true. They may however, be either very complex computationally, or be seen to 
overly simplify the problem being tested, by ignoring possible contributing 
factors. If a model still holds true when a particular factor is excluded it 
suggests that any relationship between this factor and the modelled biological 
process is indirect. Likewise, if it doesn‟t hold true, it would suggest that the 
factor has a direct effect on the process being processed. 
    Deterministic models, also known as compartmental models, give fixed 
reproducible results and take no account of individual random variation. They 
are useful when working with large populations and attempt to describe the 
average of what happens to the population by categorising individuals into 
separate subgroups (Trottier and Philippe 2001). In this project, only stochastic 
modelling is used as the remodelling effect of UVB on psoriatic patients is 
variable, and individuals with similar demographic data or type of psoriasis do 
not react to UVB in a similar or typical manner. 
    To create a successful model it is important to include as many known and 
relevant parameters as possible, and this is largely done through collation and 
evaluation of previously published experimental work. These parameters can 
then be inserted into the model and tested to see if the model holds true within 
a given range of values. This exercise in itself will often highlight relevant gaps 
in the literature, and can guide the researcher to undertake further relevant 
bench work to inform the model.  
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1.5.1. Keratinocyte behaviour 
    The keratinocyte compartment can be further subdivided into the stem cell, 
TA cell and differentiating cell compartments (Dover and Wright 1991; Webb, Li 
et al. 2004) and this can be helpful when considering the physical location of 
the cells within the epidermis, their role in proliferation or differentiation and 
their different kinetic behaviour patterns. Each of these is addressed below. 
 
1.5.1.1. Stem cells 
    Epidermal keratinocytes comprise stem cells, transit amplifying (TA) cells 
and differentiating cells. Non-follicular stem cells are located on the basement 
membrane and although distributed throughout the length of the basement 
membrane, are thought to have a greater density towards the tips of the dermal 
papillae in normal skin (Jones, Harper et al. 1995; Ghali, Wong et al. 2004). 
Stem cells have the potential to divide indefinitely (Potten and Loeffler 1990), 
and can either divide symmetrically to produce two stem cells, or 
asymmetrically giving one stem cell and one TA cell. During times of 
homeostasis asymmetrical division occurs, but in times of stress e.g. wound 
repair, symmetrical division may occur, and this may lead to epidermal 
acanthosis (Fuchs 2008).  
    The proportion of proliferating cells within the normal epidermis has been 
estimated to be as high as 43-66% (Bata-Csorgo, Hammerberg et al. 1993; 
Jones, Harper et al. 1995), with putative stem cells accounting for 
approximately 3-12% of epidermal cells (Webb, Li et al. 2004; Youn, Kim et al. 
2004). The proportion of stem cells is likely to be variable depending on body 
site (Jones, Harper et al. 1995; Webb, Li et al. 2004). Estimates of the 
proportion of epidermal stem, TA and differentiating cells and how many of 
them are actively dividing, comes predominantly from flow cytometry, 
immunohistochemistry and in vivo labelling techniques. Reliable evidence has 
been hampered by lack of good keratinocyte stem cell markers, and such cells 
are usually identified as being „stem-cell-like‟ but in fact maybe early TA cells; 
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this may explain why the quoted ranges in the older literature are so variable. 
However, stem cells have been shown to express β1 integrin at levels which 
are up to 2-3 times higher (β1 integrin-bright) than in TA cells (β1 integrin-dim) 
(Jones and Watt 1993), although early TA cell will have a similar expression 
profile to stem cells. Some studies have attempted to overcome this problem by 
comparing properties of the α6-integrin bright (proliferating) cells and identifying 
CD71 (transferin) negative cells amongst these as stem-cell like, and  CD71 
positive cells as TA cells (Hayashi, Yamato et al. 2008). However, these 
antibodies enrich the cells rather than specifically identify them. 
    Stem cells are thought to pass through the cell cycle at a slower rate than TA 
cells (Dover and Wright 1991), and have been estimated to have a cell cycle 
time of 100-200 hours in normal epidermis (Potten and Bullock 1983; Potten 
1986; Morris and Hopewell 1990), although cell cycle times as slow as 400h 
have been described in human epidermis (Weinstein and Frost 1968). 
However, it is likely that cell cycle times will vary considerably both within and 
between different individuals (Dover and Wright 1991). 
 
1.5.1.2. TA cells 
    TA cells retain a limited ability to proliferate but are committed to differentiate 
at some stage. They are located in the basal/ suprabasal layer, dividing 
approximately three to five times (Watt 1998; Savill 2003) before migrating 
upwards, and eventually differentiating. Actively dividing cells are located 
basally or suprabasally, possibly because younger cells have a higher binding 
affinity to the basement membrane or because successful cell division requires 
a given concentration of soluble factors released from the basement 
membrane/ dermis (e.g. keratinocyte growth factor).  What makes the 
basement membrane length increase in conditions such as psoriasis is unclear, 
although arguably if cells are actively dividing and require certain basement 
membrane or dermis derived soluble factors to do this, an increased number of 
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dividing TA cells may induce the basement membrane to expand in order to 
accommodate this.  
    TA cells have been shown to divide either symmetrically (giving rise to two 
TA cells), or asymmetrically (giving rise to one TA cell and one differentiating 
cell) and it is likely that they can switch between these in certain states. This 
has been demonstrated in mouse skin (Clayton, Doupe et al. 2007), and in 
other tissue types including cortical development and haemopoeitic cells 
(Mione, Cavanagh et al. 1997; Estivill-Torrus, Pearson et al. 2002; Bullock, 
Wen et al. 2007). This has not yet been studied in human skin, although it can 
be assumed that certainly in disease states such as psoriasis, symmetrical 
division occurs since differentiating cells are not scatted throughout the lower 
epidermis; instead they are situated above the TA cells in the upper epidermis. 
This physical distinction implies that TA cells will continue to migrate up the 
epidermis and will either differentiate when they reach a certain age, or after a 
certain number of divisions. This has been demonstrated within the eye, and it 
is thought that a gradient may exist which determines whether cells remain as 
transit amplifying cells or differentiate (as they progress further towards the 
surface of the eye) (Revoltella, Papini et al. 2007). 
    In normal epidermis the turnover time for proliferating cells has been 
estimated at 152-580h (Epstein and Maibach 1965; Weinstein and McCullough 
1973; Allegra and De Panfilis 1974; Potten 1986), and the total epidermal 
turnover time in normal human epidermis has been estimated as 672-840h 
using heavy water labelling of keratin in vivo (Lindwall, Hsieh et al. 2006).  Cell 
turnover can be defined as the time taken to replace all the cells within a 
compartment and if the birth rate and death rate are equal, and when the 
epidermis is in equilibrium, can be defined as: 
 
Turnover rate =   Number of cells within the defined compartment 
                                        Birth/ Death rate 
 
1-27 
 
    As the rate of cell proliferation increases, there is a corresponding increase in 
the number of cells replaced within the compartment, and so epidermal 
turnover time is decreased (Iizuka, Honda et al. 1999). 
    TA cells may be resting or cycling, but when cycling, are thought to progress 
through the cell cycle faster than stem cells (Potten and Bullock 1983).  The cell 
cycle time has been estimated using the FLM (fraction of labelled mitosis) 
technique extended over 45h to minimize the effects of diurnal variation or cell 
synchronization. The FLM curve allows analysis of the time of cell cycle by flash 
labelling of the pre-mitotic phase of proliferating cells with Thymidine and repeat 
analysis. This technique has shown a mean cell cycle time of 56h with a 75% 
coefficient of variation (Duffill, Wright et al. 1976), with other estimates ranging 
from 50-65h (Chopra and Flaxman 1974; Goodwin, Hamilton et al. 1974; Bauer 
and Grood 1975; Wright 1976). 
 
1.5.1.3. Differentiating cells 
    It is thought that the overall proportion of nucleated cells in normal epidermis 
within the differentiating compartment is 40-66% (Weinstein, McCullough et al. 
1984; Bata-Csorgo, Hammerberg et al. 1993). Differentiated cells continue to 
migrate up the epidermis until they die and become part of the stratum 
corneum. The transit time is the time taken for a cell to migrate from the bottom 
of a compartment to the top, and in normal epidermis this is estimated to be 
240-336 hours for cells within the differentiating compartment (Epstein and 
Maibach 1965; Weinstein and Van Scott 1965; Allegra and De Panfilis 1974). 
    What defines when a TA cell differentiates is unclear, however histological 
evidence showing differentiation markers such as keratin 10 and S100A 
proteins, suggest differentiation may be due to an inverse gradient arising from 
the basement membrane (Figure 1-5). 
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1.5.2. Altered kinetics in psoriatic epidermis 
    In psoriasis there is epidermal hyperproliferation. In general, 
hyperproliferation can arise by either: 
1. increasing epidermal turnover time,  
2. increasing the proportion of proliferating cells  
3. altering the rate of the cell cycle 
    Following epidermal wounding of normal skin either by repeated tape 
stripping or incision, there is a delay of 15-65h before proliferation is observed 
(Dover and Wright 1991). The rate of proliferation peaks, and then settles over 
the following 3-4 days. Such a period of latency is consistent with stimulation of 
cells in the G0 phase, and may suggest that resting stem cells or TA cells are 
recruited into the cell cycle. Tape stripping of uninvolved psoriatic skin however, 
produces over-expression of TGFα in contrast to normal epidermis, and a 
significantly exaggerated proliferative response occurs (Hatta, Takata et al. 
1997). This may explains how plaques can develop over a matter of days in 
previously normal looking skin. Interestingly, the hyperproliferative response is 
seen following wounding which physically removes cells from the system (e.g. 
tape stripping), but not where the cells are damaged in situ (e.g. burning) 
(Denekamp and Fowler 1976). This suggests that proliferation can be driven in 
response to local cell barrier disruption, and this may be partly explained by 
disruption of the calcium gradient (Elias, Ahn et al. 2002).  
    The epidermal turnover time in normal human epidermis is estimated at 28-
35 days (approximately 19 days for proliferative compartment and 10-14 days 
for the differentiating compartment) in normal epidermis excluding stratum 
corneum (Epstein and Maibach 1965; Weinstein and Frost 1971; Bergstresser 
and Taylor 1977; Lindwall, Hsieh et al. 2006), whereas psoriatic epidermis has 
a reduced estimated turnover time of 7-10 days (Goodwin and Fry 1974; Laptev 
and Nikulin 2005). This reduction in turnover time suggests that alteration in 
turnover time is not the cause of hyperproliferation seen in psoriasis, since if 
cells are removed from the epidermis at a quicker rate (but all other factors e.g. 
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cell cycle length remain the same) the epidermis would be expected to be 
thinner. This is clearly not the case in psoriasis. Cell cycle times in psoriasis 
have a large coefficient of variation which has been estimated at 75% (Duffill, 
Appleton et al. 1977), but studies suggest that there is no reduction in the cell 
cycle time of psoriatic keratinocytes (Chopra and Flaxman 1974; Bauer and 
Grood 1975). In normal human epidermis, studies have shown that up to 80% 
of cells in the basal layer (stem and TA cells) are not actively dividing (Gelfant 
1976). Although proliferation within normal epidermis is generally thought to be 
confined to the basal layer, Penneys et al demonstrated that approximately 
30% of cycling cells (identified by flash labelling) were located suprabasally in 
normal epidermis (Penneys, Fulton et al. 1970). The following differences have 
been reported in psoriatic epidermis compared to normal skin: 
 An increase the number of proliferating cells is approximately six times 
normal (Doger, Dikicioglu et al. 2007), and in total epidermal mitosis of 
10-23% (Weinstein and Frost 1968; Goodwin, Hamilton et al. 1974; 
Duffill, Wright et al. 1976). However, evidence exists to show that the cell 
cycle time does not change in psoriasis compared to normal skin (van 
Ruissen, de Jongh et al. 1996). 
 The turnover time for psoriatic epidermis is up to four times faster than in 
normal skin (Weinstein and Van Scott 1965). 
 The overall number of epidermal cells increases by up to two to five 
times normal (Vanscott and Ekel 1963; Weinstein, McCullough et al. 
1984; Weinstein, McCullough et al. 1985). 
 The estimated turnover time for the proliferating compartment is reduced 
from 150-600h in normal skin to 36-114h in psoriasis (Weinstein and 
Frost 1968; Wright 1976). 
 The estimated transit time for the differentiating compartment is reduced 
from 240-330h in normal epidermis to down to as rapid as 48h in 
psoriasis (Weinstein and Van Scott 1965; Weinstein and Frost 1968).  
 Several lines of evidence indicate gradients of differentiation markers 
within epidermis (Korver, van Duijnhoven et al. 2006),(Ishida-Yamamoto 
and Iizuka 1995; Martinsson, Yhr et al. 2005) (Figure 1-5). Although the 
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molecular signals that drive this process remain to be fully elucidated, 
the histological pattern of induction of keratinocyte differentiation is not 
consistent with a gradient emanating from a fixed distance beneath the 
stratum corneum, but rather indicates a gradient arising from the basal 
layer or dermis (Figure 1-5). 
 In psoriatic epidermis, a six to sevenfold increase in the number of cells 
in the S/G2M phase of cell cycle was found among CD29+ K1/K10- cells 
(the putative stem cell population).  Furthermore, all lesional putative 
stem cells showed high PCNA positivity, indicating that these cells had 
all been induced into the cell cycle recently (Bata-Csorgo, Hammerberg 
et al. 1993); therefore providing evidence that the proportion of actively 
cycling stem cells in markedly increased in psoriasis. 
 Cells with the highest proliferation potential will have greater adhesion to 
the basement membrane and /or other cells of higher proliferative 
potential (Fuchs 2008). 
 
Figure 1-5. Epidermal section showing characteristic distribution of 
keratin 10 (red) and keratin 6 (green). Short dashed line shows outline of 
differentiation markers, and the long dashed line shows the basement 
membrane. Note the greater gap between the 2 lines at the bottom of the rete 
ridges (arrows), than at the top; consistent with a gradient produced from the 
basement membrane (see Figure 2-8). Adapted from Korver et al (Korver, van 
Duijnhoven et al. 2006). 
1.5.3. Existing mathematical models of the epidermis 
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1.5.3.1. Models of normal epidermis 
    A mathematical model has been proposed to examine how the hierarchical 
cell populations maintain equilibrium within the normal epidermis (Savill 2003). 
This model examined the effects of various parameters on epidermal 
homeostasis including variation in both cell cycle time and the number of transit 
generations produced. Reduced cell cycle time has been proposed as a 
possible cause of hyperproliferation seen in psoriasis, but Savill showed that 
reducing cell cycle time doesn‟t necessarily lead to hyperproliferation. 
Furthermore his model demonstrates that increasing the TA cell cycle time 
(assuming that number of TA divisions remains constant, and the cell spends 
the same amount of time within the TA compartment) leads to an increase in 
cell density, but doesn‟t affect the birth rate. In contrast he showed that 
increasing the number of TA divisions has a substantial impact on increasing 
birth rate. In conclusion, Savill showed that hierarchical cell populations need to 
be modelled by taking into account properties of different cell compartments 
within the epidermis, e.g. different cell cycle times for stem and TA populations, 
and variation in the number of transit generations produced. 
    A computational model of epidermal homeostasis has been developed using 
a multi-agent systems approach (Grabe and Neuber 2005; Sutterlin, Huber et 
al. 2009). This allows each cell to follow a set of rules which will determine how 
it will interact with other cells within the model. The advantage of this type of 
model is that it allows the modeller to directly visualise what the effects of 
altering specific cellular parameters can have on interactions with neighbouring 
cells and on the model system as a whole. The purpose of Grabe and Neuber‟s 
model was to computationally show how cells could get from an undulating 
basal layer to form a flat epidermal surface following agent-based rules about 
morphology, kinetics and calcium flow. They included an arbitrary maximum 
age a cell can reach (1000h) which is integral to the model, and specified that 
TA cells proliferate for the first 10% of their life time. They assumed a cell cycle 
of 62h for both stem and TA cells and would only permit a cell to divide if there 
was room for it to do so within a fixed epidermal structure. The epidermis has a 
vertical calcium ion gradient, with low calcium in the basal layers and higher 
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levels at the top of the epidermis (Elias, Ahn et al. 2002). As the gradient 
reaches a given threshold they will differentiate, and this is reflected in the 
Grabe model. With the above parameters they predicted an epidermal turnover 
time averaging 672h (27 days), which is fairly consistent with existing literature 
quoting 28-35 days (Epstein and Maibach 1965; Weinstein and Frost 1971; 
Bergstresser and Taylor 1977; Lindwall, Hsieh et al. 2006). However, many of 
the above assumptions are not supported by experimental evidence, yet are 
pivotal to the models function; therefore results need to be interpreted 
cautiously.  
    Recently a 3D computational model of normal epidermis has been developed 
to investigate the effects of cell proliferation and migration on wound healing 
(Adra, Sun et al. 2010). TGF-β1 was used to explore the “subcellular rules” of 
cultured keratinocytes which cause cells to alter their behaviour pattern in 
response to external events such as wound healing. The authors used FLAME 
(Flexible Large-scale Agent Modelling Environment) (Coakley 2007) and 
COPASI (Complex PAthway SImulator) (Hoops, Sahle et al. 2006) modelling 
environments to incorporate intracellular signalling pathways into an agent-
based model. A 3D model was produced based on a flat surface to which stem 
cells attach. As cells migrate upwards they progress to become TA cells and 
then differentiated cells. This model did not consider cell cycle times, the 
mechanism of TA cell division (e.g. symmetrical or asymmetrical), and assumes 
that progression from TA cell to differentiation occurs due to a cell reaching a 
set distance from the stem cells. It does however provide a framework to 
investigate the roles of growth factors and signalling pathways within the 
epidermis. 
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1.5.3.2. Models of psoriatic epidermis 
    There has only been one published computational model of psoriasis 
morphology to date (Grabe and Neuber 2007). However, this model published 
in 2007, claimed that psoriasis could be simulated by increasing the fractional 
time period during which TA cells proliferate from 8% to 100% (Grabe and 
Neuber 2007). This one change led to an increase in both the germinative and 
differentiated compartments, with a greater increase in the former, and a 
reduction in turnover time by approximately 40% to 450h (19 days). This 
compares to an estimated turnover time of down to 7-10 days in other 
published studies (Goodwin, Hamilton et al. 1974; Laptev and Nikulin 2005). 
However, the Grabe model showed a relatively modest increase in total cell 
numbers of 50%, although evidence suggests that the total cell number is 
increased by 4-5 times in psoriatic epidermis compared to normal skin (Iizuka, 
Ishida-Yamamoto et al. 1996).  Furthermore this model required that all cells 
within the proliferating compartment are actively cycling, whereas previous 
experimental studies for psoriasis estimate that the proliferative indices 
increased by 10-23% (Weinstein and Frost 1968; Goodwin, Hamilton et al. 
1974; Duffill, Wright et al. 1976). 
    Iizuka et al created a non-computational geometric model of psoriasis based 
on quantitative analysis of psoriatic epidermis (Iizuka, Honda et al. 1999).They 
suggested that “while the differentiating compartment increases its size by 
increasing its volume (cell number), the proliferative compartment increases by 
increasing the size (area) of dermo-epidermal interface”. They argue that this is 
the explanation for the typical morphology observed in psoriatic plaques, and 
that the total epidermal volume is determined by the size of the proliferative 
compartment; thus the shape of the basement membrane may predict the 
number of proliferating cells within the compartment. As the rate of proliferation 
is increased in the epidermis, the turnover time reduces accordingly. Iizuka et al 
later showed that psoriasis with a granular layer (i.e. resolving lesions) had a 
turnover time at least 1.28 times longer than plaques without this layer (Iizuka, 
Takahashi et al. 2004), although it was still increased compared to normal skin. 
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1.6. Gene Arrays 
    The ability to study changes in gene expression has revolutionised our 
understanding of many disease processes. Different disease states are 
associated with up or down regulation of a variety of genes, with consequent 
altered levels of protein production which directly influences cellular activity. 
Therapeutic options may work by directly modulating gene expression returning 
it to a normal state, and the ability to detect these changes can help us 
understand which mechanisms to target when designing or modifying treatment 
options.  
     
 
1.6.1. Gene array studies in psoriasis 
    A large gene profiling study has recently been published examining gene 
expression profiles between untreated lesional/ non lesional psoriasis and 
control patients without psoriasis (Gudjonsson, Ding et al. 2009). Whole punch 
biopsies were analysed (i.e. epidermis and dermis) following a short washout 
period of just two weeks for systemic psoriatic treatment and one week for 
topical treatment. Results showed a marked difference in expression profile 
between lesional and non lesional psoriasis, but the difference between non-
lesional and control skin was more subtle (maximum fold change of 24-134 in 
the former and 1.8-1.9 in the latter) although this still amounted to 179 
statistically significant differentially regulated genes. Some of the most strongly 
up-regulated genes included those encoding for epidermal differentiation such 
as SPRR2B, SPRR2G and SPRR3, and genes involved in innate immunity 
such as S100A family, DEFB4 (encoding human beta defensin-2), RNASE7 
(with broad spectrum anti-microbial activity) and IL1F9 (encoding IL-1ᵋ the 
proinflammatory cytokine). Down-regulated genes were predominantly lipid 
biosynthesis genes such as ELOVL3 and FADS1. Interestingly, none of the 
down-regulated genes had been identified by other studies (Bowcock, Shannon 
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et al. 2001; Zhou, Krueger et al. 2003; Kulski, Kenworthy et al. 2005; al Yacoub, 
Romanowska et al. 2008) and S100A7 was the only up-regulated gene in 
common to have been previously identified (Zhou, Krueger et al. 2003); 
although the concordance between these studies was higher for gene changes 
between lesional and non-lesional psoriatic skin. 
    Gene expression profiling has also been used to analyses differences 
between punch biopsies taken from untreated lesional and non-lesional 
psoriasis in seven Japanese patients (Kulski, Kenworthy et al. 2005). The 
authors showed that lesional psoriatic plaques contained up-regulated genes 
coding for apoptotic stress signals, with other affected genes encoding for a 
range of functions including interferon mediation, immunity, cell adhesion, 
signal transduction and cytoskeletal restructuring.  
    Biomarkers can prove a highly useful tool in predicting patient‟s response to 
treatment. One small study has used microarray data from peripheral blood 
mononucleocytes (PBMCs) of 16 patients with psoriasis to identify candidate 
genes which may predict response to treatment with Alefacept (Suarez-Farinas, 
Shah et al. 2010). The authors identified 23 candidate genes which may be 
useful markers, but in particular responders had up-regulation of genes such as 
cAMP response element (CREM) which is associated with reduced IL-2 and T 
cell anergy, and MAFF which is involved in the cellular stress response. The 
relevance of this will become clearer following completion of prospective 
studies.  
 
 
1.6.2. The effects of UVB on the epidermis 
     UVB radiation has been shown to suppress the adaptive immune system 
contributing to photocarcinogenesis, but enhance the innate immune response. 
In particular antimicrobial peptides (AMPs), which are secreted by keratinocytes 
in the stratum granulosum (Zasloff 2002), have been shown to have enhanced 
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expression following exposure to UVB in primary keratinocytes in vitro (Glaser, 
Navid et al. 2009). AMPs are located in the stratum corneum and are an 
effective defence against bacteria, viruses, fungi and protozoa. In contrast to 
eczema where their levels are suppressed, their expression is markedly over-
expressed in psoriasis. At high levels AMPs can induce necrosis by physically 
disrupting the cell membrane, or if internalised, can induce apoptosis by 
disruption of intracellular organelles (Zasloff 2002; Barlow, Li et al. 2006). UVR 
also induces production of LL-37 (cathelicidin) by keratinocytes, which protects 
keratinocytes from apoptosis when expressed at high levels by regulation of 
cycloxygenase-2 (COX2) and inhibitor of apoptosis protein (IAP-2) (Chamorro, 
Weber et al. 2009). It has been suggested that inhibition of PGE2 would lead to 
LL-37 induced apoptosis of basal keratinocytes (Zasloff 2009), which may be 
enhanced by drugs which inhibit COX-2 such as non-steroidal anti-inflammatory 
agents (NSAIDs). 
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1.7. Study hypothesis 
    The study hypothesis was that keratinocytes are of primary importance in the 
pathogenesis of psoriasis, and that apoptosis of psoriatic keratinocytes is 
induced by therapeutic wavelengths of UVB but not by non-therapeutic 
wavelengths. Moreover, it was hypothesised that UVB-induced apoptosis of 
lesional psoriatic keratinocytes leads directly to clearance of psoriatic plaques.  
 
 
1.8. Study aims  
The overall aims of this study were: 
1. To compare the in vivo effects of clinically effective and ineffective 
wavelengths in psoriatic epidermis. This provides a novel way to distinguish 
which of the many effects of UVB are important in clearing psoriasis, and 
which occur as a non-specific response to UVB irradiation.  
2. To investigate the mechanisms of clearance of psoriasis following 
therapeutic UVB irradiation, and in particular to increase our understanding 
of the role of keratinocyte apoptosis in this process. 
3. To test dynamically whether the rate of apoptosis observed in psoriatic 
epidermis is sufficient to account for remodelling of psoriatic plaques back to 
normal. 
4. To examine the apoptotic response of a range of wavelengths within the 
UVB spectrum to see which wavelength induces the greatest amount of 
apoptosis. If keratinocyte apoptosis is an important mechanism of psoriatic 
clearance, this could potentially indicate a more effective treatment 
wavelength. 
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1.9. Objectives 
1. To obtain ethical approval. 
2. Recruit patients to the study if they had been prescribed narrowband UVB 
for their psoriasis. 
3. Obtain written informed consent from patients. 
4. Calculate MEDs. 
5. Irradiate matched psoriatic plaques on the patients‟ lower back with equi-
erythemogenic doses of UVB. 
6. Biopsy irradiated plaques at defined time-intervals after irradiation. 
7. Analyse biopsies for cellular differences including apoptosis, proliferation, 
and markers of other cell types such as T cell and Langerhans‟ cells. 
8. Confirm the presence of apoptosis by electron microscopy. 
9. Create an interactive mathematical model of normal and psoriatic epidermis  
10. Integrate experimental data into mathematical model and use this as a tool 
to assess the likely impact of the observed number of apoptotic cells on 
overall tissue homeostasis. 
11. Look for early changes in gene expression levels in biopsies of irradiated 
plaques, and assess whether or not genes controlling apoptosis are 
differentially regulated following irradiation with clinically effective UVB 
rather than clinically ineffective UVB. 
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2. Materials and Methods 
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2.1. Volunteers 
    Volunteers were recruited from tertiary referral clinics at the Royal Victoria 
Infirmary, Newcastle-upon-Tyne. All patients had been prescribed narrowband 
UVB for their psoriasis, were given detailed information about the study, and 
gave written permission to be included (appendix B). Ethical approval was 
obtained from County Durham and Tees Valley Research Ethics Committee. 
Each patient had a maximum of four 6mm punch biopsies following irradiation 
to small areas (15mm diameter) of their skin, with specific wavelengths within 
the UVB waveband. 
    Patient demographics were collected including age of onset of psoriasis, 
presence of joint or nail involvement and skin type. A detailed history and 
examination of each patient was performed prior to entry into the trial, and 
clinical response measured using PASI scores taken prior to treatment.  All 
patients were then given their routine UVB treatment course, and PASI 
assessments were made at weekly intervals during the routine weekly 
irradiation UVB treatment. Routine treatment consisted of three times weekly 
whole body exposure to narrowband UVB using a starting dose of 70% of the 
MED. The dose was increased after alternate treatments by 40%, decreasing 
stepwise to 5% by the 18th treatment. 
 
 
2.1.1. Patient recruitment 
Patients were recruited if they met the following criteria: 
 Given informed consent to the study 
 Had chronic plaque psoriasis and had been routinely prescribed  
narrowband UVB treatment 
 Over 18 years of age 
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 Had not used immune modifying drugs, systemic psoriatic treatments, UVB, 
PUVA, sun beds, or received significant exposure to sunlight for three 
months (e.g. sunny holidays etc) prior to inclusion in the trial  
 Had not used topical treatments for two weeks prior to inclusion with the 
exception of emollients 
 
    Patients were recruited to the study sequentially into 1 of 6 groups:  
1. The first group was to establish a time-course of apoptosis following single 
exposure to a medium dose  (2-3 MED) of 311nm and/ or 290nm UVB 
(n=36) 
2. To examine whether apoptosis is detectable following a single low dose of 
311nm UVB (0.75-1 MEDs) which is more frequently used in clinical practice 
(n=11) 
3. To examine whether apoptosis occurs following repeated low dose 
irradiation of 311nm, as occurs in routine phototherapy (n=5) 
4. To examine intra-patient variation 24h following 311nm-irradiation to 
neighbouring matched plaques (n=6) 
5. To examine early gene changes which occur within plaques following 
irradiation with 311 and 290nm UVB (n=6)  
6. To examine the effects of other wavelengths within the UVB spectrum to 
determine whether any of these may cause a greater apoptotic effect, which 
may potentially improve patient treatment (n=18).  
 
    Group sizes were determined according to pilot data obtained, and proof of 
principle. It was previously estimated that approximately three out of five 
patients showed a 311nm-induced apoptotic response above baseline, however 
with ethical approval, group sizes were modified from the original study design 
according to the level of apoptosis seen in the individual patients recruited. 
Furthermore, several of the groups overlap, and patients‟ results were therefore 
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Convenient time 
arranged for 
patient to start 
4-12h later 
2-24h later 
Yes 
No 
Patient routinely prescribed 
UVB for psoriasis 
Patient satisfies inclusion 
criteria for study and gives 
consent to be included? 
Demographic data collected, and MED 
testing for 311nm and 290nm UVB 
MEDs measured and patient given 2-3 
MEDs of a single dose of 311nm (x2) 
or 290nm (x1) to psoriatic plaques on 
lower back. PASI score calculated. 
Patient returns for a biopsy of UVB 
irradiated psoriasis. Biopsy of non-
irradiated lesional psoriasis also taken 
Patient returns again for a further biopsy 
of irradiated psoriasis  
Continues with routine 
treatment until discharged 
Patients PASI checked 
weekly by named 
phototherapy nurse 
analysed together where possible (e.g. most patients had a biopsy 18-24h post 
3 MED 311nm, and this was analysed in the time-course study as well as in the 
subgroup for which they were recruited). 
    The flowcharts below show the patients‟ journey following recruitment into 
each group: 
 
Group 1: Time course of 311nm and 290nm UVB. 
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Convenient time 
arranged for 
patient to start 
24h later 
Yes 
No 
Patient routinely prescribed 
UVB for psoriasis 
Patient satisfies inclusion 
criteria for study and gives 
consent to be included? 
Demographic data collected, and MED 
testing for 311nm UVB 
MEDs measured, and patient given 
0.75, 1, 2 and 3 MED doses of 311nm 
to 4 psoriatic plaques on lower back. 
PASI score calculated. 
Patient returns for 4 biopsies of UVB 
irradiation sites 
Continues with routine 
treatment until discharged 
Patients PASI checked 
weekly by named 
phototherapy nurse 
Group 2:  Apoptotic effect of sub-erythemogenic doses of 311nm UVB. 
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Returns 24h post 
treatment at weeks 
4, 8 and 12. 
Convenient time 
arranged for 
patient to start 
24h later 
Yes 
No 
Patient routinely prescribed 
UVB for psoriasis 
Patient satisfies inclusion 
criteria for study and gives 
consent to be included? 
Demographic data collected, and MED 
testing for 311nm UVB 
MEDs measured, and patients given a 
single 3 MED dose of 311nm UVB to 
psoriatic plaques on lower back. PASI 
score calculated. 
Patient returns for a biopsy of irradiated 
psoriasis.  
Patient starts routine treatment  
Continues with routine 
treatment until discharged 
Patients PASI checked 
weekly by named 
phototherapy nurse 
Patient returns on 3 occasions for a 
further biopsy of irradiated psoriasis  
Group 3: Apoptotic effect of repeated 311nm UVB in clinical treatment 
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Group 4: Intra-patient variation in apoptotic effect. 
Convenient time 
arranged for 
patient to start 
24h later 
Yes 
No 
Patient routinely prescribed 
UVB for psoriasis 
Patient satisfies inclusion 
criteria for study and gives 
consent to be included? 
Demographic data collected, and MED 
testing for 311nm UVB 
MEDs measured and patient given 3 
MEDs of a single dose of 311nm (x 3) 
to different psoriatic plaques on lower 
back. PASI score calculated. 
Patient returns for 3 biopsies of the 
irradiated plaques, and 1 biopsy of un-
irradiated lesional psoriasis.  
Continues with routine 
treatment until discharged 
Patients PASI checked 
weekly by named 
phototherapy nurse 
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Convenient time 
arranged for 
patient to start 
14h later (if less 
than 4 biopsies 
taken already) 
4-18h later 
Yes 
No 
Patient routinely prescribed 
UVB for psoriasis 
Patient satisfies inclusion 
criteria for study and gives 
consent to be included? 
Demographic data collected, and MED 
testing for 311nm and 290nm UVB 
MEDs measured and patient given 3 
MEDs of a single dose of 311nm or 
290nm to 4 psoriatic plaques on lower 
back. PASI score calculated. 
Patient returns for 1-2 biopsies from 
irradiated plaques (311 and 290nm). 
Biopsies of non-irradiated lesional / 
non-lesional psoriasis also taken.  
Patient returns again for further biopsies 
of irradiated psoriasis  
Continues with routine 
treatment until discharged 
Patients PASI checked 
weekly by named 
phototherapy nurse 
Group 5: Early effects of UVB on gene regulation within psoriatic plaques.
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Convenient time 
arranged for 
patient to start 
24h later 
Yes 
No 
Patient routinely prescribed 
UVB for psoriasis 
Patient satisfies inclusion 
criteria for study and gives 
consent to be included? 
Demographic data collected, and MED 
testing for 311nm and 3 of the following 
UVB wavelengths: 296,301,306 and 
320nm. 
MEDs measured and patient given 3 
MEDs of a single dose of each of the 
above wavelengths to psoriatic plaques 
on lower back. PASI score calculated. 
Patient returns for 4 biopsies to 
irradiated plaques.  
Continues with routine 
treatment until discharged 
Patients PASI checked 
weekly by named 
phototherapy nurse 
Group 6: Apoptotic effects of other UVB wavelengths (296-320nm). 
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2.1.2. Patient irradiation 
    Patients had MED testing to narrow-band UVB (narrowband UVB; TL01 
lamp; herein referred to as 311nm) and other wavelengths of UVB used as 
appropriate, on sun-protected non-lesional skin of the lower back. All UV 
irradiation was given at least 3cm from the midline of the vertebral column, as 
the midline is known to be less sensitive to UV (Farr and Diffey 1984) and could 
lead to spurious results. The MED was taken as the lowest dose required to 
induce just perceptible erythema 24h after irradiation with a specific wavelength 
(Gordon, Saunders et al. 1998). A handheld 10 aperture TL01 lamp was used 
for narrowband UVB irradiation. In front of each aperture was a metal grid with 
a regular pattern of holes.  The size of the grid hole varies such that the ratio of 
irradiance between adjacent grids is the square root of two.  This allows the 
patient to be exposed to geometric series of doses with a single application of 
the device. An irradiation monochromator was used for 290, 296, 301, 306 and 
320nm wavelengths, set at a bandwidth at half maximum intensity of 5nm for 
wavelengths of 306nm and below, and 10nm for 320nm (Figure 2-1). Both the 
monochromator and the TL01 lamp had a 10min warm up-time before use and 
output was checked with a radiometer before and after patient exposure. 
 
 
Figure 2-1. Devices used to administer specified wavelengths of UVB. a) 
Showing hand-held TL01 lamp to determine MEDs; and b) A monochromator 
used to administer 290nm wavelength.  
A  
A B 
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    After measuring the MED at 24h, each patient was irradiated with predefined 
multiples of the MED for each wavelength using a 15mm UV guide from a 
monochromator or suitable irradiation source (e.g. handheld narrowband UVB 
lamp). The edges of matched target-plaques were irradiated, along with non-
lesional skin adjacent to each of these (Figure 2-2) so that the erythema 
induced could be objectively measured with the erythema meter. This allowed 
confirmation that patients had received equi-erythemogenic doses of UVB when 
different wavelengths had been used.  
 
   
 
Figure 2-2. Diagram of typical position of UV irradiation within psoriatic 
plaques. Fifteen millimetre areas at the edge of a plaques (red) were irradiated, 
along with adjacent non-lesional skin, which was used as a control to ensure 
equi-erythemogenic doses had been delivered. 
  
Psoriatic plaque 
Psoriasis irradiated with 
290nm and later biopsied 
Non-lesional skin irradiated 
with 290nm then erythema 
measured at 24h 
Psoriasis irradiated 
with 311nm, and 
later biopsied 
Non-lesional skin 
irradiated with 311nm then 
erythema measured at 24h 
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2.1.3. Patient biopsies 
    Six-millimetre punch biopsies were then taken from up to four matched sites 
on the patients‟ back, at pre-specified time intervals between 2-48h post UV 
exposure. A suture was used at each site to aid healing. The patients then 
received their normal UV treatment regime, and the suture was removed a 
week later in the phototherapy department. Previous reports have suggested 
that there may be cellular differences within individual psoriatic plaques, with 
the active edge of a plaque having an increased vascular component 
(Goodfield, Hull et al. 1994), and biopsies were therefore taken from small 
plaques (where the majority of the plaque was removed) or the edge of larger 
plaques. All biopsies were taken from the lower back, at least 3cm from the 
spine. Punch biopsies were snap frozen in liquid nitrogen, mounted in OCT 
(Raymond A Lamb) embedding medium then stored at –80°C until analysed. 
 
 
2.1.4. Immunohistochemical methods 
    Frozen tissue was cut into 6µm sections using a Leica CM 1900 cryostat 
(Leica Microsystems, Milton Keynes, UK), and mounted on APES/ TESPA 
coated glass slides (2% aminopropyltriethoxy-silane in dry acetone). Tissue 
sections were defrosted at room temperature for 15 mins, and fixed. The 
fixation method was optimised for key antibodies using either paraformaldehyde 
(4% in PBS + 1mM NaOH), 100% acetone, 100% methanol or a combination of 
acetone and methanol (1:1) for 10 minutes (see appendix D). A Dako pen 
(Dako, Cambridgeshire, UK) was used to delineate the tissue section on the 
slide. 
    Following fixation, sections were permeabilised with 0.2% Triton X-100 for 10 
mins and blocked with normal goat serum (1:60 dilution, 30 mins). They were 
incubated with anti-active caspase-3 (1:500 for 60 mins, R and D Systems, 
Oxfordshire, UK) at room temperature. Stored biopsies from patients with lichen 
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planus were used as a positive control for epidermal apoptosis. Cells were 
secondarily labelled with goat-anti-rabbit conjugated to Oregon Green 488 for 
45 mins (1:300; Molecular Probes, Paisley, UK).  
    If double labelling was performed, sections were incubated with goat serum 
again for 20 mins, and then labelled with an antibody raised in a different 
species, and incubated with the appropriate secondary flurochrome. Finally, 
Toto-3 (1:7000 for 10 mins; Invitrogen, Paisley, UK) was added as a nuclear 
stain. Between each of the above steps, sections were washed three times with 
Tween 20 (0.05%) in PBS.  Sections were then washed a further three times 
with PBS followed by a rinse with double-distilled water and then ethanol, and 
allowed to air-dry. A coverslip was then fixed in place with Mowiol mounting 
medium (see appendix E). All antibodies, serums and flurochromes were 
dissolved in 2% bovine serum albumin (BSA) in PBS. 
 
2.1.4.1. Identification of Cell Type 
Double labelling was performed with the following antibodies for 45 mins, 
secondarily labelled with Alexa Fluor 568 goat anti-mouse (1:300) secondary 
antibody (where appropriate) (see appendix E). Concentrations of each were 
optimised, and different fixation methods (see appendix D) were tried for each 
antibody to ensure the optimal antibody detection. 
 AE1-AE3 (1:50; Abcam, Cambridge, UK), a monoclonal broad cytokeratin 
marker which identifies cytokeratins 1-7, 10, 14, 15, 16 and 19, but 
excludes simple epithelial markers such as cytokeratin 8 and 18. To ensure 
even staining, cytokeratin 14 (1:200; Novocastra, Newcastle-upon-Tyne, 
UK) was added. 
 Anti CD3 (1:100; Dako, Cambridgeshire, UK), a pan T cell monoclonal 
antibody which is specific to T cells when detected in the skin. It is 
cytoplasmic in immature T cells within the thymus, and becomes membrane 
bound as the cell matures. 
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 Anti CD8 (1:100; Dako, Cambridgeshire, UK), a monoclonal antibody which 
detects the transmembrane glycoprotein CD8. This is present on mature 
cytotoxic/ suppressor T cells, which is the most common type of T cell 
infiltrate in the psoriatic epidermis. 
 Anti CD68 (1:2000; Dako, Cambridgeshire, UK), a monoclonal antibody 
which identifies a 110 kD transmembrane glycoprotein which is highly 
expressed in monocytes, macrophages, Langerhans cells and 
plasmacytoid dendritic cells . 
 Anti langerin (1:500; Beckman, Buckinghamshire, UK): a monoclonal 
antibody specific for Langerhans‟ cells, and expressed on the membrane 
and in cytoplasm of cells within the epidermis. 
 Anti Cd1A (1:50; BD PharMingen, Cambridge, UK); a monoclonal antibody 
to Langerhans‟ cells and other myeloid dendritic cells. 
 MelanA (1:100; Abcam, Cambridge, UK): a monoclonal melanocytes 
antibody recognising the protein MART-1 (melanoma antigen recognised by 
T cells), a subcellular fraction found in melanosomes. 
 Anti Bax (1:500; Axxora, Nottingham, UK): a monoclonal pro-apoptotic 
protein which is over-expressed  in psoriasis (Kocak, Bozdogan et al. 
2003), and up regulated after UV exposure in normal skin peaking in 
expression at 33h (Murphy, Mabruk et al. 2002)  
 Anti-p53 (1:100; Novocastra, Newcastle-upon-Tyne, UK): a monoclonal 
antibody to p53. p53 accumulates in response to DNA damage, and 
induces growth arrest and/ or apoptosis (intrinsic pathway). 
 Anti Ki67 (1:200; Novocastra, Newcastle-upon-Tyne, UK): a marker of cells 
active in the cell cycle. It is detected in G1, S, M and G2, but not in G0. 
Localised to the nucleus.  
 Cyclin B1 (1:200; Dako, Cambridgeshire, UK), which is maximally 
expressed in late G2/M and then degraded during anaphase. 
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 Anti-p63 (1:200; Abcam, Cambridge, UK), which is associated with cells 
with a high proliferative potential, and absent from those undergoing 
terminal differentiation (Parsa, Yang et al. 1999). 
 
 
2.1.5. Microscopy of the epidermis 
    For colocalisation experiments, a Leica TCP SP2 scanning confocal 
microscope was used to visualise cells, using sequential scanning. Oregon 
Green was excited at 488nm with the Argon ion laser using a detection window 
of 497-535, Alexa red was excited at 543nm with the krypton laser set at a 
detection window of 580-620 and Toto-3 excited at 633nm with the Helium red 
neon laser set at a detection window of 645-689. Cells were visualised using a 
x60 oil objective. 
    For biopsy cell counts a BDTM Pathway 850 Bioimaging system was used 
with a x40 objective. This allowed the entire biopsy to be imaged in 2-3 
montages of 9 adjacent images, and allowed all cells within the biopsy to be 
imaged, for counting. The Pathway microscope is a non-laser system that 
utilises dual-mercury metal halide lamps and a series of 16 excitation filters to 
allow fluorescence imaging from 340 to 750nm, therefore fluorescence was 
detected using alexa-488 and cy5 settings for anti-active caspase-3 and Toto-3 
respectively.   
    Volocity 4.01 image analysis software was used to quantify apoptotic cells 
within the epidermis, determine the strength of colocalisation, and to express 
apoptotic cells as a proportion of the total cell count. A region of interest (ROI) 
line was manually drawn around the epidermis, and the following protocol was 
created which allowed automated counting of cells: 
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Find Objects Using SD (select voxels) Intensity (intensities are represented as 
standard deviations from the mean intensity) 
 
Exclude Objects Not Touching ROI 
 
Exclude objects > 1000 µm2 
 
Exclude objects < 50 µm2 
   For caspase-3 activity a maximum of 0.65 apoptotic cells per 1000 nucleated 
epidermal cells was used as the cut-off point for a normal baseline, with 
anything greater than 1.75 positive cells per 1000 defined as convincingly 
positive. This value was chosen as it represents the upper limit of apoptosis 
observed within un-irradiated psoriatic epidermis. 
    To measure the thickness of psoriatic epidermis consecutive measurements 
were made from each biopsy by measuring the maximum epidermal thickness 
including the stratum corneum, as shown in Figure 2-3. 
 
Figure 2-3. Measuring the maximal thickness of the epidermis using 
Volocity software. This allows inter-and intra-patient comparison of plaque 
thickness. 
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2.1.6. Electron microscopy 
    Epidermal sections of 2mm diameter were processed for transmission 
electron microscopy, following fixation in 2% gluteraldehyde in Sorensons 
phosphate buffer, and secondary fixation in 1% osmium tetraoxide. Samples 
were then dehydrated in acetone and embedded in resin before analysis. 
Microscopy was performed using a Philips CM100 TEM with Compstage and a 
high resolution digital image capture. Images were scanned in a sequential 
manner and apoptotic cells identified morphologically by changes including cell 
shrinkage and condensation of chromatin. Cell typing was possible by 
identification of features unique to specific cell types, e.g. keratin filaments and 
hemi-desmosome connections between neighbouring keratinocytes. 
 
 
2.2. Cell culture 
    Primary keratinocytes derived from human skin were obtained from routine 
circumcision procedures carried out within the Newcastle Hospitals NHS Trust. 
Ethical committee approval was obtained, and each patient or their parents 
gave informed consent as appropriate.  
    Skin samples were rinsed in PBS and excess subcutaneous tissue was 
trimmed away. A blade was then used to mark the surface of the epidermis in a 
grid-like manner, and skin was incubated in dispase overnight at 40C. The 
following day, the epidermis was gently peeled away from the dermis, and 
incubated in 5ml of Trypsin at 370C for 5 minutes. Cells were then shaken, 
500µl FCS was added, and then centrifuged at 1250rpm for five minutes and 
washed. Cells were seeded in a 75ml tissue culture flask, with 10ml medium 
(described below); a further 300µl FCS was added to the cells for the first 24h 
of culture to aid attachment to the flask. To grow cells, Epilife® medium 
(Invitrogen, Paisley, UK) was used, supplemented with bovine pituitary extract 
0.2%, EGF (0.2 ng/ml), hydrocortisone (0.18 µg/ml), insulin (5 µg/ml), 
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transferrin (5 µg/ml), penicillin G (50 U/ml) and streptomycin (50 µg/ml). Cells 
were incubated at 37ºC with 5% CO2. 
 
 
2.2.1. Seeding Cells 
    Cells were washed twice with PBS, and detached using trypsin over the 
minimum amount of time required (approximately 10 mins). Trypsin was 
neutralised with the addition of 10ml medium and 1ml FCS, and transferred to a 
universal container. A cell pellet was obtained by centrifugation at 1250rpm for 
five minutes. The pellet was re-suspended in 10ml medium, and cell counts 
were obtained using a haemocytometer. When seeding into 24 well 
sensoplates for UV irradiation, 60 000 cells were allocated per well to allow 
confluency within 48h. Each well was made up to a volume of 400µl with 
Epilife® medium. As Epilife is slightly coloured, medium was temporarily 
replaced with PBS during the irradiation process, to ensure that this did not 
affect the dosing regimen. Cells were used up to and including passage two 
only, as higher passages yielded very variable results. 
 
 
2.2.2. UV Irradiation of Cells 
  Cells were grown to 70-80% confluency and then irradiated with increasing 
doses of UVB (2-10 SED) using either four TL01 lamps (311nm) mounted in a 
wooden ventilated light box positioned 29cm above the irradiation surface or an 
irradiation monochromator for 290nm UVB (set at a 5nm bandwidth).  An SED 
is a measure of effective radiant exposure (section 1.4), with approximately 
three SEDs being equivalent to one MED. The weighted doses used were 20-
100mj/cm2 for each wavelength (total unweighted doses of 20-100mj/cm2 for 
290nm UVB and 350-1750mj/cm2 for 311nm UVB). Spectral irradiance was 
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measured using a Bentham Instruments portable monochromator, calibrated to 
National Physical Laboratory standards, and for 290nm irradiation). For 290nm 
irradiation, a 15mm input optic (attached to a light guide) was positioned directly 
above the cells, which gave a uniform 15mm diameter field of irradiation 
(equivalent to 1 well in a 24-well plate). A calibrated radiometer was used to 
ensure consistent irradiation between experiments. Where different SEDs were 
given to individual wells within a single 24-well plate, wells were covered 
appropriately to prevent irradiation from reaching the cells. The plates used for 
irradiation (Sensoplates, Greiner bio-one, Germany) had black opaque sides to 
each well, which prevent stray UV from being transmitted. A control well was 
included in each experiment. 
 
 
Figure 2-4. Diagram of real-time caspase-3 assay in NHEK cells. (a) The 
caspase-3 substrate enters through an intact cell membrane. If active caspase-
3 is present within the cell, the moiety is cleaved, and the substrate fluoresces 
green in the nucleus. (b) when the cell dies the membrane integrity is lost, and 
PI can enter (cell fluoresces red). The time between green and red 
fluorescence can be used to estimate the rate of keratinocyte apoptosis. 
 
  Following irradiation, NucViewTM 488 Caspase-3 assay kit for live cells 
(Biotium, Cambridge, UK) was added at a concentration of 1μM, to allow 
visualisation of cells undergoing apoptosis. This is a live cell membrane-
permeable fluorogenic substrate which detects caspase-3 activity within cells 
(Figure 2-4). It can be used in real time, and will show the onset of caspase-3 
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activity, but will remain positive after activity has ceased and the cell has died. 
Therefore Propidium Iodide (PI; 1μM) was used as a marker of cell death, 
allowing an estimation of the time that a live cell will remain caspase-3 positive 
for before dying (at which point it would be phagocytosed in vivo). Control wells 
included the addition of a specific caspase-3 inhibitor (supplied as part of the 
Biotium kit), non-irradiated cells, and wells containing either anti-active 
caspase-3 alone or PI alone. Etoposide (5µM) was used as a positive control 
for caspase-3 activity. Total cell counts were obtained at the end of experiment 
by the addition of a membrane permeable dye with a high affinity for dsDNA, 
such as Hoescht 33258 (Invitrogen, Paisley, UK; 45µM) or DRAQ5 (Biostatus, 
Leicestershire, UK; 5µM). Incubation with either of these dyes from the start of 
the experiment (even at the lowest possible concentration for detection) was 
found to enhance both caspase-3 and PI detection in cells after approximately 
4h, indicating that these induce toxicity over time, and this was therefore 
avoided.  
 
 
2.2.3. Live Cell Imaging 
    Live cells were imaged within an hour following irradiation, until a maximum 
of 48 hours post-UV exposure.  A BDTM Pathway Bioimager 850 microscope 
was used with a x20 objective, which was set up to autofocus, and images 
taken in time-lapse every 10-15 mins from each well using a predefined macro. 
Each image consisted of a montage of 9 adjacent images, allowing 
approximately 100 cells to be tracked over time. The cell conditions during 
imaging were kept constant, with the temperature set to 370C, and CO2 at 5%, 
and the cells kept in a darkened environment. 
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2.2.4. Image Analysis 
    An algorithm was developed using Volocity 4.01 software to automatically 
analyse these results, allowing calculation of a median time of caspase-3 
positivity prior to the onset of PI detection (signalling cell death). This was done 
by allowing Volocity to track individual cells over time, and measuring the time-
points of first detectable green fluorescence (caspase-3) and the first detectable 
red fluorescence (PI entry) within each cell. These were subtracted from each 
other to give an estimate of how long cells remain apoptotic for before 
membrane integrity is breached and they die.  
 
 
 
2.3. Flow cytometry 
    Flow cytometric analysis was employed to examine differential susceptibility 
of cells to apoptosis following irradiation with six SEDs of 311nm or 290nm 
UVB. Furthermore, apoptosis occurring within different stages of cell cycle and 
with different proliferative ability (i.e. stem, TA and differentiating cells) was 
examined following irradiation with six SEDs of 311nm UVB. All experiments 
described below were repeated a minimum of three times (and in triplicate 
within each experiment for cultured cells), although numerous similar 
experiments were performed as part of the optimisation process. A BD LSR11 
four colour flow cytometer was used to process the cells, and analysis was 
performed using VenturiOneTM software. 
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2.3.1. Flow Cytometric analysis of cultured cells  
    Primary keratinocytes were grown to 90% confluency in six well plates, then 
incubated with PBS and irradiated as described below. The cell medium was 
changed immediately after this process and cells were incubated with 
NucViewTM 488 caspase-3 substrate (1µM) for 24h. After this time, the 
medium was removed and stored, and the remaining cells were detached from 
each well by trypsinisation. To neutralise the trypsin, FCS was added to the 
cells as previously described and these were centrifuged with their previous 
medium, and washed. PI (1µM) was then added to each sample. Controls 
included an irradiated well with PI alone, and an un-irradiated well incubated for 
4h with caspase-3 substrate and Etoposide (5µM) only.  
    Approximately 30 000 cells were collected for each sample, and analysed 
using VenturiOneTM software. Doublet cells (approximately 5-8% of total cells) 
were gated out, then the proportion of caspase-3 positive and PI positive cells 
were analysed. 
 
2.3.1.1. Comparison of the apoptotic effect of 311nm and 
290nm UVB. 
    Primary keratinocytes were irradiated in 6-well plates with six SEDs of 311 or 
290nm UVB, 24h prior to analysis. For 311nm irradiation, a bank of four TL01 
lamps were used as described in section 2.2.2, and for 290nm UVB the light 
guide was positioned 47mm above to 35mm diameter wells, and this provided a 
uniform irradiation field to the well (total unweighted doses were 20-100mj/cm2 
for 290nm and 350-1750mj/cm2 for 311nm UVB). Three control (un-irradiated) 
wells were used as a comparison for the effects of UVB. The numbers of anti-
active caspase-3 and PI positive cells induced by both wavelengths were 
compared.  
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2.3.1.2. Cell cycle analysis 
    An automated cell cycle analysis on the dead (PI positive) cells. The 
proportion of dead caspase-3 positive cells in the G1, S and G2M phase were 
compared between the irradiated and mock irradiated cells both within 
experiments and between experiments. 
 
 
2.3.2. Proliferation analysis 
2.3.2.1. Cell sorting 
    To identify the scatter location of keratinocytes, and ensure other epidermal 
cell types were not being analysed, cells were analysed according to their 
scatter distribution. Four scatter locations were identified (Figure 2-5) and cells 
were collected from each using a FACSDiva cell sorter. A minimum of 10 000 
cells were collected from each area and allowed to air-dry on slides. These 
were then fixed in methanol: acetone (1:1), stained for markers of cell type 
(section 2.1.4.1), and identified using a BDTM Pathway 850 Bioimaging system. 
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Figure 2-5. Scatter plot showing regions of sorted epidermal cells. Cells 
collected from each area were labelled with markers of cell origin by 
immunohistochemistry, to identify which areas contained keratinocytes, and 
which were cells derived from other lineages. 
 
2.3.2.2. Identifying apoptosis in cells of different 
proliferative potential 
    Fresh human foreskins were divided into two sections and prepared for 
dispase-separation of the epidermis from the dermis. Prior to overnight 
incubation, half of the intact epidermis was irradiated (epidermal-side up) in 
PBS with six SEDs 311nm UVB (TL01 lamp). After 18h cells the epidermis was 
peeled off the dermis and incubated in trypsin for five minutes. The trypsin was 
then inactivated with fetal calf serum and the cells washed twice. The 
keratinocytes were then incubated with PE-CD49f (α6-integrin; BD Pharmingen, 
Oxford, UK) and APC-CD71 (BD Pharmingen, Oxford, UK) for 45 minutes. 
Cells were washed and incubated with FITC-annexin V for 15 minutes 
(Molecular Probes), and 20 000 cells per sample collected for analysis. 
Following initial collection, PI was added and cells re-examined.  
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    Spectral overlap exists between the excitation of PI and PE (Figure 2-6), 
therefore analysing these two dyes together can lead to confusion. For this 
reason, most of the analysis was done without PI. However, it is useful to know 
the proportion of dead cells within each sample, and therefore to partially 
circumvent this problem PI was added after initial analysis, and PI positivity was 
assessed using the Hoescht channel (which will detect only the 1st excitation 
peak of PI; approximately 350nm). All cells which are PI positive can then be 
gated out of the analysis leaving live cells only. This is not ideal however, as PI 
entry is not an all or nothing event, and cells which may have been slightly (but 
not fatally) damaged will contain small amounts of PI (but not enough to be 
gated out as dead cells), and may be falsely analysed as PE positive. 
 
 
 
Figure 2-6. Excitation spectrum of the 4 flurochromes used. Note that PI 
has 2 excitation peaks, the second of which overlaps with PE. Diagram 
modified from the BD flurorescence spectrum viewer 
(http://www.bdbiosciences.com/external_files/media/spectrumviewer/index.jsp) 
 
    Analysis was performed by first gating cells which lie within the region 
consistent with intact keratinocytes. The number of annexin V positive cells was 
compared between irradiated and un-irradiated samples. Expression levels of 
α6-integrin and CD71 antibodies within the cells were examined on a scatter 
plot, and cells with the high levels of α6-integrin  and CD71 expression were 
deemed TA cells, those with high levels of α6-integrin but low CD71 expression 
PI PE APC FITC 
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were deemed putative stem cells, and those with low levels of α6-integrin were 
deemed differentiating cells. The proportion of annexin-V positive cells within 
each of these groups was then compared. 
 
 
2.4. Mathematical modelling 
2.4.1. Modelling environment 
    A model was creating using NetLogo version 4.1, which is an agent-based 
modelling environment. Agent-based modelling can be used to simulate the 
effects of cells (agents) on each other and their local environment, which can 
lead to prediction of higher level behaviour. This theory behind this is that 
complex biological processes are dependent on the regulation of relatively few 
cellular mechanisms (Sun, Adra et al. 2009).  Agent-based modelling allows 
each type of cell to be given a list of instructions and then operate 
independently, allowing the effects of micro-level behaviour to be observed at 
the macro-level. NetLogo (Wilensky 1999) is written in Java and runs as an 
independent application; it can be downloaded as freeware from 
http://ccl.sesp.northwestern.edu/netlogo/download.shtml. Netlogo was 
developed out of StarLogoT in 1999 because of the need to expand the 
language, make it more user-friendly, more powerful and to support the HubNet 
(multiuser participatory simulation environment) architecture. Hubnet allows 
simulations to be run by human interaction rather than just according to a set of 
rules, therefore allowing participation by the user. 
    In NetLogo the „world‟ appears as a grid, the size of which can be determined 
by the user. The grid comprises patches, each of which can be identified by its 
x-y coordinates, and turtles which are the agents that move and interact on top 
of the patches. Each turtle has its own unique identity tag (known as „who‟) 
allowing the user to track the progress of individual turtles using their „who‟ 
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number. All commands are directed specifically at either „the observer‟ (an 
overview of the whole model), the patches or the turtles. The interface allows 
direct modification of turtle/ patch behaviour using buttons, switches and 
sliders, and observation of output using monitors or graphical displays. The 
model can be visualised in 2- or 3-dimensions and can output detailed results 
which can be analysed using Excel.  
    Programming in NetLogo is fairly straight-forward and does not require a 
programming background. Basic commands are used such as „ask‟, „if‟, „set‟, 
„move-to‟, „stop‟ and „die‟ and a series of brackets identifies what each 
command refers to. As the model is dynamic, the program automatically 
calculates an arbitrary measure of time with each unit of time referred to as a 
„tick‟. At the beginning of the model a list of parameters used within the code 
are declared under the headings „turtles-own‟, „patches-own‟ or „globals‟, so that 
the model can correctly assign the parameters as it runs. NetLogo has a useful 
„check‟ facility which can be used to ensure that the code is accurate and all 
brackets are correctly positioned prior to running. This helps prevents the model 
from „crashing‟ and helps the user identify any problem that needs addressing. 
 
 
2.4.2. Components of the model 
    The model is divided into a series of procedures, the first of which is „setup‟ 
which puts all patches and turtles in their initial positions. The „go‟ command 
(which can be accessed as a button from the interface) will then allow 
sequential execution of all other procedures according to the parameters set by 
the user on the interface (Figure 2-7). The model can be stopped at any time 
and restarted by clicking the „go‟ button on the interface or reset by clicking 
„setup‟. 
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Figure 2-7. The interface for the model created in Netlogo. The two buttons 
at the top allow the epidermis to be setup and the programme to be run. There 
are a series of sliders (blue) which allow easy adjustment of parameters, and 
monitors (grey) to visualise what is going on when the model runs. The „ticks‟ at 
the top of the model equate to the number of hours since the simulation began. 
The number of cells present over time is also represented graphically in the 
„populations‟ window. 
     
    Kinetic data describing epidermal homeostasis is not absolute, and it is likely 
that parameters vary substantially both between and within patients and cells. 
To allow exploration of the effects of altering some of these parameters a series 
of sliders are provided on the interface allowing the user to test the effects of 
altering the following (permissible range shown in brackets): 
 The cell cycle time of dividing stem cells (1-500h) 
 The cell cycle time of dividing TA cells (1-400h) 
 The potential number of rounds a TA cell can divide (1-8) 
 The frequency of UV administration (1-96h intervals) 
 The number of UV treatments administered (0-40) 
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 Whether the patches display a normal or psoriatic epidermal phenotype 
initially 
 Whether there has been a “cytokine stimulus” which would trigger an 
increase in the proportion of stem and TA cells actively proliferating (e.g. a 
super-antigen response). Therefore, leading to the development of 
psoriasis. 
 
The following monitors allow quantification of the model, and are also displayed 
on the interface: 
 Number of TA cells present (cycling and non-cycling) 
 Number of differentiating cells present 
 Total number of cells (includes stem, TA and differentiating cells) 
 Number of UV treatments administered 
 Position of basement membrane („1‟ (normal), through to „7‟ (thickest 
psoriasis modelled)) 
 
 
2.4.3. Model assumptions 
The model makes the following assumptions 
 At a specified distance above the dermal papillae, differentiated cells are 
incorporated into the stratum corneum (not represented in the model) 
resulting in a „flat‟ surface to the epidermis  
 Under normal conditions each stem cell divides asymmetrically to produce 
one stem cell and one daughter TA cell 
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 The daughter cell will divide symmetrically for the user-defined number of 
times at the beginning of its life. It will gradually migrate up the epidermis. 
 A gradient arising from the basal layer determines when cells differentiate. 
This was created to be consistent with the pattern of differentiation 
observed with immunohistochemical analysis (Korver, van Duijnhoven et al. 
2006) (Figure 1-5), while keeping the proportion of differentiating: 
proliferating cells consistent with published evidence (Weinstein, 
McCullough et al. 1984; Bata-Csorgo, Hammerberg et al. 1993). 
 Stem cells always remain in the basal layer and do not move. 
 If the actively dividing TA cells become too numerous to fit within the 
specified area for division, the basement membrane stretches (i.e. the rete 
ridges elongate) to accommodate the cells. Conversely, if too few non-
dividing TA cells are within this area, the rete ridges will reduce in length. 
 To create „psoriasis‟ the number of  actively dividing stem cells were 
increased by a factor of four and the number of times a TA cell can divide 
was increased from an average of 4 times to 4.5 times.  
 The model assumes that lesional psoriasis contains twice the number of 
nucleated epidermal cells compared to non-lesional skin, representing 
psoriasis of moderate severity (typical of the patients who are treated with 
UVB), however the model could be used to examine thicker psoriasis; 
which would take longer to clear. 
    Unlike previous models (Grabe and Neuber 2005; Grabe and Neuber 2007; 
Sutterlin, Huber et al. 2009) there is no maximum age specified for individual 
cells, and no cell is destined to spend a set period of time in either the 
proliferating or differentiating compartment. Actively dividing cells are always 
situated on the basement membrane or suprabasal layers, although this area is 
greater in the rete ridges than adjacent to the dermal papillae as it is 
determined by a gradient diffusing from the basement membrane/ dermis 
(Figure 2-8). Several lines of evidence indicate gradients of differentiation 
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markers within epidermis (Ishida-Yamamoto and Iizuka 1995; Martinsson, Yhr 
et al. 2005; Korver, van Duijnhoven et al. 2006). Although the molecular signals 
that drive this process remain to be fully elucidated, the histological pattern of 
induction of keratinocyte differentiation is not consistent with a gradient 
emanating from a fixed distance beneath the stratum corneum, but rather 
indicates a gradient arising from the basal layer. Cells with the highest 
proliferation potential will have greater adhesion to the basement membrane 
and /or other cells of higher proliferative potential (Fuchs 2008), and will 
therefore migrate from the basal layer to the epidermal surface as they age. 
    An in silico gradient is produced by giving each patch in the basement 
membrane an arbitrary value. This is diffused across the epidermal patches by 
allowing each neighbouring patch to „share‟ a proportion of the value assigned 
to a given patch. This spreads over all patches producing a gradient along 
which cells can move. For the purposes of the model, a cut off point was 
chosen whereby cells would be deemed far enough away from the basal layer 
to differentiate. This gradient was kept constant for both normal and psoriatic 
epidermis (Figure 2-8), and was chosen to reflect the in vivo expression of 
differentiation markers such as keratin 10 / S100A proteins seen within normal 
and psoriatic skin (Ishida-Yamamoto and Iizuka 1995; Martinsson, Yhr et al. 
2005; Korver, van Duijnhoven et al. 2006) (Figure 1-5). If the actively dividing 
TA cells become too numerous to fit within the specified area for division, the 
basement membrane stretches (i.e. the rete ridges elongate) to accommodate 
the cells. Conversely, if too few non-dividing TA cells are within this area, the 
rete ridges will reduce in length. 
    Psoriatic epidermis varies according to the severity of disease, and the depth 
of a plaque exists on a continual spectrum from normal to several times thicker 
than normal skin. To reflect this, and to computationally allow the epidermal 
phenotype to remodel from “psoriatic” back to “normal”, the model contains a 
number of “positions” allowing plaque thickness to gradually return to normal. 
The seven positions vary from position „1‟ (normal) to „7‟ (thickest psoriasis 
modelled) (Figure 6-13). The latter allowed the epidermis to expand to contain 
twice the number of cells compared to position „1‟. The stratum corneum is not 
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represented, as the hyperkeratosis seen in psoriasis is an effect of 
hyperproliferation rather than a cause. Although psoriatic skin can clinically be 
thicker than the model allows in vivo, the model aims to represents a typical 
plaque. 
 
 
Figure 2-8. Gradient of patches within the model represented with a colour 
scheme. a) represents normal epidermis and b) represents psoriatic epidermis. 
Two inverted gradients were applied within the model arising from the 
basement membrane; one maps to the pattern of keratin-10 immunostaining 
(green) with a specified threshold determining the onset of keratinocyte terminal 
differentiation; a second gradient contains actively dividing TA cells and stem 
cells (red) and regulates expansion/ contraction of the basement membrane. 
Yellow represents the basement membrane. 
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2.5. Gene Array 
2.5.1. Samples 
    Changes in gene expression were examined in psoriatic plaques at 4h and 
18h post three MEDs of 311nm or 290nm UVB. Six patients (24 samples) were 
initially recruited and had four biopsies each (Table 2-1). Samples were 
analysed without knowing whether the patient would respond to their routine 
treatment or would have high levels of apoptosis on IHC. As the patients 
response to treatment/ apoptotic levels became known it became clear that a 
larger sample number would be needed to extrapolate meaningful results. 
Therefore, a further 24 samples taken from other patients within the study were 
analysed; attempting to make the number of patients in each treatment group 
equal (although in several cases this was not possible as insufficient number of 
biopsies were taken at the 4h time points).  Total numbers of samples within 
each group is shown at the bottom of Table 2-1. 
 
Patients Un-
irradiated 
non-
lesional 
Un-
irradiated 
lesional 
311nm 290nm 
4h 18h 4h 18h 
1       
2       
3       
4       
5       
6       
Overall 3 11 9 11 6 8 
Table 2-1. Patients’ biopsies for gene array studies. Each patient had a 
maximum of four biopsies taken, at least three of which were from lesional 
psoriatic skin. The above design allowed at least three samples to be collected 
for each time-point and wavelength from the initial six patients (24 samples). A 
further 24 samples were later analysed, and the total number of samples for 
each group is expressed. 
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    Frozen tissue was mounted in OCT and kept at -800C as previously 
described. Three to four 35µm sections were cut using a Leica CM 1900 
cryostat, and collected onto glass PEN membrane slides (Leica Microsystems, 
Milton Keynes, UK). The slides were kept at -200C in the cryostat during 
preparation, although local re-warming of a small area of the slide with a finger 
tip was necessary to allow adhesion of each section. Slides were stored at         
-800C until micro-dissection. For each array batch, all sections were processed 
on the same day for both epidermal micro-dissection and also RNA extraction, 
in order to minimise handling variation. 
 
 
2.5.2. Epidermal micro-dissection 
    Slides were kept on dry ice prior to fixation, then dipped sequentially for one 
second into 50ml falcons containing ethanol at the following concentrations: 
100%, 100%, 70%, 50%, then in 0.5% toluidine blue containing 6.1mM 
nitrotetrazolium blue, then ethanol again at 50%, 70%, 100% and 100%. All 
dilutions were made with double distilled autoclaved water. Slides were air dried 
briefly then the epidermis was micro-dissected using a scalpel (with a new 
sterile blade for each sample) on a dissection microscope, and placed in the 
cap of an inverted 0.5ml microcentrifuge tube containing 10µl extraction buffer 
(PicoPureTM RNA Isolation kit, Arcturus Biosciences, USA). Tubes were briefly 
centrifuged then incubated at 420C for 30 minutes, then stored at -800C until 
RNA extraction. 
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2.5.3. RNA extraction 
    Prior to RNA extraction 1µl of Polyinosinic Acid Potassium salt (Sigma, 
Poole, UK; 200ng/ml) was added to each cell extract, to reduce the quantity of 
RNA sticking to the microcentrifuge tube. The standard protocol supplied with 
the PicoPureTM isolation kit was followed as below: 
 The RNA purification columns were preconditioned by pipetting 250µl 
conditioning buffer onto the purification column filter membrane, and 
incubated for five mins at room temperature. The columns were then 
centrifuged at 16 000x g for one min. 
 10µl of 70% ethanol was added to each RNA extract and mixed by pipetting 
up and down. 
 RNA was bound by centrifuging for two mins at 100x g, immediately 
followed by centrifugation at 16 000x g for 30 secs to remove flow through. 
 100µl wash buffer 1 was pipetted into each purification column and 
centrifuged for one min at 8 000x g. 
 100µl wash buffer 2 was then pipetted into each purification column and 
centrifuged for one min at 8 000x g. 
 A further 100µl wash buffer 2 was pipetted into each purification column 
and centrifuged for two mins at 16 000x g.  
 The purification column was transferred to a new 0.5ml microcentrifuge 
tube, and 11µl elution buffer was pipetted directly onto the membrane of the 
purification column, and incubated for one min at room temperature. 
 The columns were centrifuged for one min at 1000x g to distribute the 
buffer in the column, then for a further minute at 16 000x g to elute the 
RNA. The entire sample was then stored at -800C. 
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    Quantity of eluted RNA was measured using a Nanodrop spectrophotometer, 
and RNA quality was checked using a Bioanalyser  (Agilent technologies). Total 
RNA required for each sample was 10-100ng. 
 
 
2.5.4. Array processing 
    Samples were processed using Illumina cDNA-mediated Annealing, 
Selection, Extension, and Ligation (DASL) whole genome array technology. 
This permits RNA profiling of more than 24 000 transcripts per sample using 
partially degraded RNA, allowing frozen tissue sections to be analysed with an 
improved sensitivity. This assay begins by converting RNA to cDNA using 
random primers and annealing the biotinylated cDNA to the DASL assay pool, 
which consists of small (50 base-pair) probes specifically designed to the target 
within the transcripts to be investigated. Oligos are then extended and amplified 
by PCR before being deployed on a HumanRef-8 BeadChip. The latter allows 
eight samples to be processed in parallel, therefore reducing experimental 
variation. These BeadChips have been shown to have high concordance and 
reproducibility (r2>0.86) between hybridisation replicates, with each BeadChip 
having a 30-fold redundancy to increase accuracy 
(http://www.illumina.com/technology/whole_genome_dasl_assay.ilmn). The 
assays were performed on two separate occasions as described as above, 
using  Aros Technologies, Denmark  (http://www.arosab.com/inhouse.htm) and 
Cambridge Genomic Services, UK (http://www.cgs.path.cam.ac.uk/), following 
the steps outlined below (Figure 2-9). 
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Figure 2-9. The sequence of events for RNA profiling with the whole-
genome DASL assay. The above is performed over a three day period; firstly 
involving synthesis and PCR amplification of cDNA, then binding of the PCR 
product and hybridisation to the BeadChip, and finally washing and analysis of 
the array.  Diagram modified from the Illumina website 
(http://www.illumina.com/technology/whole_genome_dasl_assay.ilmn). 
 
 
2.5.5. Array analysis 
    Expression values were derived from importing raw data into GeneSpring GX 
11.0 (Agilent technologies).  Expression values were log transformed (log base 
2) and normalised using quantile normalisation with a baseline transformation 
to the median of all samples.  Batch variability between the two sets of 
microarray data generated were removed using the empirical Bayes method 
implemented in Combat.R (Johnson, Li et al. 2007) prior to analysis. Differential 
expression between groups was performed using the RankProducts package 
(Breitling, Armengaud et al. 2004) in BioConductor (Gentleman, Carey et al. 
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2004). Genes considered to be significantly different between groups were 
selected with a p-value of <0.05 after 100 permutations. GeneSpring GX 
software allowed visualisation of the median and IQR for differentially regulated 
genes and further assesses the likely relevance of the observed fold changes. 
Further analysis was performed using Ingenuity Pathway Analysis (IPA) 8.7 
software and comparisons of gene expression were made within the following 
groups of psoriatic skin: 
1. Untreated lesional v untreated non-lesional 
2. Untreated lesional vs 4h post 311nm irradiation 
3. Untreated lesional vs 18h post 311nm irradiation 
4. Untreated lesional vs 4h post 290nm irradiation 
5. Untreated lesional vs 18h post 290nm irradiation 
6. 4h post irradiation with 311nm vs 290 UVB 
7. 18h post irradiation with 311nm vs 290 UVB 
8. Irradiation with 311nm after 4h v 18h 
9. Irradiation with 290nm after 4h v 18h 
    IPA allows modelling and analysis of gene-to-gene interactions by creating 
pathways which link genes by identifying relationships using mechanisms, 
functions and relevant connections e.g. upstream/ downstream relationships. 
This allows the build up of novel connections which can identify gene pathways 
that may be relevant to the system under investigation. Each of the above 
datasets underwent a functional (biological) analysis to assess the most 
significant biological functions (with a p-value cut-off of 0.05). These networks 
typically contain molecules involved in several pathways and do not have 
directionality, but do show known interactions between the different genes of 
interest. Canonical (classical activation) pathways were also investigated. 
These may be either metabolic or signalling pathways, do have directionality, 
and are not changed upon data input (i.e. based on the literature rather than 
generated in response to inputted data). These canonical pathways are derived 
from journal articles, review articles and text books and KEGG Ligand. 
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    To investigate which relevant genes may be differentially regulated by 311nm 
and not 290nm UVB, the function of the top 200 genes was manually checked 
using pubmed and Entrez Gene, and canonical and biological pathways were 
created using all significantly expressed genes to find associations. 
Furthermore, possible interactions of genes of interest were examined by 
exploring known connections and pathways between these using the My 
Pathway function in IPA. 
 
 
2.6. Real-time PCR 
    Real-time PCR analysis was used to confirm the gene array data. Five of the 
most highly differentially regulated genes identified from the array analysis were 
selected for PCR. The chosen genes represented significant up and down 
regulation of genes following irradiation with either 311nm or 290nm UVB, 
some reaching significance at early time-point (4h and 18h) post irradiation. 
These genes were CDKN1A, DEFB103A, FOSL1, GDF15, and KRT77 with 
GAPDH as a loading control; their sequences are shown in Table 2-2. 
  
Probe Sequence Amplicon Length 
CDKN1A GCAGACCAGCATGACAGATTTCTAC 66 
DEFB103A TGGTGCCTGTTCCAGGTCATGGAGG 93 
FOSL1 CAGCCCAGCAGAAGTTCCACCTGGT 100 
GDF15 CGCCAGAAGTGCGGCTGGGATCCGG 78 
KRT77 GACTACAAGAGCAAGTATGAGGATG 101 
GAPDH CGCCTGGTCACCAGGGCTGCTTTTA 122 
Table 2-2.  Probes used in PCR, showing amino-acid sequence and 
amplicon length.  
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2.6.1. CDNA preparation 
    cDNA was initially prepared from RNA using a SuperscriptTM III first-strand 
synthesis system for RT-PCR, based on the standard protocol shown in Table 
2-3, and was then stored at -200C until real-time PCR analysis 
    Prior to PCR all cDNA was quantified using a Quant-IT ssDNA kit 
(Invitrogen). cDNA was then diluted in water to a standard concentration of 
10ng/μl. 
 
 
Summary of 
Procedure 
Reagents Amount 
per 
reaction 
(μl) 
Temp 
(0C) 
Time 
(mins) 
Denature RNA 
50ng/μl random hexamers 
dNTP 
DEPC-treated water 
5 (max) 
1 
1 
to 10 
65 5 
 4 1 
Anneal To RNA/ primer mix add.. 
10x RT buffer 
25nM MgCl2 
0.1M DTT 
RNaseOUTTM (40 U/μ) 
SuperScriptTM III RT (200 u/μl) 
 
2 
4 
2 
1 
1 
25 10 
cDNA 
Synthesis 
  50 50 
Terminate 
Reaction 
  85 5 
Remove 
RNA 
RNase H 1 37 20 
Table 2-3. Summary of cDNA preparation prior to PCR. 
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2.6.2. Real time PCR  processing 
    TaqMan® Gene Expression Assay probes were purchased from Applied 
Biosystems using probes which span an exon junction and do not detect 
genomic DNA.  A reporter dye (FAMTM) is linked to the 5‟ end of the probe and 
binds to DNA allowing quantification in the PCR reaction. A minor grove binder 
(MGB) is attached to the 3‟ end of the probe and allows an increase in melting 
temperature without increasing the probe length. A non-fluorescent quencher 
dye is also attached to the probe; cleavage by DNA polymerase separates the 
reporter and quencher dyes leading to increased fluorescence by the reporter, 
which only occurs if the target sequence is complementary to the probe. The 
genes shown in Table 2-4 were selected for PCR analysis, and GAPDH used 
as a reference gene for “loading control”. cDNA from 4 different patients was 
examined (where obtained quantities of cDNA were sufficient) for each 
wavelength and time-point, and all experiments were done in duplicate. 
Negative control wells (containing no DNA) were used for each probe to check 
for contamination. 
    A gene expression assay mix was made for each probe by combining the 
following: 
1. 20x probe mix (1μl per reaction) 
2. 2x Taqman universal mastermix (1μl per reaction) 
3. H20 (4μl per reaction) 
    For each reaction a 15μl aliquot of the assay mix was added to well in a 96 
well plate, with 5μl of the prepared cDNA, making a total volume of 20μl per 
well. Standard PCR cycle conditions were run as follows using a Chromo4 
qPCR continuous fluorescence detector: 
1. 500C for 2 minutes 
2. 950C for 10 minutes 
3. 950C for 15 seconds 
4. 600C for 60 seconds 
5. Plate read 
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6. Repeat steps 3-5 x40 times 
7. Incubate at 100C for 10 minutes 
    Where heating DNA to 950C denatures the DNA allowing the two strands to 
separate and cooling to 600C allows primers to anneal to complementary 
strands. The process repeats 40 times, and at each repeat the primer is used 
allowing with the short copy made in the previous rounds of synthesis allowing 
exponential amplification. The reaction will typically plateau around 31-35 
cycles giving over 1.5x109 copies of the amplified DNA. 
 
Gene Samples examined 
 
Expression 
change to be 
demonstrated 
CDKN1A Un-irradiated 
psoriasis 
311nm at 4h 290nm at 4h Increased with 
311nm only at 
4h 
DEFB103A Un-irradiated 
psoriasis 
311nm at 
18h 
290nm at 
18h 
Increased with 
311nm only at 
18h 
FOSL1 Un-irradiated 
psoriasis 
311nm at 4h 290nm at 4h Increased with 
311nm only at 
4h and 18h 
GDF15 Un-irradiated 
psoriasis 
311nm at 4h 311nm at 
18h 
Increased with 
311nm only at 
4h and 18h 
KRT77 Un-irradiated 
psoriasis 
311nm at 4h 290nm at 4h Decreased 
with 290nm 
only at 4h 
GAPDH All samples used for the above 
 
 
 
Baseline 
reading 
Table 2-4. Taqman® gene expression assay probes used to validate the 
gene array assay. The probes were chosen to demonstrate expression 
changes relevant to apoptosis and proliferation effects following irradiation with 
311nm and 290nm UVB compared to un-irradiated psoriasis. 
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A Ct (cycle threshold) value was measured for each reaction, and GADPH was 
used to calculate a fold change correction for each sample. The Delta-Delta Ct 
method was used for analysis (i.e. the difference between the two Ct values), 
after correction of the loading control (Livak and Schmittgen 2001). This 
difference was expressed as a fold change (equivalent to 2Delta-Delta Ct). 
 
 
2.7. Statistical analysis 
    Means and standard error of the mean were used to describe normally 
distributed data, and medians and inter-quartile ranges used for non-normally 
distributed data.  
    The repeatability of measurements of apoptotic cells was calculated using 
Measurement error (intra-patient standard deviation). This test requires 
transformation of the data so that the inter-patient variances are unrelated to 
the magnitude of the measurement. The difference between the biopsies 
measurement and true value is expected to be 1.96 x sw (square root of the 
variance) 95% of the time. This is used to calculate the acceptable range in 
which the intra-patient variation should lie if intra-patient variation < inter-patient 
variation. Significance was determined at a level of p<0.05. Further explanation 
has been published by Bland (Bland 1996). 
    Paired data was analysed with a paired T-test, and non-parametric paired 
data analysed using Mood‟s median. Mann Whitney-U tests were used to 
compare non-parametric data such as the number of apoptotic cells induced by 
311 and 290nm, and a one-way ANOVA was used to compare differences 
between groups with two or more factors. Ordinal logistic regression was used 
to analyse demographic associations in section 3.2.1. All calculations have 
been carried out in Minitab statistical software v15. 
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3. Effects of 311nm and 
290nm UVB on psoriasis in 
vivo 
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3.1. Introduction 
    To distinguish which cellular effects may be important in plaque clearance, 
the in vivo effects of 311nm irradiation were compared to another UVB 
wavelength (290nm) which is known to be clinically ineffective in clearing 
plaques, even at doses of up to 28 times the MED (Parrish and Jaenicke 1981). 
Although clinically ineffective for psoriasis, 290nm UVB causes erythema of the 
skin, allowing equal erythemogenic doses of the wavelengths to be compared. 
Biopsies of treated lesional skin at time-points between 2h and 48h post 
irradiation allowed investigation of any cellular changes in the psoriatic 
epidermis following each wavelength; thereby allowing identification of specific 
effects which may be relevant to plaque clearance. 
    Psoriatic keratinocytes have been reported to be relatively resistant to 
apoptosis in vitro (Wrone-Smith, Mitra et al. 1997), and perhaps as a result, 
keratinocyte apoptosis has not been studied as a possible mechanism of 
plaque clearance in psoriasis. Apoptosis of T cells has been proposed as a 
mechanism of plaque clearance, although this was based on results obtained 
using TUNEL (Ozawa, Ferenczi et al. 1999) which is known to show false 
positives in psoriasis (Wrone-Smith, Mitra et al. 1997),  circumstantial evidence 
that T cells deplete during plaque clearance (Krueger, Wolfe et al. 1995; 
Ozawa, Ferenczi et al. 1999), and observation that direct irradiation of 
peripheral T cells instigates their apoptosis (Novak, Berces et al. 2004). 
However, this chapter clearly demonstrates that significant keratinocyte 
apoptosis occurs in response to the clinically effective wavelength (311nm) but 
not to the ineffective wavelength (290nm), at doses which are relevant to 
clinical practice. 
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3.2. Aims 
 Identify the apoptotic cell types within psoriatic epidermis following 
irradiation with clinically effective UVB (311nm) 
 Determine an apoptotic time-course following irradiation with 290nm and 
311nm UVB in psoriatic epidermis in vivo 
 Measure the apoptotic effect of increasing doses of 311nm UVB on 
psoriatic epidermis 
 Assess whether epidermal apoptosis occurs in psoriatic epidermis during a 
routine phototherapy course 
 Examine the differential apoptotic response following UVB irradiation within 
individual plaques of the same patients 
 Measure the differential effect of 290nm and 311nm UVB on epidermal T 
cells and proliferation markers in vivo 
 Correlate overall PASI improvement with maximal epidermal apoptotic 
levels    
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3.3. Results 
3.3.1. Patient demographics 
    Eighty four patients were recruited overall (54 males and 30 females), with 
one patient dropping out prior to the start of the study due to transport 
problems. The majority of patients who were asked to join the study consented 
to do so, and for those who did not, the reasons given were almost always 
either not having the time to attend for extra appointments or not wanting 
biopsies. No patients had any symptomatic burning due to UVB administered 
for the study, although one patient went on to develop repeated burning during 
his routine course of treatment, resulting in the course being discontinued. Two 
patients developed infection in a biopsy site out of a total of 322 biopsies 
overall, but these settled quickly with antibiotics. No other complications 
occurred. All patients met the study entry criteria described in section 2.1.1, and 
details of their demographic data are given in Table 3-1.  
 
Patient characteristics    Number at   N 
       baseline 
Mean age and SD (years)   45± 15  83 
Median disease activity (PASI) with IQR 9 (7-13)  68 
Number with joint involvement   53 (75%)  71 
Number with nail involvement   45 (63%)  71 
Number of patients with onset of psoriasis  66 (80%)  81 
      below 40 yrs   
Median 311nm MED with range (mJ/cm2) 459 (172-1459)* 83  
Median 290nm MED with range (mJ/cm2) 12.6 (5-50.4)* 36 
Table 3-1. Baseline demographic data and clinical characteristics of 
patients. Key:  SD= standard deviation; IQR= inter-quartile range; N= number 
of patients with details recorded. * Refers to un-weighted dose (equates to 
three MEDs at each wavelength). 
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    Recruited patients were Fitzpatrick skin type 1-5, with the following number 
of patients in each group (Table 3-2). 
 
Skin type Definition Number of 
patients 
1 Burns easily, doesn‟t 
tan 
6 (7%) 
2 Usually burns, 
sometimes tans 
39 (48%) 
3 Sometimes burns, 
usually tans 
26 (32%) 
4 Rarely burns, tans 
easily 
10 (12%) 
5 Naturally pigmented 
skin, tans easily 
1 (1%) 
Table 3-2. Recruited patients according to their Fitzpatrick skin type. The 
majority of patients were skin type 2 and 3. 
 
    Ordinal multiple regression analysis showed no association between the 
number of apoptotic cells from each patient and their age (according to 
decade), sex, skin type, age of onset of psoriasis or nail/ joint involvement 
(p=0.667). Patients given a larger dose of UVB due to higher MEDs had a 
positive trend towards a greater yield of apoptotic cells (p<0.01), although 
results for individual patients were variable (Figure 3-1). 
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Figure 3-1. Relationship between the actual dose of UVB applied to an 
individual plaque (three MEDs) and the resultant number of apoptotic 
cells 24h post irradiation. Note that this data is skewed by a few outliers 
resulting in a low r2 value, although there is a positive association even when 
these are excluded (p<0.05, n=73). There was no significant effect of dose on 
apoptotic response at lower doses (below 900 J/m2); p=0.2, n=66). 
 
 
3.3.2. Induction of apoptosis with 311nm but not 290nm UVB in 
psoriatic epidermis 
   Apoptotic cells were identified by positive anti-active caspase-3 expression, 
and were predominantly located in the lower epidermis. Dermal apoptotic cells 
were rarely seen. Equal erythemogenic doses of UVB which is clinically 
effective in clearing psoriasis (311nm) and UVB which is clinically ineffective 
(290nm) were compared, but only 311nm caused a significant apoptotic 
response in psoriatic epidermis in vivo (Figure 3-2). 
r2=0.17 
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    As expected, the background number of apoptotic cells in un-irradiated 
lesional psoriatic skin (n=29) was very low (median 0.1 cells per 1000 nucleated 
epidermal cells), consistent with previous literature (Laporte, Galand et al. 
2000).  In contrast, a significant increase in the number of apoptotic cells were 
seen in lesional epidermal cells between 16h and 48h following irradiation with 
equally erythemogenic (three MED) doses of 311nm but not 290nm UVB 
(P<0.001) as shown in Figure 3-2 and Figure 3-3. 
 
 
Figure 3-2. Representative confocal image of immunostained lesional 
psoriatic epidermis 18h post in vivo irradiation. Anti-active caspase-3 
(apoptosis) is stained green and Toto-3 (nuclear dye) is blue. Dotted line shows 
the basement membrane. 
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Figure 3-3. Significant apoptosis following irradiation of psoriatic plaques 
with 311nm UVB in vivo. Number of anti-active caspase-3 (apoptotic) cells 
within lesional psoriatic epidermis seen 16-48h following irradiation with either 
311nm or 290nm UVB compared with un-irradiated psoriasis.  Lines show 
medians (12/1000 and 0/1000 epidermal cells for 311nm and 290nm UVB 
respectively) and inter-quartile range. **P<0.01. 
 
 
3.3.3. Identification of apoptotic cell type 
    To identify which epidermal cell type was undergoing apoptosis, a minimum 
of 100 apoptotic cells from at least five different patients 24h post irradiation 
with 311nm were triple labelled with the following monoclonal antibodies: anti-
CD3 (a pan T cell marker), Langerin (specific for Langerhans‟ cells), Melan A 
(specific for melanocytes) and CD68 (a marker of monocytes/ macrophages) 
(Figure 3-4). To identify keratinocytes, the pan keratinocyte marker AE1-AE3 
was combined with CK14 to improve previously suboptimal basal layer staining 
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(Figure 3-5). The majority of apoptotic cells colocalised with keratinocyte 
markers (94.5%), with occasional apoptotic T cells (0.38%) and CD68 positive 
cells (1.7%). Apoptotic melanocytes and Langerhans‟ cells were not observed 
(Table 3-3). Apoptotic keratinocytes were confirmed by transmission electron 
microscopy (n=3) in biopsies taken 24h post irradiation with 311nm but was not 
seen following irradiation with 290nm UVB (Figure 3-6). 
 
Figure 3-4.Colocalisation of apoptotic cells within lesional psoriatic 
epidermis with markers specific for epidermal cell types 24h post 
irradiation with 311nm UVB. Mid Z-section of a confocal image showing 
colocalisation of apoptotic cells (green) with CD3 is a marker for T cells, 
Langerin for Langerhans‟ cells, Melan A for melanocytes and CD68 for 
monocyte/ macrophages. Dotted lines represents the basement membrane. 
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Figure 3-5. Colocalisation of apoptotic cells within lesional psoriatic 
epidermis with markers specific for epidermal cell types 24h post 
irradiation with 311nm UVB. Mid Z-section of a confocal image showing 
colocalisation of apoptotic cells (green) with keratinocyte markers and other 
epidermal cell types (red). 
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Epidermal cell type Colocalisation coefficient with 
anti-active caspase-3 
Keratinocytes 0.945 
T cells 0.0038 
Melanocytes 0 
Langerhans‟ cells 0 
Monocytes/ macrophages 0.017 
Table 3-3. Table summarising the colocalisation coefficients for apoptotic 
cells and the specific epidermal cell markers. Note that a small number of 
cells (3.4%) could not be identified by colocalisation. These cells were 
presumed to be a very late stage of apoptosis, and had lost their surface 
markers. 
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Figure 3-6. Transmission electron micrograph showing an apoptotic 
keratinocyte 24h post irradiation with 311nm UVB in psoriasis. Insert 
shows keratin filaments. Desmosomal junctions between the cells were also 
seen, confirming cells are keratinocytes. 
 
 
3.3.4. Time-course of apoptosis following UVB irradiation 
    Time-course studies showed that the peak time of epidermal apoptosis was 
16-24h post irradiation with 311nm UVB in psoriasis in vivo, although apoptosis 
was detected in significantly increased levels from 8h post irradiation. Low 
levels of apoptosis occurred following irradiation with equal (three MEDs) doses 
of 290nm, but this was not significantly different to un-irradiated psoriasis. 
Furthermore, a comparison was made between 311nm and 290nm UVB, and 
did not show a differential time-course of apoptosis between the two 
wavelengths (Figure 3-7), and at no time points were significantly increased 
numbers of apoptotic cells seen following 290nm UVB irradiation.  
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Figure 3-7. Time-course showing number of apoptotic cells in lesional 
psoriatic epidermis post UVB. Median number of apoptotic cells per 1000 
epidermal nucleated cells (crosses), and inter-quartile ranges shown. Red bars 
represent irradiation with 311nm UVB, blue represents 290nm UVB (note 
median and inter-quartile range is zero at time-points 0-8h, 8-16h and 24-32h) 
and black bar is un-irradiated psoriatic epidermis. Unweighted doses given at 
different time-points were similar (p=0.75, median 1377mj/cm2 for 311nm and 
p=0.83, median 37.8mj/cm2 for 290nm UVB). Significant differences were 
shown between un-irradiated psoriasis and at the time-points identified, where  
* p<0.05, ** p<0.01 following irradiation with 311nm UVB only. 
 
    Apoptotic cells were predominantly located in the basal and suprabasal 
epidermis consistent with an effect on the proliferative compartment. Despite 
the count of apoptotic cells declining after 24h, apoptotic cells still localised to 
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the lower epidermis rather than migrating up to the stratum corneum (Figure 
3-8). This suggests that these cells are being phagocytosed within the lower 
epidermis, and that this process is complete within a matter of hours. Moreover, 
the number of apoptotic cells were counted in patients who had biopsies over 
several time points. Following the peak in apoptosis, the median time for 
number of apoptotic cells to declined by 50% was 2.14h (inter-quartile range 
1.32-6.25; n=11), again suggesting that the cells were being removed within a 
few hours (Figure 3-9). Consequently, in order to show maximal apoptotic 
response, biopsies were taken at 18h-24h post UVB for the remaining parts of 
the study (with the exception of the biopsies for gene array as described in 
chapter seven). 
 
Figure 3-8. Apoptotic cells are located in the lower epidermis between 18h 
and 48h, without appearing to migrate into the upper epidermis. Apoptotic 
cells (green) are located in the basal and suprabasal layers at different time 
points. Figure shows three biopsies taken from a typical individual at three time 
points: a) 18h, b) 24h, and c) 48h post in vivo irradiation with 311nm. Toto-3 
(blue) used as a nuclear dye, and basement membrane shown as white line. 
Arrow shows fragmented apoptotic cells. 
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Figure 3-9. Individual’s time-courses following irradiation with 311nm UVB 
in 11 patients. Timing of the peak number of apoptotic cells varied from less 
than 18h (green) to 24h (red) in different patients. Note the rapid decline in the 
number of apoptotic cells detected with time, consistent with these cells being 
removed from the in vivo epidermis within a matter of hours.  
 
 
3.3.5. Apoptotic effect of UVB in routine treatment 
    Higher doses (three MEDs) of UVB have been used in this study to augment 
the effects of smaller clinical doses, which may otherwise be difficult to detect. 
To test whether the responses observed following erythemogenic doses of 
311nm are representative of lower routine clinical doses, apoptosis was 
measured in matched plaques biopsied 24h following irradiation with single 
doses of 0.75, 1, 2 and 3 MEDs in vivo (Figure 3-10).  As expected, 2-3 MEDs 
of 311nm induced a significantly higher rate of apoptosis than 0.75 and 1 MEDs 
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(p<0.001).  Importantly though, apoptosis induced by 0.75 and 1 MED was 
significantly greater than un-irradiated psoriasis (p<0.001).  
 
 
Figure 3-10. Number of apoptotic cells in lesional psoriatic epidermis in 
10 patients 24h post 311nm UVB irradiation.  Increasing apoptotic response 
is seen with increasing doses of UVB (means of 1.3, 2.1, 9.1 and 14.3 per 1000 
epidermal cells respectively), which is significantly different to un-irradiated 
psoriasis at all doses. Mean and SEM shown. ** p<0.01. 
 
 
    Routine clinical treatment of psoriasis uses repeated sub-erythemogenic 
doses of UVB three times per week for approximately eight weeks. To confirm 
that epidermal apoptosis occurred during low dose repeated irradiation (as in 
clinical therapy), apoptotic cells were counted following biopsies of plaques 
taken 24h following the 4th, 8th and 12th routine treatment (n=5).  Apoptosis 
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was significantly greater (mean of 2.5 cells per 1000 epidermal cells) compared 
to un-irradiated psoriasis (p=0.001; n=29) (Figure 3-11). Linear regression 
analysis did not show a significant correlation between the number of 311nm 
UVB-induced apoptotic cells within the epidermis and maximal plaque thickness 
(p=0.079, r2=0.06, n=43; representing the patients with apoptosis detected 16-
48h post irradiation) following three MEDs of 311nm UVB. 
 
 
Figure 3-11. Apoptotic response in psoriatic plaques following routine 
clinical UVB treatment.  A single three MED dose of 311nm UVB was 
administered to a psoriatic plaque in vivo and biopsied 24h later. This was 
compared to the apoptotic response seen 24h after the 4th, 8th and 12th dose 
during a routine treatment course in the same patients (n=5). One patient 
dropped out after the 4th treatment due to burning.  Mean and standard error of 
the mean shown.  Note the number of apoptotic cells induced by the three MED 
dose was not significantly different to values obtained during routine treatment. 
* P<0.05, **P<0.01. 
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3.3.6. Effects of epidermal thickness on apoptotic response. 
    As described in section 3.3.4, apoptotic cells were predominantly basal or 
supra-basal. The thickness of psoriatic epidermis is very variable both between 
patients and at different stages of the evolution of plaques, and this may impact 
on the proportion of UVB that penetrates down into the lower epidermis. The 
majority of apoptosis seen was observed to be in the rete ridges rather than 
adjacent to the dermal papillae, therefore the maximum epidermal thickness 
(including and excluding the stratum corneum) was measured in up to 12 areas 
per patient (three sites in up to four biopsies per patient), and the mean 
maximal thickness was correlated to the maximum number of apoptotic cells 
observed 18-24h post 311nm UVB irradiation; n=53. There was no correlation 
between plaques thickness and the number of apoptotic cells whether the 
stratum corneum was included in the measurement (p=0.0695) (Figure 3-12) or 
not (p=0.0748). Moreover, there was no correlation between overall PASI 
improvement during routine treatment and initial plaque thickness (p=0.795). 
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Figure 3-12. No significant correlation exists between the maximal 
epidermal thickness of psoriasis (including the stratum corneum) and 
apoptotic response 18-24h after 311nm UVB. Linear regression line shown. 
Note the split axis. n=53. 
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3.3.7. Intrapatient variation of apoptosis in psoriatic plaques 
    Throughout the study, biopsies were taken from the edge of psoriatic 
plaques, and where possible, small plaques were biopsied as there is evidence 
to suggest that plaques have a leading edge (Goodfield, Hull et al. 1994), which 
may behave differently in response to treatment. To test whether apoptosis in a 
single biopsy was representative of other similarly irradiated biopsies taken 
from the same patient, six patients had biopsies taken from different plaques on 
their lower back 24h post irradiation with three MEDs of 311nm UVB. A further 
biopsy was taken from un-irradiated psoriasis in each patient, as a control. No 
apoptosis was seen in untreated psoriasis except in one patient, who had 1.3 
apoptotic cells per 1000 epidermal cells (patient 2) (Figure 3-13). 
 
Figure 3-13. The number of apoptotic cells produced following a single 
three MED dose of 311nm UVB to lesional psoriatic skin in vivo shows 
intra-patient variability but is reproducible. Biopsies from different psoriatic 
plaques within individuals taken 24h post 311nm irradiation, a measurement 
error test showed significantly greater interpatient variation than intra-patient 
variation (P<0.05). Matched un-irradiated psoriatic plaques in each patient did 
not show any apoptosis, confirming no pre-existing apoptosis. 
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    Measurement error testing was used to assess repeatability of the count of 
apoptosis in different biopsies from the same individual. As the counts included 
zero and had a range of variances, all values were log transformed using the 
equation y= log (x + 1). Repeatability is taken as 2.77 x square root of the mean 
variance (Bland 1996), and gave an overall value of 0.58; the difference 
between the three measurements from the same individual was within 0.58 in 
each case, suggesting that any variation in the number of apoptotic cells 
observed between biopsies from the same individual can be explained by the 
expected natural variation within the subject or processing error, rather than 
being a true difference between different plaques within the same individual. 
Therefore, a single biopsy can be assumed to be representative of the patient, 
and any interpatient variability in apoptosis count will be greater than any intra-
patient variability. 
 
 
3.3.8. Effect of 311nm and 290nm on epidermal T cells 
    To assess the effect of UVB on epidermal T cells, the count of T cells present 
in plaques irradiated with 290nm UVB were compared to those irradiated with 
311nm UVB at time points from 4-48h. Patients with paired biopsies following 
irradiation with equal doses of 290nm and 311m taken at the same time-point 
were compared. The variation in number of T cells present ranged from 0.5- 21 
per 1000 epidermal cells. A paired T test showed no significant trend towards 
reduced T cell numbers following 311nm UVB compared to 290nm UVB 
(p=0.129; n=14), and this is illustrated in Figure 3-14. When divided into time 
periods following irradiation the p values were 0.413, 0.787 and 0.179 for        
4-12h, 18-24h and 48h respectively; therefore no significant difference occurred 
at any time point. 
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Figure 3-14. Change in epidermal T cell count at time-points between 4 
and 48h post irradiation with 311 or 290nm UVB in paired plaques in vivo. 
Median and inter-quartile ranges shown. Blue line represents time points 
between 4-8h, red line 18-24h and black line is 48h. Overall, there was no 
significant difference in T cell numbers following either wavelength; p=0.129 
(n=14). 
 
    Overall the average number of epidermal T cells in biopsies taken between 
16h and 48h post UVB irradiation was 4.64 per 1000 epidermal cells, and the 
proportion of apoptotic T cells at these time-points comprised 0.38% of all 
epidermal apoptotic cells (Table 3-3). As the ratio of T cells: keratinocytes is 
1:214 of all epidermal cells, and the ratio of apoptotic T cells: apoptotic 
keratinocytes is 1:249, this suggests that the proportion of T cells undergoing 
apoptosis is similar to that in keratinocytes. Therefore, no preferential apoptotic 
susceptibility has been demonstrated. 
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3.3.9. Effect of 311nm and 290nm on proliferation markers 
   UVB causes cell cycle arrest which may contribute to the therapeutic effects 
of UVB in the clearance of psoriatic plaques. To investigate any potentially 
significant effect on cell cycle, the numbers of epidermal Ki67+ cells were 
counted at time points between 4h and 48h following irradiation with 311nm or 
290nm UVB in matched plaques within the same individuals (n=21).   
    A one-way ANOVA showed no significant difference in the number of Ki67+ 
cells observed following irradiation with 311nm or 290nm compared to un-
irradiated lesional skin (p=0.091 and p=0.339 respectively), although a paired T 
test showed significantly higher Ki67+ counts were observed following 
irradiation with 290nm than 311nm UVB (p=0.026). However, when this was 
subdivided according to time following irradiation (Figure 3-15) there was no 
significant difference in the number of Ki67+ cells at any time-point following 
irradiation with 290nm and 311nm UVB at 4-12h (p=0.727, n=4), 18-24h 
(p=0.105, n=11) or 30-48h (p=0.131, n=6).  The mean numbers of Ki67+ cells 
were 143, 162 and 111 per 1000 epidermal cells for un-irradiated, 290nm and 
311nm UVB-irradiated lesional skin respectively. 
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Figure 3-15. Change in epidermal Ki67+ cell count at time-points between 
4 and 48h post irradiation with 311nm or 290nm UVB in paired plaques in 
vivo. Median and inter-quartile ranges shown. Blue line represents time points 
of 4-12h, red line 18-24h and black line 30-48h. Overall, higher numbers of 
Ki67+ cells were observed following irradiation with 290nm rather than 311nm 
(p=0.026, n=21), although this was not significant when subdivided according to 
time.  
 
 
3.3.10. Correlation of PASI score to measured variables 
    Patients PASI scores were measured at baseline and at weekly intervals by 
a named nurse while attending for their routine treatments, and the median 
percentage PASI score improvement at the end of treatment was 95% (IQR 85-
99); n=66. There was no correlation between baseline PASI score and 
apoptotic response 16-48h following irradiation with 311nm UVB (p=0.386). 
Overall, three patients did not achieve a PASI 50. In two cases the patients 
stopped attending treatment after two or six weeks of treatment respectively 
and in the third case the patient experienced a flare up during the treatment 
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course. PASI 75 was achieved by 56/66 (85%) patients, PASI 90 by 43/66 
(65%) and total clearance by 18/66 (27%) patients. However, 26/66 (39%) of 
patients experienced a flare of their psoriasis during their phototherapy course, 
and 10/66 (15%) did not complete their course (defined as attending for less 
than six weeks of treatment but still improving until this point, or stopped within 
the first 2-3 weeks of treatment). Overall patients attended for a median of eight 
weeks in total (range 2-11 weeks). The best PASI score improvement obtained 
within a one week period was used to calculate patient‟s overall response to 
treatment, as shown in Figure 3-16. 
     
 
 
Figure 3-16. The observed number of apoptotic cells did not predict 
patients’ overall improvement in PASI scores. Green dots represent patients 
who did not complete their prescribed treatment course, and red dots represent 
patients whose psoriasis flared up towards the end of their UVB treatment. 
Linear regression did not show a significant association; p=0.35 (line shown 
represents overall regression). 
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    Linear regression analysis did not show any significant association between 
PASI improvement and caspase-3 levels (p=0.38), however, interpretation of 
this is hampered by the very low number of patients who did not achieve a 
PASI change of less than 50% overall. When analysed by weekly PASI 
improvement, it was observed that patients who exhibited rapid improvements 
in their PASI score during the first month of treatment (i.e. PASI reduced by 
50% or greater within a one week period), were significantly more likely to have 
higher numbers of apoptotic cells (median of 25 per 1000 epidermal cells; 
n=30) compared to gradual responders (median of 7 per 1000 epidermal cells; 
n=27); p=0.013 (Figure 3-17). 
 
 
Figure 3-17. Maximum percentage improvement in PASI score occurring 
within a 1 week period during the first 4 weeks of routine UVB treatment. 
Patients with a PASI improvement of greater than 50% had a significantly 
higher number of apoptotic cells. Median and inter-quartile ranges shown. 
Mann Whitney U test was used for statistical analysis. 
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3.4. Discussion 
    UVB wavelengths of 300-313nm are highly effective at clearing psoriasis 
(Parrish and Jaenicke 1981), and phototherapy is one of the few treatments 
which can induce periods of complete remission of psoriasis after therapy has 
been withdrawn (Dawe, Wainwright et al. 1998). In this chapter the differential 
cellular effects of two wavelengths of UVB (311nm and 290nm) have been 
compared in vivo; both of which cause erythema of the skin, but only 311nm is 
clinically effective in clearing psoriasis. The results clearly show that 311nm 
induces keratinocyte apoptosis, and this is significantly different to the very low 
background levels seen in un-irradiated lesional psoriasis or psoriasis irradiated 
with 290nm UVB.  
    Of the 84 patients recruited to the study, nearly two thirds were male which is 
likely to reflect the ratio of men: women seen during the recruitment period. In 
this patient group 63% had nail involvement, which is slightly higher than the 
expected proportion of effected patients from published data (Reich 2009); 75% 
had joint involvement which is the upper limit of previously estimated levels of 
30-73% of patients (Sadek, Abdel-Nasser et al. 2007; Reich 2009); and 80% 
had manifested psoriasis for the first time below the age of 40, which is broadly 
consistent with previous reports (Henseler and Christophers 1985). The 
majority of recruited patients were skin type 2 and 3 (70%), reflecting both the 
local population and the higher incidence of psoriasis amongst Caucasians. 
Patients were recruited sequentially into one of six groups within the study. 
Further details of how patients were subdivided are described in section 2.1. 
However, most patients had at least one biopsy 18-24h following irradiation with 
three MEDs of 311nm UVB, and where some overlap existed between groups, 
all relevant biopsy results were included in the analysis. 
    Each patient had a maximum of four biopsies taken in accordance with the 
ethical permission obtained for the study. This did cause some limitations for 
the study however, as it was not possible to follow the effects of UVB in detail 
over time. To define a time course, it would be preferable to biopsy non-
irradiated lesional psoriasis, and then re-biopsy the same patient at regular 
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intervals over 48h; however, this would cause maximum disruption for patients 
(in particular as all patients in this study were outpatients), and even if biopsies 
were only taken every 6h, would require nine biopsies from each patient. 
Therefore the results taken from all patients were pooled, but this in itself 
causes problems. Figure 3-9 shows how the rate of apoptosis differs between 
patients, and more importantly the peak in apoptosis also varies from under 12h 
post UVB until 24h or later; perhaps explaining why some patients who have 
been irradiated with 311nm UVB do not appear to have an apoptotic response 
when measured at 18-24h (Figure 3-3). Reasons for these variations are likely 
to be numerous, but may include how actively proliferating the plaques are, and 
the stage of cell cycle that these proliferating cells are in when they are 
irradiated. These results may also contribute to the lack of correlation with 
plaque thickness and overall change in PASI, and these issues are addressed 
in the following chapters. 
    Equal erythemogenic doses of both wavelengths were used throughout the 
study; however it is unclear how far UV penetrates into the epidermis in order to 
induce the erythema response. If this occurs in the lower epidermis, the 
biologically effective dose of UVB reaching the lower epidermis will be 
comparable between wavelengths, but this will not be the case if it is due to a 
superficial response; however, as all plaques are likely to vary in thickness, it is 
difficult to find another way of ensuring equal doses are given. Meinhardt et al 
showed that 314nm UVB penetrates into the lower epidermis approximately 14 
times more than 290nm in forearm skin (Meinhardt, Krebs et al. 2009). If the 
erythema response occurs superficially, it would be likely that 290nm is not 
reaching the target cells in vivo accounting for the differential apoptotic 
response. This has been partially addressed in the next chapter, although 
further work would include irradiation with 14 times the dose of 290nm 
compared to 311nm UVB and examining the variation in apoptotic response. In 
this study however, the effect of penetration of 311nm was examined, and no 
significant correlation was found between the thickness of the epidermis 
(including stratum corneum) and the count of apoptotic cells using linear 
regression. 
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    Previous studies have suggested that keratinocyte apoptosis in normal 
human and mouse skin is first observed 8-12h post irradiation, peaks at 24-48h 
and is undetectable at 60-72h post UVB (Woodcock and Magnus 1976; 
Murphy, Mabruk et al. 2002; Mass, Hoffmann et al. 2003). This study suggested 
that apoptosis in psoriatic epidermis peaks slightly earlier at 18-24h following 
311nm UVB. No evidence was found to suggest that irradiation with 290nm 
UVB induces a different time-course of apoptosis, although biopsies were only 
examined up until 48h post UVB. This aspect has been taken further in chapter 
five, where the time course was more closely examined with in vitro work. 
    Two different methods have been used to confirm that the apoptotic cells 
observed are predominantly keratinocytes, although a small number of 
apoptotic T cells and CD68+ cells also identified. Overall 96.6% of all apoptotic 
cells were identified by cell type; the remaining cells could not be identified and 
are likely to represent cells in the final stages of apoptosis; at this stage cells 
may have lost their surface markers which identify their origin. T cells have 
previously been reported to be apoptotic following UVB irradiation in psoriasis 
(Krueger, Wolfe et al. 1995), and interestingly the relative proportion of T cells 
undergoing apoptosis was similar to that of keratinocytes, suggesting that there 
may not be a differential susceptibility between cells of different origins. 
    Throughout this study patients were given higher multiples of their MED than 
is routinely used in clinical practice. This was done to augment any small but 
relevant response which may be missed using sub-erythemogenic doses. To 
ensure this is relevant to low clinical doses, small groups of patients were 
assessed in a dose response study, and patients having routine UVB treatment 
were also biopsied to assess apoptotic response. In both these groups 
significant levels of apoptosis were detected in contrast to the previous reports 
that psoriatic epidermis is relatively resistant to apoptosis (Wrone-Smith, Mitra 
et al. 1997). It should be noted however, that the conclusions of Wrone-Smith et 
al were based on apoptosis in cultured keratinocytes. More recent clinical 
practice has included the use of 308nm-excimer lasers in clearing psoriatic 
plaques, and these are used effectively at doses of 3-6 MEDs. Although these 
lasers use a monochromatic wavelength slightly below 311nm, they have been 
3-110 
 
shown to be of similar efficacy to both the 308nm and 311nm lamps (Kollner, 
Wimmershoff et al. 2005; Goldinger, Dummer et al. 2006). It can be predicted 
that the epidermal keratinocytes in plaques treated with medium-high dose 
lasers are also undergoing apoptosis, although it was beyond the scope of this 
study to test this hypothesis. 
        There are many factors which influence whether a patient‟s psoriasis will 
respond to UVB treatment, and interestingly the same patients can respond 
well on some occasions and inadequately at other times. This suggests that 
external factors are important in determining clearance, and it is interesting to 
note that in the group of patients in this study, weekly PASI score indicated that 
nearly 40% of all patients experienced a flare in their psoriasis during the 
treatment period. This suggests that some external trigger was stimulating the 
disease, which could have reduced the efficacy of phototherapy treatment. In 
other words, it is important to distinguish treatment modalities that suppress 
disease initiation (or flare) from those that induce clearance. These 
observations suggest that UVB is not effective at preventing disease flare-ups. 
The other obvious confounding issue is patients not attending for all their 
treatments (15%), as they need to attend the department three times weekly for 
a period of 6-8 weeks. Surprisingly, only three patients did not achieve a PASI 
50 by the end of their treatment, and in two cases this as because the patient 
dropped out of treatment and in the third the patient had slowly been improving 
but then experienced a flare-up. This is very encouraging as the treatment has 
been effective, but it does not allow analysis of whether or not the level of 
observed apoptosis may reflect the chance of plaques clearing in response to 
UVB. This study has shown that patients may have a peak in their apoptotic 
response at variable times, and that this level can decline over a few hours. It is 
therefore likely that the peak in apoptotic response is underestimated in many 
patients as the biopsy may have been taken at a suboptimal time. It is therefore 
unsurprising that when a patient has had a low apoptotic response, it does not 
predict whether or not they are likely to clear with treatment. For this reason, 
patients‟ weekly PASI improvement was analysed, and it was found that 
patients‟ PASI improvement was often much greater in one or two weeks and 
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gradual in others. In general, patients often had a moderate level of 
improvement for some weeks then a sudden improvement over a one week 
period. Those who responded with over 50% PASI improvement in score from 
one week to the next had a significantly higher apoptotic score than those who 
did not. This sudden change in PASI may suggest that there is a threshold 
response for apoptosis, or it may indicate that UVB has had another effect such 
as synchronising cell cycle, which may make larger numbers of actively 
proliferating cells susceptible to irradiation if this occurs during specific phases 
of the cycle. Further work is needed to investigate this, but is beyond the scope 
of this thesis. 
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3.5. Conclusions 
The main conclusions from this chapter are: 
 Significant numbers of psoriatic keratinocytes undergo apoptosis in 
response to 311nm UVB, but not 290nm UVB or in un-irradiated lesional 
skin despite similar weighted doses. 
 The time-course of apoptosis following 311nm UVB shows a peak at       
16-24h after irradiation. 
 Individual patients have a very variable apoptotic response, both in terms of 
time course, and also the level of apoptosis achieved. 
 The intra-patient variability in apoptotic response was smaller than the inter-
patient variability.  
 A dose response was seen with increasing doses of 311nm UVB 
associated with higher apoptotic counts.  
 There is a positive relationship between apoptotic response and PASI 
improvement over the first four weeks of treatment, but measured apoptotic 
response cannot be used to predict overall response to treatment. 
 
  
4-113 
 
 
4. Apoptotic effects of other 
UVB wavelengths 
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4.1. Introduction 
    Knowledge of the action spectrum of UVB in the clearance of psoriasis is 
important as it allows optimisation of treatment regimes. Wavelengths of around 
311nm can be highly effective in clearing psoriasis (Coven, Burack et al. 1997; 
Gordon, Diffey et al. 1999; Kirke, Lowder et al. 2007), and narrowband UVB 
lamps (which have a peak output at 311nm UVB) are routinely used in clinical 
practice and are effective in around 70% of patients (Coven, Burack et al. 1997; 
Gordon, Diffey et al. 1999; Kirke, Lowder et al. 2007). A landmark study 
examining efficacy of UVB in psoriasis was done by Parrish and Jaenicke in 
1981, in which they showed that wavelengths between 300nm and 313nm UVB 
were effective, although this work was based on just four patients (Parrish and 
Jaenicke 1981). Over recent years, the 308nm excimer laser has been used to 
effectively clear individual plaques using doses of up to 3-6 MEDs (Menter, 
Korman et al. 2010). Irradiation of matched psoriatic plaques in 15 patients with 
the 308nm excimer laser, 308nm UVB lamp and 311nm UVB lamp has shown a 
similar efficacy over a 10 week period with all three irradiation sources, with a 
mean of 24 treatments required for clearance (Kollner, Wimmershoff et al. 
2005). A further study compared the 308nm excimer laser and 311nm UV lamp 
in 16 patients in an open single blinded right/left comparison trial, and again 
found similar efficacy overall although nine patients responded better to the 
308nm excimer laser and four to the 311nm lamp (Goldinger, Dummer et al. 
2006). Therefore although these treatments are highly effective in clearing 
psoriasis, they clear psoriasis to varying extents in different patients and don‟t 
work at all in some patients. 
    If keratinocyte apoptosis is an important mechanism of UVB-induced 
psoriasis clearance, we may be able to predict which wavelengths are optimal 
for clearing psoriatic plaques in vivo by comparing the apoptotic response 
induced by a single 2-3 MED dose of different wavelengths of UVB. Results 
from chapter three demonstrate a lack of apoptotic response following 
irradiation with 290nm UVB, and a significant apoptotic effect following 311nm 
UVB. Therefore wavelengths were examined for apoptosis following irradiation 
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of psoriatic plaques in vivo at a 5nm interval from 296nm to 311nm as well as 
320nm UVB. 
 
 
4.2. Aims 
 Compare the differential apoptotic effect of 290nm, 296nm, 301nm, 306nm 
311nm and 320nm UVB 
 Identify any demographic factors which may affect which wavelength 
induces maximal apoptosis in individual patients 
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4.3. Results 
    Eighteen patients were recruited to (and completed) this arm of the study. 
Each patient had MEDs calculated for four different wavelengths of UVB.  Four 
matched psoriatic plaques were chosen on the lower back of each patient and 
each was irradiated with a single dose of UVB wavelengths between 296nm 
and 320nm, making up the following total: 
 10 plaques irradiated with 296nm UVB (5nm bandwidth) 
 18 plaques irradiated with 301nm UVB (5nm bandwidth) 
 18 plaques irradiated with 306nm UVB (5nm bandwidth) 
 18 plaques irradiated with 311nm UVB (5nm bandwidth) 
 8 plaques irradiated with 320nm UVB (10nm bandwidth with WG305 
filter to remove unwanted wavelengths below 305nm). 
    Irradiation times varied from 12s (296nm) to 50 mins (320nm). Where long 
irradiation times were required due to high MED readings, all four of the „test‟ 
plaques in these patients were irradiated with two multiples of the MED at each 
dose instead of three, therefore keeping the irradiation times within a more 
acceptable limit for the patient. In total 10 patients therefore received three 
MEDs of 296nm, 301nm, 306nm and 311nm UVB and eight received two 
MEDS of 301nm, 306nm, 311nm and 320nm UVB. A biopsy was taken from 
each plaque 24h later, and this was then analysed for keratinocyte apoptosis. 
Previous results had shown no significant apoptosis 18-24h following irradiation 
of plaques with three MEDs of 290nm UVB (n=26) (section 3.2.2), and this was 
used as a baseline to show whether each wavelength induced significant levels 
of apoptosis.  
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4.3.1. Apoptotic effects of wavelengths between 296 and 
320nm UVB in vivo 
    Compared to the unmatched patients described in section 3.2.2 (n=26), a 
Mann Whitney-U test showed that wavelengths between 301nm and 311nm 
induced significant apoptosis (p<0.001), but those above and below this did not 
(296nm p=0.16, 320nm p=0.39) (Figure 4-1). A regression analysis did not 
show a statistically significant difference in the number of apoptotic cells 
induced following irradiation with 301nm, 306nm or 311nm UVB (p=0.17), and 
there was no association with dose administered and apoptosis overall (Figure 
4-2). Interestingly, different patients responded with higher levels of apoptosis 
following irradiation with different wavelengths, as shown below. No apoptosis 
was detected 24h following irradiation with any of the UVB wavelengths in one 
patient, and in another, only very low levels of apoptosis occurred at similar 
levels following 306nm and 311nm irradiation.  Interestingly the peak 
wavelength for apoptosis induction varied between patients, with 50% (n=9) of 
patients having maximum levels of apoptosis following irradiation with 311nm 
UVB, compared to 17% (n=3) and 22% (n=4) of patients following irradiation 
with 301nm and 306nm of UVB respectively (Figure 4-3). This variation 
between individuals suggests that the differential effect is not due to absorption 
by a chromophore, but other confounding factors (e.g. epidermal thickness) 
may be contributing. 
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Figure 4-1. Significant apoptosis occurs following irradiation with 301nm, 
306nm and 311nm UVB (p<0.001) compared to un-irradiated psoriasis or 
psoriasis irradiated with 290nm. Median and inter-quartile ranges shown.  No 
significant difference was seen in number of apoptotic cells following irradiation 
with either 296nm or 320nm UVB and un-irradiated psoriasis. Patients were 
irradiated with either three MEDs of 296, 301, 306 and 311nm (n=10), or two 
MEDs of 301, 306, 311 and 320nm UVB (n=8). Note the y-axis is a log scale * 
p<0.05. 
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Figure 4-2. No dose response was found between unweighted dose 
administered and apoptosis for the six different wavelengths (p=0.57). 
Note the log scale on the x-axis. 
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Figure 4-3. Individual patients’ action spectra for UV-induced apoptosis in 
psoriatic plaques. Each line represents an individual patients‟ response. Note 
the increasing maximum number of apoptotic cells as the peak wavelength 
increases from 301nm (a) to 306nm (b) and then 311nm (c). Maximal number 
of apoptotic cells were seen following irradiation with 301nm (three patients), 
306nm (four patients) and 311nm (nine patients).  
 
    To explore whether these differences are affected by wavelength 
penetration, the epidermal thickness of each plaque was measured as 
described in section 2.1.5, and related to the quantity of apoptosis measured as 
described below.  
a                                                                b             
c 
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4.3.2. Factors affecting variation in apoptotic response  
4.3.2.1. Consistency of intra-patient plaque thickness  
    To exclude inadvertent plaque selection bias (i.e. thinner plaques being 
irradiated with wavelengths of 311nm UVB, which is known to be effective), 
intra-patient plaque comparisons were made. The mean of 10 consecutive 
measurements of rete ridge depth were compared between the four irradiated 
biopsies taken from each patient. Results are shown in Figure 4-4 and a 
measurement error test showed significantly greater inter-patient variability than 
intra-patient variability (p<0.05) for 13/18 patients, confirming that plaques 
selected for irradiation were of similar thickness in most patients. 
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Figure 4-4. Intra-patient variation in mean epidermal plaque thickness. 
Bars show mean value and standard deviation for four biopsies, with whiskers 
showing maximum and minimum values. Measurement error testing showed 
significantly greater inter-patient variability than intra-patient variability in the 
majority of patients, confirming that plaques were of similar thickness in each 
patient. Patients circled red had at least one irradiated plaque with a 
significantly different epidermal thickness. 
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Figure 4-5. Individual plots for the five patients with significantly varying 
intra-patient plaque thickness. Red lines show apoptosis (error bars show 
standard error of the mean) and black lines show mean epidermal thickness of 
rete ridges (i.e. maximal thickness).  There does not appear to be a correlation 
between thinner plaques and increased rate of apoptosis overall. 
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    In the other five patients, at least one of the four chosen plaques was 
significantly thinner or thicker than the others, but a closer examination showed 
no overall correlation between thinner plaques and apoptosis (Figure 4-5). 
    The observed optimal wavelength for apoptosis induction in individual 
patients did tend towards a positive correlation with epidermal thickness 24h 
after irradiation (i.e. patients with a thinner epidermis had a peak apoptosis-
induction following irradiation with shorter wavelengths of UVB down to 301nm, 
and patients with a thicker epidermis had a peak apoptosis induction 24h 
following irradiation with longer wavelengths up to 311nm), although this was 
not significant overall (p=0.17, Figure 4-6). 
 
Figure 4-6. Correlation between optimal wavelength for apoptosis 
induction and relative epidermal thickness of the irradiated psoriatic 
plaque. A positive correlation was seen, although this was not significant 
(p=0.17, r2=0.13). 
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4.3.2.2. The effect of skin type and dose on optimal 
wavelength for apoptosis induction 
    No significant correlation was seen between skin type and peak wavelength 
for apoptosis (p=0.83) (Figure 4-7) or administered dose and peak apoptotic 
wavelength (p=0.71). 
 
Figure 4-7. No significant relationship was seen between skin type and 
peak wavelength for apoptosis. Linear regression line shown (p=0.85, 
r2=0.003). 
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4.3.2.3. Clinical outcome and optimal wavelength for 
apoptosis induction  
    Unsurprisingly a Mann Whitney U test showed no correlation between end 
PASI improvement (PASI 90) and which wavelength was optimal for induction 
of apoptosis (p=0.431). This is as expected because most patients had 
significant apoptosis seen following irradiation with 311nm even if the apoptotic 
response was higher following irradiation with 301nm or 306nm UVB. However, 
it remains to be seen whether or not these individuals may have had a better or 
quicker clinical response if irradiation was given with a wavelength which has 
been „tailored‟ to plaque thickness. 
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4.4. Discussion 
    The erythema action spectrum of UVB in skin is similar to the action 
spectrum of DNA damage (Setlow 1974)  and non-melanoma skin cancer 
induction (Setlow 1974; de Gruijl and van der Leun 1994), but appears distinct 
from the therapeutic action spectrum of UVB in the clearance of psoriasis 
(Parrish and Jaenicke 1981). Ideally, a large randomised study is required to 
examine the efficacy of different wavelengths of UVB, however, as patients 
have such a large variation in response to treatment anyway (both between 
different patients, and within individual patients following courses of UVB at 
different times) very large numbers of patients would be required to confidently 
show which wavelength is optimal. However, reducing the peak wavelength by 
just 11nm (from 311nm to 300nm) changes an effective treatment into a 
completely ineffective treatment (Parrish and Jaenicke 1981), therefore subtle 
changes in wavelength may have profound clinical importance.  
    In this study, five wavelengths within the UVB spectrum ranging from 296nm 
to 320nm, were used to irradiate localised plaques in 18 patients (four 
wavelengths per patient), and apoptosis was used as a „biomarker‟ of response. 
Interestingly, peak apoptotic response in 50% of the patients was at 311nm, but 
in 17% of patients the peak was at 301nm and in 22% of patients the peak was 
following 306nm UVB. As longer wavelengths penetrate deeper into the 
epidermis, and apoptosis is seen in the lower epidermis, it could be argued that 
the optimal wavelength for apoptosis induction needs to be matched to 
epidermal thickness of the plaque. However, although a positive correlation was 
found between epidermal thickness and optimal wavelength for induction of 
apoptosis, this was not statistically significant. Apoptotic response was also 
independent of irradiation dose given and patients skin type. It is therefore 
unclear from this study why some patients have a differential apoptotic 
response to wavelengths which do induce epidermal apoptosis. One 
explanation could be that this arises due to chance (sample error), and larger 
numbers of patients would be required to reduce this potential bias. 
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    If results shown here are representative of the general population of psoriatic 
patients, it could be assumed that UVB lamps with emission in the 301-311nm 
range and no significant emission of highly erythemal wavelengths < 301nm, 
would induce the most apoptosis, and therefore potentially have the best 
clinical outcome for patients if apoptosis is an important mechanism of psoriasis 
clearance. Broadband UVB lamps used to treat psoriasis may be “selective” 
(UV6), i.e. with little emission at 300nm or shorter wavelengths, or 
“conventional” (TL12), i.e. with significant emission < 300nm. It may therefore 
be predicted that narrowband UVB or selective broadband UVB would be more 
effective for a given erythemal dose than conventional broadband UVB, as a 
greater proportion of the output is within the apoptosis-inducing spectrum. Kirke 
et al found no significant difference in psoriasis clearance in a randomised 
study of 100 patients comparing TL01 and UV6 (Kirke, Lowder et al. 2007). 
Several small half-body studies have shown a significantly greater efficacy for 
narrowband rather than conventional broadband UVB (van Weelden, Young et 
al. 1980; Storbeck, Holzle et al. 1993; Coven, Burack et al. 1997; Walters, 
Burack et al. 1999). These data are consistent with the study hypothesis. 
    Throughout this study it has been assumed that peak erythema occurs      
18-24h following UVB irradiation in psoriatic epidermis, and it has previously 
been demonstrated that the peak in the erythemal time-course is similar in 
normal skin for UVA, UVB and UVC (Diffey, Farr et al. 1987; Farr, Besag et al. 
1988). Ideally an erythema time-course would be obtained at each wavelength 
to exclude a different time-course in psoriatic skin, however when patients were 
seen back for their biopsies at 48h following initial MED irradiations there was 
no suggestion of a delayed erythemal response for any of the tested 
wavelengths. 
    In clinical practice, wavelengths below 300nm UVB do not clear psoriasis, 
and if apoptosis is a marker of clinical response, then this is consistent with the 
results shown here as no apoptosis was seen following irradiation with 
wavelengths below 301nm UVB. Although other studies have not looked at the 
clinical efficacy of wavelengths of around 320nm UVB, these would present a 
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practical obstacle in clinical treatment as the irradiation time is long, and likely 
to be too excessive for patients in the absence of a very marked benefit.    
 
 
4.5. Conclusions 
 Wavelengths between 301nm and 311nm induced apoptosis in psoriatic 
epidermis 
 Differential apoptotic response did positively correlate with epidermal 
thickness, but larger numbers of patients are required to demonstrate 
significance 
 Overall irradiation with UVB of around 311nm appeared to induce 
maximal apoptosis in psoriatic epidermis 
 
  
5-129 
 
 
5. Effects of 311nm and 
290nm on primary 
keratinocytes 
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5.1. Introduction 
    Apoptosis is a dynamic process but is routinely measured by end-point 
assays such as immunohistochemistry and flow cytometry. These assays allow 
a „snap-shot‟ of the process but will not give any information about the rate at 
which apoptosis is occurring. However, this rate is fundamental to 
understanding the overall impact of the apoptosis on tissue homeostasis. For 
example, if 100 apoptotic cells are visualised within the epidermis at a particular 
time-point, the effect on tissue homeostasis would be far greater if each 
apoptotic cell is detectable for just 10 mins (i.e. the turnover of apoptotic cells is 
fast), compared to if they are present for 10h. Therefore, to interpret the in vivo 
data in chapter three, this chapter examines the rate of apoptosis in human 
keratinocytes using time-lapse imaging in vitro. 
    Shorter wavelengths of UVB do not penetrate as deeply into the epidermis, 
and as the majority of UVB-induced epidermal apoptosis occurs in the basal 
and suprabasal layers, this is arguably a reason why 290nm UV-induced 
irradiation rarely elicits any keratinocyte apoptosis. To test this, primary cultured 
human keratinocytes were directly irradiated with either wavelength and the 
apoptotic responses compared. This was assessed with both time-lapse 
imaging and flow cytometry, and gives an understanding of the contribution of 
wavelength penetration to the apoptotic effects seen. 
    Understanding why some cells undergo apoptosis when their immediate 
neighbours remain unaffected may help us understand why patients respond 
very differently to the same treatment. To explore this further, the differential 
susceptibility of cells to apoptosis in different stages of the cell cycle was 
examined, as well as the effect of the cells proliferative potential (i.e. if it is a 
putative-stem cell, TA cell or differentiating cell) on its chance of undergoing 
apoptosis.  
    Together these data support the clinical results described in chapter three, 
and further our understanding of whether or not the quantity of apoptosis seen 
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could be sufficient to directly affect plaque remodelling and clearance of 
psoriasis, using mathematical modelling techniques (described in chapter six).  
 
 
5.2. Aims 
 Compare the apoptotic effects of 311nm and 290nm UVB on primary 
cultured keratinocytes in vitro and define a time-course of apoptosis for 
each of these 
 Investigate the time taken for individual cells to complete the apoptotic 
process 
 Examine the effects of cell cycle and proliferative capacity on susceptibly to 
apoptosis 
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5.3. Results 
5.3.1. Live cell imaging of apoptosis following irradiation with 
311nm and 290nm 
    To investigate the apoptotic effects of increasing doses of UVB on human 
keratinocytes, cells were irradiated with 2-10 SEDs of 311nm or 290nm UVB. 
Cells were initially incubated with DEVD-NucViewTM caspase-3 substrate, PI 
and a nuclear marker (Draq5 or Hoescht 33258) for total cell count. However, 
although SRB (sulphorhodamine) assays, which measure cytotoxicity, had 
shown that these nuclear markers did not induce additional toxicity over the 24h 
incubation period. Live-cell imaging experiments repeatedly showed significant 
cell death in all wells within 4-8h of the onset of imaging. Spectrophotometer 
measurements of the spectral output from the Pathway Bioimager excluded any 
unexpected emissions (in particular in the UV range), and all experiments were 
carried out in a dark environment. Hoechst 33258 (a bis-benzimidazole 
derivative compound), binds to the DNA and requires UV excitation for 
detection. Cells were being imaged every 30-60 mins, and even if very low 
doses of UV are required for excitation, this may in theory contribute to 
apoptosis. In practice however, no difference was noted in the overall number 
of apoptotic cells detected when cells were imaged every 30 mins versus every 
60 mins.  To eliminate any potential confounding effects, experiments were 
carried out by incubating with DEVD-NucViewTM caspase-3 substrate and PI 
alone, then adding the nuclear marker at the end of 24h to count the total 
number of cells present.   
    Repeated experiments (n=3) showed that the cumulative number of apoptotic 
cells reached a plateau by approximately 18h, although cells continued to be 
imaged at 30 min intervals until 24h post irradiation.  Maximal cumulative 
apoptotic response occurred after irradiation with six and eight SEDs of 311nm, 
with medians of 49% (inter-quartile range 44- 53%) and 55% (inter-quartile 
range 52- 58%) respectively (Figure 5-1). However, examining each of these 
doses in isolation showed that higher doses of 311nm or 290nm UVB (6-8 
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SEDs) induced apoptosis earlier than lower doses (2-4 SED) (Figure 5-2 and 
Figure 5-4), with an overall EC50 of 14.5h and 16h respectively (n=3), although 
these were not significantly different at the 95% confidence interval. The 
highest dose of 311nm used, 10 SEDs, was not as effective at inducing 
apoptosis as irradiation with 8 SEDs (p<0.001), although there was no 
significant difference in the percentage of PI+ cells following 8 and 10 SEDs 
(p=0.591), suggesting that cells may be undergoing necrosis following the 10 
SED dose.  
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Figure 5-1. Cumulative apoptosis in NHEKs is maximal following eight 
SEDs of 311nm at 18-24h time-points. A membrane-permeable caspase-3 
substrate and live cell imaging was used to detect the onset of apoptosis in 
normal human epidermal keratinocytes (NHEK). Minimal apoptosis was seen in 
un-irradiated cells, following two SEDs of UVB and when a specific caspase-3 
inhibitor was incubated with irradiated cells. Median and inter-quartile ranges 
shown for hourly time-points between 18 and 24h in cells derived from three 
patients. A significant difference in the cumulative proportion of apoptosis was 
seen between indicated doses and sham irradiated cells (*) or irradiated cells 
incubated with caspase-3 and inhibitor (♦) (p<0.05).   
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Figure 5-2. Apoptosis occurs following irradiation with 311nm UVB in 
primary foreskin derived keratinocytes.  A membrane-permeable caspase-3 
substrate and live-cell imaging was used for detection of onset of apoptosis in 
normal human epidermal keratinocytes (NHEK) between 4 and 24h. Cumulative 
percentage of apoptosis following irradiation with increasing doses of 311nm 
shown. Note the earlier onset of apoptosis with doses causing higher overall 
apoptotic effect. 
 
    Irradiation with 290nm showed maximal cumulative apoptosis following 
irradiation with eight SEDs at the 24h time-point (Figure 5-3), which peaked at 
approximately 24h (Figure 5-4). The cumulative percentage of apoptotic cells 
induced by irradiation with 311nm and 290nm (Figure 5-1and Figure 5-3) were 
compared at each dose, and no significant difference (p<0.05) was found 
between the two wavelengths at each dose using a Mann Whitney U test. 
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Figure 5-3. Cumulative apoptosis in NHEKs is maximal following eight 
SEDs of 290nm at 24h. A membrane-permeable caspase-3 substrate and live 
cell imaging was used for detection of onset of apoptosis in normal human 
epidermal keratinocytes (NHEK). Minimal apoptosis was seen in un-irradiated 
cells, and when a specific caspase-3 inhibitor was incubated with irradiated 
cells. Median and inter-quartile ranges shown for a single 24h time-point in cells 
derived from three different patients. A significant difference in the cumulative 
proportion of apoptosis was seen between indicated doses and sham irradiated 
cells (*) or irradiated cells incubated with caspase-3 and inhibitor (♦) (p<0.05).   
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Figure 5-4. Apoptosis occurs following irradiation with 290nm UVB in 
primary foreskin derived keratinocytes.  A membrane-permeable caspase-3 
substrate and live cell imaging was used for detection of onset of apoptosis in 
NHEKs. Cumulative percentage of apoptosis following irradiation with 
increasing doses of 290nm UVB shown. Note the earlier onset of apoptosis with 
doses causing higher overall apoptotic effect. 
 
5.3.1.1. The duration of apoptosis in individual cells 
    Over 300 cells from three separate experiments were automatically tracked 
using Volocity 4.01 software, and individually analysed to calculate the time 
between the onset of caspase-3 fluorescence, and PI entry into the cell. As 
shown in Figure 5-5, there was considerable variation in cellular response. The 
duration of apoptosis prior to loss of cell membrane integrity ranged from less 
than 10 mins to over 9.5h, and was randomly distributed. Analysis of each 
individual experiment and the results from all three experiments combined gave 
a median time of 20 mins for the onset of caspase-3 activity until breach of 
membrane integrity, however 28% of cells had completed the apoptotic 
process, turning from green to red fluorescence, in less than 10 mins, the 
minimal time-frame imaged. 
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Figure 5-5. Time taken for apoptotic cells to die following the onset of 
caspase-3 activity, induced within the first 24h following six SEDs of 
311nm UVB. Three hundred cells are shown here (100 from each of three 
separate experiments). The median time of apoptosis was 20 mins in each 
separate experiment and 20 mins overall, (inter-quartile range 10-70 mins). 
 
 
5.3.2. FACS analysis of apoptosis following irradiation with 311 
and 290nm 
    To support the theory that lack of 290nm induced apoptosis in vivo may be at 
least in part, due to reduced penetration of 290nm compared to 311nm, flow 
cytometry was also used to compare the proportion of apoptotic cells induced 
by direct irradiation of primary keratinocytes. Cells were then incubated with 
DEVD-NucViewTM caspase-3 substrate and PI for 24h in the dark, thus any 
augmentation of apoptosis induced by the imaging process of the Pathway 
were eliminated (section 5.3.1). Figure 5-6 shows a result from a representative 
experiment, and although both 311nm and 290nm UVB caused a significant 
increase in the proportion of apoptotic cells observed (Figure 5-7), the 
difference between the two wavelengths was not significant with repeated 
experiments (p<0.05). 
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Figure 5-6. Comparison of the apoptotic effects of 290 and 311nm UVB 
24h irradiation of NHEKs.  Flow cytometry scatter plots showing that 
irradiation with 290nm UVB induces a greater proportion of apoptotic (caspase-
3+) and dead (PI+) cells than 311nm, at 24h. Cells in top left quadrant are early 
apoptotic, and those in the top right quadrant are late apoptotic. 
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Figure 5-7. Comparison of the apoptotic effects of 290nm and 311nm UVB 
24h irradiation of NHEKs versus sham irradiated cells. The proportions of 
apoptotic cells detected by flow cytometry are compared. Each experiment was 
repeated in triplicate, and the average of these are shown (n=3). No significant 
difference was observed in apoptosis following irradiation with 290nm versus 
311nm UVB (p=0.44), although these wavelengths were both significantly more 
apoptotic than sham-irradiation (p<0.05). 
 
 
5.3.3. Effects of cell cycle on susceptibility to apoptosis 
    One explanation for the observed variation in the rate and time of onset of 
apoptosis following UVB irradiation could be that cells have differential 
sensitivity to apoptosis in different stages of the cell cycle. To investigate this 
further, PI+ /caspase-3+ cells (late stage apoptosis) were analysed 24h after 
irradiation with 311nm UVB and the number of cells in the G1, S and G2M 
phases of the cell cycle were compared to un-irradiated cells. Figure 5-8 shows 
a significantly greater number of cells die in G2M following UVB, with a similar 
number of cells dying in G1 and S phase as un-irradiated controls. 
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Figure 5-8. A greater number of cells undergo apoptosis in G2M. Primary 
keratinocytes were sham irradiated or irradiated with 311nm UVB, 
incubated with caspase-3 and PI, and analysed by flow cytometry at 24h. 
Analysis of the caspase-3+ dead (PI+) cells showed a significantly greater 
proportion of cells died in G2M compared to G1 or S phase following 311nm 
irradiation but not sham-irradiated cells. Mean ± SEM shown.  *P<0.05.  n=3 
with each experiment repeated in triplicate. 
 
 
5.3.4. Effects of proliferative potential on susceptibility to 
apoptosis 
    To determine whether cells of differing proliferative potential had altered 
susceptibility to apoptosis, intact normal epidermis was irradiated ex vivo, and 
analysed at 24h for apoptotic stem, TA and differentiating cells. As the 
epidermis comprises more than just keratinocytes, and the scatter of epidermal 
cells showed distinct clustering, cells were initially sorted (as shown in Figure 
5-9) according to their scatter distribution and then analysed by 
immunocytochemistry using markers for keratinocytes, T cells, melanocytes, 
and Langerhans‟ cells. Material with a very low forward scatter was cell 
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fragments/ debris and excluded from further analysis (see Figure 5-9). 
Keratinocytes were found in all areas, and comprised a mean of 99% cells in 
areas 1, 98% in area 4, 86% in area 2 and 9% in area 3. Melanocytes were 
seen in areas 2 (2%), 3 (5%) and 4 (2%), CD3+ T cells were confined to area 1 
(<1%), and CD1a+ Langerhans‟ cells were not seen. The majority of cells in 
area 3 could not be identified with the above epidermal markers, and were also 
negative for Ki67, a marker of cell proliferation. It was therefore assumed that 
these cells are likely to be dying and had lost their original cell surface markers. 
Area 2 was not present in over 50% of the epidermis samples studied. These 
data were used to inform gate locations in the experiments described below 
with areas 2 and 3 excluded from analysis. 
 
 
Figure 5-9. Cells were harvested from fresh intact human epidermis and 
isolated by cell sorting according to their scatter profile. Analysis of the 
scatter distribution of cells was performed to ensure that keratinocytes could be 
identified. Cells showed distinct clustering on the SSC (side scatter) and FSC 
(forward scatter) indicating different sizes.  Cells clustering on the far left were 
identified as debris. A sample of cells from each cluster (1-4) was isolated by 
cell sorting and further analysed to identify the cell types at each scatter point.  
n=3. 
5-142 
 
    Apoptotic keratinocytes (Annexin V+) were subdivided according to their 
expression of proliferative markers, α6-integrin (CD49f; positive in cells of 
proliferative potential, but not differentiating cells) and transferrin (CD71, 
positive in TA cells but not stem cells). At least 20 000 cells were collected and 
the change in number of apoptotic putative-stem, TA and differentiating cells 
between sham-irradiated and 311nm-irradiated epidermis was compared at 
24h. Figure 5-10 shows that there was an increase in the total number of 
apoptotic cells in each compartment following 311nm UVB, but this was most 
noticeable for TA cells, which accounted for the majority of Annexin-V+ cells 
(Figure 5-11). When each compartment was analysed individually, 20% of TA 
cells were found to be apoptotic, in contrast to 13% of stem cells and 9% of 
differentiating cells (Figure 5-12). However, these results represent a „snap-
shot‟ of what is occurring in the epidermis 24h after irradiation ex vivo, and do 
not take into account the fact that many of these cells are dividing in vivo, and 
therefore many of these cells would have already been replaced 24h after an 
epidermal insult.  
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Figure 5-10. Apoptosis induced by 311nm UVB occurs in cells of all 
proliferative potential. Flow cytometric analysis of the apoptotic effect of a 
single six SED irradiation of 311nm UVB on normal human skin ex vivo.  
Keratinocytes were harvested from fresh skin 18h after irradiation and stained 
for apoptosis (Annexin-V-FITC), and markers of proliferative potential; CD49f-
PE and CD71-APC. Putative stem cells were identified as CD49f+ APC – (blue 
gate), TA cells as CD49f+ APC + (orange gate), and differentiating cells as 
CD49f – (aqua gate). The top left panels show all the cells, and the gate of 
nucleated cells (A) was used for the analysis. The top middle and right panels 
show the actual number of apoptotic cells, and differential expression of 
proliferative markers from all the nucleated cells gated in A. The lower panels 
show that actual numbers of apoptotic cells according to the expression of 
proliferation markers. (a) Representative example of sham irradiated epidermis, 
and (b) skin irradiated ex vivo with six SEDs of 311nm UVB in the same patient.  
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Figure 5-11. The majority of apoptotic cells are TA cells.  Apoptotic cells in 
irradiated epidermis were divided into three categories according to their α6-
integrin/ transferring expression, and the proportion of cells in each group is 
shown here. Stem cells (α6-integrin+/ transferrin-) accounted for a mean of 7%, 
TA cells (α6-integrin+/ transferrin+) 88%, and differentiating cells (α6-integrin-) 
for 5% of all Annexin-V+ cells. A significantly higher number of apoptotic cells 
expressed surface markers consistent with TA cells (p<0.001), rather than stem 
or differentiating cells. 
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Figure 5-12.  Cells of differing proliferative potential (proliferative 
compartments) have a similar susceptibility to apoptosis following UVB-
irradiation ex vivo. The increase in the actual number of apoptotic cells within 
each compartment was compared following a single six SED dose of 311nm 
UVB and sham-irradiated controls, and expressed as a proportion in each 
experiment (n=3).  Mean and standard error of the mean are shown. There was 
no significant difference between the three groups (p=0.51). 
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5.4. Discussion 
    These experiments indicate that 6-8 SEDs of both 311nm and 290nm UVB 
induce greater total apoptosis and an earlier onset of apoptosis than lower 
doses. The latter may be because apoptosis is occurring in response to a 
„threshold‟ level of damage accumulating in cells, and it would therefore follow 
that cells exposed to higher doses of UVB should accumulate DNA damage 
faster (Li and Ho 1998). It was also observed that the highest dose of UVB 
used (10 SED) appeared to induce less apoptosis than 6-8 SEDs in both 
wavelengths, although a similar proportion of cells were PI+  indicating that 
cells may be dying via other pathways e.g. necrosis. The data presented here 
demonstrate by two different methods: live cell imaging and flow cytometry, that 
311nm and 290nm induce a similar degree of apoptosis in primary (monolayer) 
human keratinocytes. This suggests that when equal erythemal doses of these 
wavelengths reach a cell they can induce similar apoptotic effects when 
penetration is not a confounding factor. In normal forearm skin, 290nm has 
been shown to penetrate into the lower epidermis approximately 14 times less 
than 314nm (Meinhardt, Krebs et al. 2009).  This suggests that differential 
penetration of 290nm and 311nm UVB contributes, at least in part, to the 
differences in number of apoptotic cells observed in psoriatic epidermis after 
290nmand 311nm irradiation. 290nm UVB clearly penetrates sufficiently to 
induce DNA damage (Setlow 1974) and non-melanoma skin cancer (Setlow 
1974; de Gruijl and van der Leun 1994).  Indeed, evidence suggests that 
293nm is a more potent inducer of non-melanoma skin cancer in humans than 
longer UVB wavelengths, although this data is extracted from mouse data (de 
Gruijl and van der Leun 1994) , suggesting that differential penetration may not 
be the only explanation for our findings or a different chromophore is involved. 
    These in vitro studies were performer in normal human keratinocytes derived 
from neonates/ children. Ideally adult psoriatic keratinocytes would have been 
studied, but successful culture psoriatic keratinocytes remains difficult; this has 
yet to be achieved within our laboratory. Culture of adult keratinocytes was 
performed however, but this yielded very few stem cells and results obtained 
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were extremely variable. All experiments were therefore carried out using 
donations from neonates/ children. 
    Toxicity of live-cell nuclear dyes over time is an under-reported phenomenon, 
but is known to occur due to the formation of oxygen-dependent free-radicals, 
generated during the light-induced excitation of nuclear dyes with surrounding 
cellular components (Frigault, Lacoste et al. 2009). The primary purpose of 
using a nuclear dye in live-cell imaging is to provide a reliable cell marker for 
auto-focussing over a prolonged time period. Without a nuclear marker, the 
auto-focussing had to be dependent on PI, as minimal caspase-3 activity was 
detectable for the first 6-8h. This resulted in suboptimal measurement on 
occasions as the image was sometimes out of focus. The secondary reason for 
using a dye was to count the total number of cells imaged within a montage, 
allowing the proportion of apoptotic cells to be calculated. To contend with the 
latter issue, the dye was added at the end of 24h to allow accurate cell counts. 
As exclusion of these dyes until the end of the experiments resulted in a stable 
environment with only very low levels of apoptosis occurring in non-irradiated 
controls, it was concluded that both Draq-5 and Hoescht 33258 become toxic to 
cells when combined with the visible light or UV used to measure fluorescence 
over time. 
    The data showed a wide variation in the time for a cell to turn caspase-3 
positive until its membrane was breached, indicating cell death. Cells are more 
likely to undergo UV-induced apoptosis whilst in G2M of the cell cycle. Arguably 
cells may be more susceptible to apoptosis if they are already in G2M and may 
therefore complete the apoptotic process quicker in this situation. Alternatively, 
cells may get damaged at any stage of the cell cycle and start the apoptotic 
process, but continue cycling and only die when they reach G2M. These 
experiments only addressed late stage apoptosis as PI was used to analyse the 
cell cycle. Various techniques were used to fix all cells prior to analysis 
(including freezing in 100% methanol, permeabilising with 0.5% triton X and 
fixation with 3.75% formaldehyde) to allow inclusion of early stage apoptosis in 
the analysis (using a live -dead cell marker to distinguish early and late 
apoptosis), however analysis was hindered by poor PI entry with all of these 
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methods. Further studies are needed to address this, but are beyond the scope 
of this thesis.  
    The cell sorting experiments (Figure 5-9) showed that the majority of the 
epidermal cells isolated had cell surface markers consistent with keratinocytes 
as expected, and that the purest keratinocyte population is located in areas one 
and four. Only cells from these areas were therefore analysed. In 2010 we 
currently still do not have any reliable stem cell markers for the human 
epidermis. However, evidence exists to suggest that proliferating human 
keratinocytes express high levels of α6-integrin and these can further be 
subdivided into those expressing high levels of transferrin (TA cells) and those 
with low levels (putative stem cells) (Tani, Morris et al. 2000; Youn, Kim et al. 
2004; Hayashi, Yamato et al. 2008). However, cells express these markers as 
part of a continuum rather than all or nothing expression. For this reason, 
analysis of putative stem, TA and differentiating cells was performed by 
examining the cells which fitted most neatly into each category, rather than 
trying to subdivide all cells. Surprisingly only a small proportion of the cells 
isolated by flow cytometry were classified as differentiating cells, although the 
literature suggests that 40- 60% of all epidermal cells are differentiating 
(Weinstein, McCullough et al. 1984; Bata-Csorgo, Hammerberg et al. 1993). It 
is possible that differentiated cells may be differentially susceptible to cell 
damage during trypsinisation, or that these larger cells undergo higher levels of 
shear stress during centrifugation, resulting in a higher proportion of these 
larger cells fragmenting, and are therefore not included in the analysis.  
    DEVD-NucView caspase-3 substrate allowed more accurate counting of 
apoptotic cells over a prolonged period as this is freely membrane permeable 
and cells retain this marker even after death. However, the fluorescence of this 
marker has a wide excitation spectrum, and it is therefore not suitable for use 
with other fluorescent markers such as PE and APC (which were used here to 
delineate proliferative potential of cells). Therefore this was substituted by 
Annexin V in further experiments which binds to phosphatidyl serine and has a 
more distinct excitation spectrum. During early apoptosis and necrosis, 
changes occur within the plasma membrane as phosphatidyl serine 
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translocates from the inner to outer leaflet of the lipid bilayer. However, in 
contrast to necrosis, the cell membrane remains intact during apoptosis, 
therefore Annexin V in combination with a marker of cell membrane integrity 
can distinguish apoptosis from other methods of cell death. As a result, dead 
(PI+) Annexin V+ cells were excluded from analysis resulting in a type 2 bias, 
i.e. any dead cell that had previously undergone apoptosis was discounted. 
    In all, this chapter shows for the first time that UVB induced keratinocyte 
apoptosis takes a median time of just 20 mins to complete, and that a wide 
intracellular variation was seen. Reasons for this variation were explored. 
Altogether, these results can be integrated with the in vivo data obtained in 
chapter three to inform the mathematical model described later (chapter six). 
 
 
5.5. Conclusions 
 Both 311nm and 290nm of UVB induce similar amounts of apoptosis in 
primary human keratinocytes using weighted equally erythemogenic doses. 
This suggests that poorer penetration of 290nm into the lower epidermis 
may account, at least in part, for the difference in apoptotic effect observed 
in vivo when skin is irradiated with these two wavelengths. 
 Draq5 and Hoescht 33258 are toxic to primary keratinocytes over time 
when repeatedly exposed to visible light or UV during imaging. 
 The median rate of UVB-induced apoptosis in primary keratinocytes is 20 
mins, with a large intercellular variation which may reflect different cell cycle 
stage of DNA damaged cells. 
 The majority of UV-induced apoptotic cells are TA cells, although a similar 
proportion of the putative stem cell and TA cell population are induced into 
apoptosis by 311nm UVB. 
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6. Mathematical modelling of 
psoriatic epidermis 
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6.1. Introduction 
    Although the preceding chapters showed that keratinocyte apoptosis occurs 
in psoriasis following the clinically effective but not the ineffective UVB 
wavelength, the overall relevance of this to clearing psoriasis was not directly 
addressed. Mathematical modelling allows dynamic investigation and testing of 
the experimental data to determine whether they may be sufficient to directly 
explain the observed clearance in patients.  
    A mathematical model of normal epidermis was created using a stochastic 
agent-based modelling environment as previously described (section 2.4.1). 
Until now, no dynamic in silico model of psoriasis development has been 
described, but development of such a model has allowed exploration of the 
contribution of specific quantifiable parameters (such as the analysis of cell 
cycle time for both stem and TA cells and the proportion of stem and TA cells 
actively dividing) on the overall homeostasis of the epidermis. Uniquely, the 
model combined known kinetic parameters with characteristic histological 
features of normal and psoriatic epidermis, and iterative stimulation allowed 
rigorous testing and establishment of robust boundaries within which the model 
remained stable. 
    To assess the contribution of keratinocyte apoptosis to remodelling of 
psoriatic epidermis back to normal, the measured apoptotic effects of UVB on 
psoriatic epidermis as determined by both the in vivo and in vitro data described 
above were inserted into the model. This showed that apoptosis of 
keratinocytes is sufficient to result in remodelling of psoriasis back to normal 
epidermis within the clinically expected time-frame for the dose given. Cell cycle 
arrest was also explored as a possible alternative mechanism for clearance of 
psoriasis. The model was used to predict the relative importance of apoptosis in 
cells of differential proliferative ability (i.e. stem, TA and differentiating cells). 
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6.2. Aims 
Specifically, the aims of this chapter where to: 
1. Create a robust model of normal and psoriatic epidermis using observed 
histological features and kinetic parameters derived from the literature. 
2. Test whether the numbers of apoptotic cells observed in UV-irradiated 
psoriatic plaques in vivo were sufficient to account for plaque clearance 
following a series of repeat irradiations, which would be consistent with 
observed clinical clearance. 
3. Use the model to predict which cells of different proliferative potential 
were more likely to undergo apoptosis in response to UVB, assuming 
that this is an important mechanism of clearance. 
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6.3. Results 
    Using the criteria defined in section 2.4, a model was created with the 
Netlogo 4.1 programming environment (appendix F). The model was designed 
to allow user friendly adjustment of parameters derived from the literature, via a 
series of sliders adjacent to the model window (Figure 6-1). This enabled 
testing of multiple scenarios which may account for the hyperproliferative state 
seen in psoriasis. 
 
Figure 6-1.  The model interface consists of buttons, sliders, and monitors 
to allow easy adjustment of parameters by the user, and observation of 
the result of these adjustments. Each „tick‟ represents one hour, and is 
displayed at the top of the interface. As each turtle is born into the model its 
sequential and unique identifying number is displayed at the bottom of the 
interface in the observer panel. „Start-with-psoriasis-phenotype on/ off‟ allows 
the user to choose whether to start the model as normal or psoriatic phenotype, 
but does not affect the running of the model in any way. The positions monitor 
goes from „1‟ (normal) to „7‟ (maximal psoriatic phenotype for this model), and 
will change according the number of cells and proliferation rate within the 
model. „Cytokine-stimulus‟ allows the user to choose to „switch on a stimulus‟ to 
increase the proportion of actively proliferating stem and TA cells. Note that it 
takes over 900h for the model to start to reach equilibrium (as shown in the 
overview display window). Yellow patches represent the basement membrane, 
dermis and below. Stem cells are shown as blue, TA cells as pink (light pink 
when actively dividing and darker pink when resting), and green cells are 
differentiating. 
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6.3.1. Model of normal epidermis 
    The keratinocyte compartment of normal epidermis was modelled in silico by 
setting the parameters outlined below, which represent typical values derived 
from the literature (see section 1.5.1 and Table 6-1): 
Parameter used in the model of 
normal epidermis 
 
Evidence 
 
Stem cell cycle is 150h 
 
Estimated to be 100-200h (Potten and 
Bullock 1983; Potten 1986; Morris and 
Hopewell 1990) 
TA cell cycle is 60h 
 
Estimated to be 50-65h (Chopra and 
Flaxman 1974; Goodwin, Hamilton et 
al. 1974; Bauer and Grood 1975; 
Wright 1976) 
TA cells start to age as they are born, 
but will divide four times before 
becoming „resting‟ TA cells 
 
Estimated to divide 3-5 times (Watt 
1998; Savill 2003) 
TA cells differentiate when they move 
out of the lower epidermis along a 
gradient, and reach a defined gradient 
from the basal layer 
 
Demonstrated in the eye (Revoltella, 
Papini et al. 2007) and supported by 
histological evidence in skin (Ishida-
Yamamoto and Iizuka 1995; 
Martinsson, Yhr et al. 2005; Korver, 
van Duijnhoven et al. 2006) 
Differentiating cells die when they are 
pushed beyond a boundary of the top 
of the epidermis 
 
This is an assumption based to 
histological evidence that the surface 
of the stratum corneum is flat, and the 
upper epidermal layer forms a 
continuous sheet 
The stratum corneum is not 
represented in this model as it is the 
consequence not the cause of the 
underlying epidermis, and removing 
this in vivo does not affect the rest of 
the epidermis 
 
The stratum corneum consists of dead 
cells therefore they cannot undergo 
apoptosis. The model doesn‟t attempt 
to deal with penetration of UVB. 
Table 6-2. Parameters used for stochastic modelling and the evidence to 
support their inclusion. 
    
 Applying the above parameters creates an epidermis which fulfils the criteria 
set out in section 2.4.3. Specifically, the epidermis is 15 cells thick, contains 
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proliferating: differentiating cells in a ratio of approximately 1:1, has an 
epidermal turnover time of approximately 29 days (706 hours) and a transit time 
of 336h (14 days) for differentiating cells (Figure 6-2). 
    To test the stability of the epidermis, each of the following was tested by 
altering each parameter independently: rate of the stem cell cycle; proportion of 
stem cells dividing; rate of the TA cell cycle; and number of TA divisions 
occurring.  Manipulation of each of these parameters was used to try to induce 
a psoriatic phenotype as described below.  
 
 
Figure 6-2. The normal epidermis in silico. Yellow patches represent the 
basement membrane and area below this, blue cells represent stem cells (only 
a small proportion of these will be cycling at any time), TA cells are shown in 
pink (dark pink cells are no longer cycling), and differentiated cells are shown in 
green. This epidermis maintained its stability over a tested period of 5000h. 
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6.3.2. Model of psoriatic epidermis 
6.3.2.1. Altering the stem cell cycle time 
    Lengthening the stem cell cycle from 100 to 175h increased the overall 
turnover time by 16 days while still maintaining a stable epidermis. If the time 
taken for stem cell division was shortened to 60h the epidermis expanded to 
position 2 in the model, and the turnover time for the epidermis reduced to a 
total of 12 days (Figure 6-3). Therefore a shortened stem cell cycle time gives a 
turnover time that would be in keeping with psoriasis, but with a very modest 
increase in total cell numbers of just 16%. 
 
 
 
Figure 6-3. Turnover time of the epidermis gets longer as the stem cell 
cycle increases in length.  Stochastic modelling shows that altering the stem 
cell cycle between 80h and 100h does not affect the total turnover time of the 
epidermis (p=0.21), but other changes were significant (p<0.05). Median and 
inter-quartile ranges shown (n=50). 
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6.3.2.2. Altering the TA cell cycle time 
    TA cell cycle adjustments of 20h intervals were tested within the model, to 
see if this would affect the turnover rate of the epidermis (Figure 6-4).  Adjusting 
the TA cell cycle between 20h and 60h had no significant effect on turnover rate 
(p=0.307). This is as expected, because TA cells have a period of time where 
they rest within the epidermis, before being pushed too far from the basal layer 
and differentiating. After 100h the number of proliferating cells is too great and 
the basement membrane would need to expand in order to contain the cells, 
although total time for cell turnover increases ( 900h; 37.5 days), rather than 
shortens as is seen in psoriasis.  
 
 
 
Figure 6-4. Turnover time of the epidermis increases as the TA cell cycle 
increases in length.  Note that altering the TA cell cycle between 20h and 80h 
does not affect the total turnover time of the epidermis. Median and inter-
quartile ranges shown (n=50). 
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6.3.2.3. Altering the number of TA cell divisions 
    After a TA cell is produced by a stem cell, it will normally divide four times 
before differentiating. Increasing the number divisions from four to five resulted 
in an increase in proliferation within the epidermis. The basement membrane 
elongated to position „2‟ of the model and the turnover time reduced to 
approximately 430h (18 days) but with a modest increase in total cell numbers 
of 12%. Increasing the number of TA-divisions to six resulted in the model 
reaching position „7‟, with a doubling of the total number of epidermal cells and 
a shortening the turnover time to 12-13 days.  However, because each stem 
cell division then resulted in a total of 64 new TA cells (rather than 16 cells if the 
TA cells divided four times) the pattern of proliferation within the epidermis 
became patchy, with minimal proliferation occurring in some areas while too 
many cells are dividing in others (Figure 6-5). In vivo however, there is little 
evidence to suggest that the proliferative rate is so variable throughout the 
epidermis. 
 
 
Figure 6-5. Increasing the number of TA cell divisions from four to six 
within the epidermis results in patchy proliferation. Note the high number of 
proliferating TA cells (bright pink) in the fourth rete ridge which extend well 
outside the suprabasal layer, whereas there are very few proliferating cells in 
the first rete ridge (dark pink). This patchy configuration is not seen clinically in 
psoriasis. 
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6.3.2.4. Altering the relative percentage of stem cells 
actively dividing 
    The baseline normal model contained 48 stem cells. To maintain stability of 
normal epidermis, 20% of these cells cycle at any time. If this proportion is 
increased by 20% intervals (while maintaining all other parameters as 
described above), the turnover time decreases as shown in Figure 6-6.  
    Although the turnover time gets quicker by increasing the proportion of 
dividing stem cells, it is not reduced as far as would be expected if this was the 
only change required to cause the increase in cell numbers in psoriasis. 
However, if the average number of TA cell divisions increases from 4 to 4.5 and 
the proportion of dividing stem cells increases from 20% to 80% then the 
turnover time reduces from 29 days (706h) to 11 days (270h) in the model of 
psoriatic skin. Furthermore the transit time of differentiated cells in silico 
reduces from 336h (14 days) to 100h (4 days), and this may explain how 
psoriatic plaques can develop over a period of just days following a known 
trigger such as a streptococcal throat infection. If the proliferative change 
occurred only at the stem cell level, then even if all stem cell start to divide at 
once it would take at least six days (i.e. approximately the length of the stem 
cell cycle) to have any noticeable clinical effect, and a further 8-10 days for the 
TA cells to complete four rounds of cell divisions; therefore maximal plaque 
thickness would take a minimum of 14 days after exposure. Clinical evidence 
suggests that the onset of plaques is much faster than this, often within four 
days of the onset of a sore throat (Gudjonsson, Thorarinsson et al. 2003). The 
model predicts that approximately four times the number of stem cells would 
need to be actively cycling, along with an increase in the number of rounds of 
TA cell division from four to five in at least 50% of TA cells, to induce this 
change in turnover time and a psoriatic phenotype (Figure 6-7 and Figure 6-8). 
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Figure 6-6. Turnover time of the epidermis increases as the proportion of 
actively dividing stem cells increases. Median and inter-quartile ranges 
shown (n=50). 
 
 
6.3.3. Model of normal and psoriatic epidermis 
    A range of theories were tested which may explain the hyperproliferative 
keratinocyte compartment seen in psoriatic epidermis. Each was initially tested 
by altering just one parameter from the model described in section 6.3.1 above. 
The model was designed to allow flexibility of the basement membrane (as 
described in section 2.4.3), therefore elongation of the rete ridges can be seen 
as the total number of cells within the epidermis increases (Figure 6-13). This 
reflects the morphological pattern observed in psoriasis. 
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Figure 6-7. Relative increase in cycling stem cells from 20% to 80%, and 
an average number of rounds of TA cell divisions to 4.5, causes changes 
consistent with psoriasis. a) „normal‟ epidermis with a total turnover time of 
29 days for all cells, and transit time of 14 days for differentiating cells; and b) 
psoriatic‟ epidermis with a turnover time of 11 days and transit time of 4 days. 
Yellow patches represent the basement membrane and area below this, blue 
cells represent stem cells, pink cells are actively dividing TA cells (which are 
shown as dark pink when they are no longer dividing) and green cells represent 
differentiating cell. 
 
 
Figure 6-8. Turnover time for normal and psoriatic epidermis in silico. The 
mean (706h (29 days) in normal and 270h (11 days) in psoriatic epidermis) and 
SEM are shown for repeated simulations (n=50). 
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    The model incorporated a threshold switch in the proportion of stem and TA 
(transit-amplifying) cells that proliferate, consistent with an immunological 
stimulus initiating psoriasis through cytokine signals that induce keratinocyte 
proliferation. Iterative simulation of the model allowed rigorous testing and 
establishment of robust boundaries within which the model remained stable 
(Figure 6-3- Figure 6-6). In contrast to adjusting cell cycle times, the model 
showed that increasing both the proportion of actively dividing stem and TA 
cells within „normal‟ epidermis were key events contributing to the development 
of psoriasis. The model showed excellent concordance with existing data 
(sections 1.5.2) including an absolute increase in both the proliferative and 
differentiating compartments to levels found in psoriasis, and a reduction in total 
epidermal turnover time and the transit time of differentiating cells. Therefore to 
attain the above parameters the model predicted that an absolute increase in 
both the number of proliferating stem and TA cells was required to simulate 
psoriasis.  
 
 
6.3.4. Model of UV treatment to psoriatic plaques 
    To model whether UV-induced keratinocyte apoptosis could directly impact 
on epidermal remodelling, it was necessary to first design experiments to 
determine the rate and duration of keratinocyte apoptosis as well as the 
differential sensitivity of stem, TA and differentiating cells to apoptosis. 
Apoptosis detection in human tissue in vivo is limited by the requirement for 
tissue sampling to determine the time course of events and the clearance rate 
of apoptotic cells; for example, immunochemistry can only provide a „snapshot‟ 
of what is occurring in the skin at any one time. As real-time imaging of 
individual cells within human epidermis is not possible in vivo, further 
experiments were designed to address this question in vitro using primary 
keratinocytes (section 5.3.1), and these data were combined with observations 
from the in vivo data (section 3.3.4). 
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6.3.4.1. Estimate of number of apoptotic cells induced by 
a single exposure to UVB 
    Apoptosis of keratinocytes in vivo approximated to a Gaussian distribution, 
which can be described by the equation (TutorVista 2010): 
    f(x) = ae – (x-b)2 
             2c2 
Where:  
a = height of the peak 
b = mean (time) 
c = standard deviation 
e = Euler‟s number (2.718) 
 
    Integration of this equation gives the area under the curve, which can be 
used to approximate the number of cells induced by a single three MED dose of 
311nm UVB, and is expressed as: 
 
             ae-  (x-b)2 dx   = ac √(2π)  
                                             2c2 
 
    This study has shown that a single six SED irradiation of 311nm to whole 
epidermis ex vivo causes apoptosis in 13% of stem cells, 15% of TA cells and 
8% of differentiating cells (section 4.2.4). Section 5.3.1.1 shows that it takes 
around 20 mins from the onset of caspase-3 activation to cell membrane 
disruption, however it is unknown how quickly apoptotic cells are removed by 
phagocytosis within the epidermis.  Data from this study indicate that the true 
figure is between 20 mins and 6 hours (the in vivo analysis showed significant 
differences between individual‟s number of apoptotic cells between 18h and 
∫
∞ 
-∞ 
6-165 
 
24h post irradiation). If it is assumed that each apoptotic cell remains detectable 
within the epidermis for 3-6h (sections 3.3.4), this would predict that 120-240 
epidermal cells per 1000 cells undergo apoptosis over a 56h period following a 
single three MED irradiation (not including the number of new cells which would 
be produced by the epidermis during this time). Approximately seven 3 MED 
irradiations would then be required in silico to remodel psoriatic epidermis back 
to normal (Figure 6-12). If apoptosis also peaks at 18h (with a similar standard 
deviation to the observed three MED dose) for sub-erythemogenic doses of 
311nm UVB, it would be possible to predict the number of apoptotic cells after 
different MED doses. Section 3.3.5 showed that in 10 patients the median 
number of apoptosis cells is 14.3 per 1000 epidermal cells 24h after three 
MEDs of 311nm, and that this reduces to 1.3 per 1000 epidermal cells 24h 
following 0.75 MED of 311nm (i.e. ratio of 11: 1). The 18h peak number of 
apoptotic cells following three MEDs is 29, therefore it follows that the 18h peak 
for 0.75 MED would be around 2.6 per 1000 epidermal cells. Using these data, 
the area under the curve calculation for 0.75 MED gives an estimate of 65 per 
1000 cells undergoing apoptosis per single 0.75 MED irradiation. The model 
predicts that 25-30 irradiations of this dose of 311nm would be required if 
apoptotic cells remain detectable in the epidermis for an average of 
approximately 3h. This fits well with clinical observation. 
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6.3.4.2. Modelling proliferative potential of apoptotic cells 
    Section 5.3.4 describes the probability of cells of differing proliferative 
potential undergoing apoptosis in response to a single three MED dose of 
311nm UVB. To test the individual effect of each of these within the model, the 
model was run sequentially, with UVB targeting either stem (Figure 6-9), TA 
cells (Figure 6-10) or differentiating cells (Figure 6-11) alone, or in combination 
(Figure 6-12).  
 
 
Figure 6-9. Model simulations of seven UVB treatments (three MEDs) if 
apoptosis occurs in only stem cells. In this model 13% of stem cells undergo 
apoptosis with each UV-irradiation. The TA cell cycle is 60h and the stem cell 
cycle is 150h. There is a delay of over 500h between the first irradiation and the 
beginning of plaque clearance. Green arrow shows time of first irradiation, and 
red arrow shows the final treatment. 
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Figure 6-10. Model simulations of seven UVB treatments (three MEDs) if 
apoptosis occurs in only TA cells. In this model 20% of TA cells undergo 
apoptosis with each UV-irradiation. The TA cell cycle is 60h and the stem cell 
cycle is 150h. Although there is a fairly rapid „clinical‟ response seen with this 
model, remodelling of the plaque is limited and temporary. Green arrow shows 
time of first irradiation, and red arrow shows the final treatment. 
 
 
Figure 6-11. Model simulations of seven UVB treatments (three MEDs) if 
apoptosis occurs in differentiating cells alone. Nine percent of differentiated 
cells undergo apoptosis with each UV-irradiation. The TA cell cycle is 60h and 
the stem cell cycle is 150h. In this model, there is minimal impact on the 
epidermis, even when over 20 irradiations were given (not shown here). Green 
arrow shows time of first irradiation, and red arrow shows the final treatment. 
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6.3.4.3. Model assumptions 
    The following data were used in the mathematical model to simulate UVB 
irradiation, based on the above findings:  
 An area under the curve calculation using data from Figure 3-7 was 
combined with the data shown in Figure 5-5 (duration of apoptosis in 
individual cells) to calculate an estimate of the rate of apoptosis. 
 Apoptosis occurs at least 12h following apoptosis, with a mean time of 
18h post-irradiation. 
 Following a single exposure of three MEDs of 311nm UVB, 13% of stem 
cells and 20% of TA cells (see Figure 5-12) randomly undergo apoptosis. 
Differentiating cells do not undergo apoptosis in the model as this does 
not fit with the distribution of apoptosis seen in vivo (Figure 3-2 and 
Figure 3-8), and does not affect the overall outcome of the model (Figure 
6-11).  
 As the number of proliferating cells decreases in response to treatment, 
it is assumed that an average of 4.5 rounds of TA divisions back to four 
will occur gradually (as immunocytes and keratinocytes produce 
cytokines which drive the proliferative process) and this is reflected in the 
model.  
 If a stem cell undergoes apoptosis it will be replaced over time by 
symmetrical division of a neighbouring stem cell. This new stem cell will 
divide 20% of the time (as for normal epidermis). Therefore the same 
number of keratinocyte stem cells would be expected in the epidermis 
before and after a course of phototherapy. 
    As cells undergo apoptosis, the basement membrane gradually contracts 
back to its „normal‟ size (Figure 6-13); this can be seen as a movie at: 
http://research.ncl.ac.uk/psoriasis. The movie starts showing normal epidermis 
(position „1‟) which is stable over time. At 1400h (hours are shown as „ticks‟ at 
the top of the movie) a „cytokine stimulus‟ is triggered (i.e. there is an increase 
in proliferation inducing cytokines due to an external trigger), and the basement 
membrane expands in a serial manner from position „1‟-„7‟. The stimulus is 
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withdrawn at 1900h but the psoriasis remains stable, and the epidermis 
maintains homeostasis in this state. At 2300h seven doses of three MEDs 
311nm UVB are administered (as described above), and these are given at 56h 
intervals (equivalent to three times per week). This returns the epidermis to the 
normal state, where homeostasis is retained until a further stimulus is received. 
Note that: 
 The thickness of the epidermis is not affected after the first UV doses are 
administered; most effects occur towards the middle/ end of the course.  
 The stratum corneum is not modelled here as it is assumed to be a 
consequence of the underlying epidermal changes, but in clinical 
practice this would result in a hyperkeratotic surface. 
    The program interface allows the user to adjust the rate of stem and TA cell 
division, as well as the number of irradiations and their frequency. The model 
can either be started in the „normal‟ position, or as „psoriasis‟. 
 
Figure 6-12. Model simulations of seven UVB treatments (three MEDs) if 
apoptosis occurs in both stem and TA cell without an effect on 
differentiating cells. In this model 13% of stem cells and 20% of TA cells 
undergo apoptosis with each UV-irradiation. The TA cell cycle is 60h and the 
stem cell cycle is 150h. This model fits well with the clinical situation, as the 
initial treatments have little impact on plaque remodelling, but complete 
clearance can be achieved at the end of the last (7th) treatment, and can be 
maintained. Green arrow shows the time of first irradiation, and the red arrow 
shows the final treatment. 
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Figure 6-13. Remodelling of psoriatic epidermis back to normal, showing 
progressive reduction in depth of rete ridges following UV-induced 
apoptosis, in response to reduced cell numbers. Eight 3 MED treatments 
are given in this example. Six of the seven possible positions of the basement 
membrane are shown, where (a) is the maximal psoriatic phenotype and (f) 
represents normal (non-lesional) skin. 
 
 
    If cell cycle arrest rather than apoptosis was the mechanism of clearance 
following UVB, the model shows that psoriasis would continue to improve for a 
period of 32 days (Figure 6-14) after a UVB treatment course had completed. In 
clinical practice further clearance of psoriatic plaques is not seen after 
completion of a course of UVB, therefore if the model is correct, it is unlikely 
that UVB clears psoriasis through cell cycle arrest. 
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Figure 6-14. Comparing time taken to remodel psoriatic epidermis during 
and following a course of three MED of 311nm UVB (UVB given every 56h, 
representing three times per week). In this model 13% of stem cells and 20% 
of TA cells undergo apoptosis (red) or cell cycle arrest (blue) with each UV-
irradiation. The TA cell cycle is 60h and the stem cell cycle is 150h. First 
irradiation was given at 500h (green arrow) and last at 836h (red arrow). Note 
that if the mechanism of clearance was cell cycle arrest, no change in 
epidermal thickness would be seen until after the treatment course was 
completed, with a lag time of 336h (14 days) post completion of the treatment 
course to clearance. 
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6.4. Discussion  
    The purpose of the model was to test the hypothesis that the observed rate 
of UVB-induced keratinocyte apoptosis in psoriatic epidermis could directly 
account for plaque clearance, and that the number of repeat irradiations 
required for clearance in the model was consistent with clinical observation. 
The results obtained in the modelling experiments were consistent with both 
these hypotheses. Moreover, if UV-induced cell cycle arrest was substituted for 
UV-induced apoptosis in the model then plaque clearance was not achieved.  
    The model created is based on parameters previously described in the 
literature, but differs from previous models as it also utilises observed 
histological features of psoriasis, and has not included fixed arbitrary 
parameters (previous models have used uninformed values such as cell‟s 
maximal lifespan or time spent within any defined compartment which have 
major consequences on the model outcome (Grabe, Pommerencke et al. 2006; 
Grabe and Neuber 2007; Sutterlin, Huber et al. 2009)).  
    The model provides evidence that the increase in the number of dividing cells 
may be directly responsible for the elongation of the rete ridges as seen in 
psoriasis, assuming that dividing cells need to be within a given distance of the 
basal layer. This is supported by immunohistochemical analysis of normal and 
psoriatic skin in which proliferating cells always appear in the basal or 
suprabasal layers, and analysis of differentiation markers such as keratin 10, 
S100A7 and involucrin show a similar pattern of distribution to that shown by 
the „gradient‟ hypothesis proposed here (Ishida-Yamamoto and Iizuka 1995; 
Martinsson, Yhr et al. 2005; Korver, van Duijnhoven et al. 2006). In this model 
cells with the greatest proliferative ability are located closest to the basement 
membrane as has previously been described (Fuchs 2008), and are gradually 
pushed up to the surface as their proliferative ability diminishes (Figure 2-8). A 
vertical calcium gradient exists within the epidermis which is highest at the 
epidermal surface and lowest in the basal layer, and has been shown to affect 
differentiation (Elias, Ahn et al. 2002). However, as the histological pattern of 
differentiation within the epidermis is undulating rather than a flat layer (Korver, 
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van Duijnhoven et al. 2006), this cannot be solely responsible for inducing cell 
differentiating.  Elucidation of the identity of soluble growth factor/ cytokine 
gradients arising from the dermis or basal layer are beyond the scope of this 
thesis, but speculation would include dermis-derived growth factors such as 
TGF-β1 or KGF (FGF-7), or that cells with the highest proliferative capacity 
have a greater number of receptors for these. The former has been shown to 
induce differentiation along an inverse gradient in skin culture (Ellis, Grey et al. 
1992; Sun, Adra et al. 2009), and the latter has been suggested as a 
mechanism of FGF control of branching morphogenesis in lacrimal and salivary 
glands (Makarenkova, Hoffman et al. 2009). 
    The model demonstrates that a psoriatic phenotype could be achieved by 
either an increase in the proportion of stem cells dividing or an increase in the 
number of times a TA cell divides or both. However it is unlikely that the 
psoriatic phenotype is caused by just an increase in the number of TA divisions 
as this would lead to patchy areas within the epidermis of very high proliferation 
rates and areas of very little proliferation. This would result in neighbouring rete 
ridges varying in size extensively within a plaque, and this is not seen in 
plaques histologically (Figure 6-5). If stem cells alone were affected, it would 
take longer than is clinically observed for plaques to develop after the onset of a 
known trigger such as a streptococcal throat infection, and a course of UVB 
would not show any clinical effect until after the entire course of treatment 
(Figure 6-9); which does not fit with clinical observation. However, combining an 
increase in both stem and TA cell proliferation satisfies all criteria and leads to 
the expected epidermal turnover time and differentiating cell transit time. 
    When UVB phototherapy clears psoriasis, prolonged remission can be 
obtained suggesting that the mechanism of clearance may be different to other 
treatment modalities in which remission is not achieved (e.g. immunocyte 
targeted therapy). If the mechanism of UV clearance is directly due to 
keratinocyte apoptosis, this suggests that the psoriatic phenotype is due to an 
increase in birth rate rather an effect on cell cycle length or increased life span 
of individual cells.  
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    Finally the model is presented as an interactive tool, whereby the user can 
control variables such as stem cell cycle time and can directly observe the 
effects of this on the epidermis over time. This will allow further application of 
the model in the future, and if sufficient data (including rate and magnitude of 
effect) describing other mechanisms of action for plaque clearance (e.g. 
autophagy) are described at a later date, the model could be utilised to assess 
whether these effects could be directly responsible for plaque clearance.  The 
model therefore has the potential to provide further insight into psoriatic plaque 
development and the impact of treatment modalities. 
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6.5. Conclusions 
 The model created is based using both observed histology and previously 
elucidated kinetic data for normal and psoriatic epidermis, and fits well with 
established data. 
 Iterative stimulation of the model showed the model remained stable when 
tested within expected boundaries. 
 When the experimental evidence from chapters three and five are used 
within the model, psoriatic epidermis is shown to remodel back to normal 
within approximately seven exposures of UVB using doses of three MEDs, 
and 25-30 exposures using sub-erythemogenic doses consistent with 
routine clinical treatment. Both these fit with published clinical observation. 
 The model demonstrates that keratinocyte apoptosis can directly account 
for plaque clearance. 
 If cell cycle arrest is substituted for apoptosis, plaque clearance will occur 
as for apoptosis but with a lag time of approximately 32 days; this does not 
fit with clinical observations, and suggests that no clinical improvement is 
likely to occur until after a course of medium dose UVB is completed. 
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7. Gene array 
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7.1.  Introduction 
    Psoriasis has a complex genetic basis, and with the exception of HLA-Cw6, 
each of the underlying alleles only makes a small contribution to the overall 
phenotype. It is therefore important to study gene expression and gene 
interactions in order to understand the likely contribution of individual factors to 
the disease process. Array technology has transformed the field, for example, 
Illumina arrays allow high throughout analysis of over 46 000 genes 
simultaneously and can be used to assess up- and down-regulation of affected 
genes. Where these genes have a common function, further understanding can 
be obtained about the relevance of these.  
    Some previous gene array studies in normal human primary keratinocytes 
have shown that UVB up-regulates pro-apoptotic genes e.g. NOXA and MAPK 
(Takao, Ariizumi et al. 2002; Nys, Van Laethem et al. 2010) which activate the 
intrinsic apoptotic pathway. In contrast however, Li et al did not find any 
differential regulation in apoptotic genes within cultured keratinocytes at any 
time point up to 24h post irradiation with broadband UVB source (Li, Turi et al. 
2001). It is unclear why these studies show different results although the latter 
used keratinocytes at one day post-confluency (rather than 80% confluent) 
which may have given cells greater protection from UVB and resistance to 
apoptosis; furthermore the cells used by Li et al were 3rd passage (rather than 
1st) and may therefore have had a significantly smaller stem cell population . It 
has been demonstrated that the response to UVB differs between in vivo 
human epidermis and cultured keratinocytes, with the profile of the former 
biased towards DNA repair (even after doses of four MEDs) and the profile of 
the latter towards genes associated with cell cycle arrest and apoptosis (Enk, 
Jacob-Hirsch et al. 2006). For the purposes of this study, it was therefore 
decided to perform a gene array study of psoriatic plaques in vivo following 
irradiation of clinically effective and ineffective wavelengths of UVB. 
    There have been few gene array studies examining differential gene 
regulation in response to therapeutic intervention in psoriasis, and just one has 
looked at UVB. In the latter, 116 genes were differentially regulated following a 
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complete course of narrowband UVB, but no control wavelength was used to 
differentiate the bystander effects of erythema etc from therapeutic effects 
(Hochberg, Zeligson et al. 2007). Furthermore, arrays taken at the end of the 
course do not provide information about the mechanism of clearance that 
occurred earlier in the treatment course when the disease was very active, as 
expression of genes rapidly changes and only a small therapeutic effect is 
occurring within the skin at the end of a treatment course. Of the other 
interventional studies, the first looked at difference in gene expression in 
lesional psoriasis in vivo following treatment with ciclosporin in three patients at 
weeks 1, 4, 8 and 12 after commencing treatment (two responders and one 
non-responder) or an experimental immunomodulatory cytokine, rhIL-11 at the 
same time-points (five responders and one non-responder) (Oestreicher, 
Walters et al. 2001). This study found differential regulation of genes 
corresponding to psoriasis susceptibility loci and also related to aberrant IFNγ 
expression within the skin, which returned to normal levels prior to clinical 
improvement. However, further analyses of the results are difficult to interpret 
with such a small control group of non-responders. Two further studies have the 
compared the differential effects of biologic drugs between clinical responders 
and non-responders at least a week after commencing treatment (Zaba, 
Suarez-Farinas et al. 2009; Suarez-Farinas, Shah et al. 2010). The first of 
these examined biopsies of psoriatic plaques in 15 patients and found that only 
clinical responder‟s (n=11) down-regulated (back to baseline) genes associated 
with the IL17 pathway (Zaba, Suarez-Farinas et al. 2009), and the second 
examined PBMNs in 16 patients and showed that in responders (n=9) 23 genes 
were differentially regulated between the two groups although they did not 
attempt to group these genes functionally (Suarez-Farinas, Shah et al. 2010). 
    In this chapter, the effects of UVB on gene regulation were studied at early 
time-points (4h and 18h)  following irradiation of psoriasis with a single 
exposure of either 311nm or 290nm UVB in vivo, and compared to each other 
and to non-irradiated epidermis. Moreover, the epidermis was studied in 
isolation by micro-dissection of frozen tissue, and there have been no studies 
looking at the gene profile of the psoriatic epidermis only. Comparing the in vivo 
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effects of clinically effective and ineffective UVB wavelengths on psoriatic 
epidermis (using equal erythemogenic doses), allows elimination of the large 
number of non-specific changes that occur in response to UVB irradiation.   
 
 
7.2. Aims 
 To investigate the differential gene response following irradiation with 
clinically effective (311nm UVB) and ineffective (290nm UVB) wavelengths 
of UVB, at early (4h and 18h) time-points post irradiation. In particular to 
examine for changes of apoptosis, and which apoptotic pathway is 
predominantly affected. 
 To investigate differential effects of 311nm versus 290nm UVB on other 
pathways  
 To validate the array findings using real-time PCR.  
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7.3. Results 
    Array analysis was performed in 48 micro-dissected epidermal samples from 
a total of 20 patients (maximum of 4 biopsies/ patient), using 30µm 
cryosections. These biopsies included involved untreated psoriatic epidermis, 
and psoriasis biopsied at 4h or 18h post irradiation with a single dose of 311nm 
or 290nm UVB (see Table 2-1). Counts of caspase-3 positive cells were 
performed in parallel for each biopsy using cryosections for IHC analysis. RNA 
is partially degraded by freezing biopsy specimens making gene array analysis 
more difficult when derived from frozen tissue. However, the recent addition of 
the whole-genome DASL (c-DNA-mediated annealing, selection, extension and 
ligation) micro-array assays to the Illumina platform (as discussed in section 
2.5.4) has made RNA analysis from such tissue possible, with highly sensitive 
and reproducible results 
(http://www.illumina.com/products/whole_genome_dasl_assay_kit.ilmn).  
    RankProducts analysis in Bioconductor  was used to identify genes within 
psoriatic epidermis which were significantly differentially expressed following 
irradiation with either: 311nm vs 290nm UVB, 311nm UVB vs un-irradiated, or 
290nm UVB vs un-irradiated; at the 4h and/ or 18h time-point post irradiation 
(p<0.05). This amounted to a total of 389 genes 4h post UVB-irradiation, and 
768 genes at 18h. These are described in more detail below. 
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7.3.1. Altered gene expression following irradiation with 311nm 
UVB compared to irradiation with 290nm UVB and 
untreated psoriasis 
    Using the analysis detailed in section 2.5.5, expression of differentially 
regulated genes induced at both 4h and/ or 18h post irradiation with 311nm 
UVB (compared to post irradiation with 290nm UVB or un-irradiated psoriatic 
epidermis) were quantified. At the 4h time-point, 46 genes were found to be 
significantly differentially regulated (n=9) and at 18h, 164 genes were 
significantly differentially regulated (n=11) (p<0.05). The Venn diagrams below 
illustrate the number of genes differentially regulated in each comparison 
(Figure 7-1). The genes differentially regulated by 311nm UVB and not 290nm 
UVB or un-irradiated psoriasis (i.e. in the purple areas of the venn diagrams) 
are listed in appendix G. At 4h, 12% (46/389) of the genes were dysregulated 
after irradiation with 311nm compared to 290nm UVB/ un-irradiated psoriasis, 
increasing to 21% (159/768) at 18h. The genes identified in the purple section 
of these diagrams are of greatest potential interest, as the study aimed to 
identify genes which are differentially regulated within lesional epidermis by 
therapeutic rather than non-therapeutic wavelengths of UVB, compared to un-
irradiated lesional epidermis. 
    Data mining using Ingenuity pathway analysis (section 2.5.5) identified the 
differentially regulated genes of interest in this study, and these have been 
analysed in more detail below. A summary of their differential regulation 
compared to either 290nm UVB-irradiated or un-irradiated psoriasis is given in 
Table 7-1.
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Figure 7-1. Venn diagrams showing the number of differentially regulated 
genes in psoriatic plaques following irradiation with 311nm and 290nm 
UVB compared with un-irradiated psoriasis. a) 4h post irradiation and b) 18h 
post irradiation. 311nm UVB differentially up-regulates 46 genes after 4h (n=9) 
and 159 after 18h (n=11), compared to irradiation with 290nm UVB and un-
irradiated psoriasis. 
 
 
a 
b 
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Gene Name 
Differential 
regulation in 
psoriatic 
epidermis 
following 311nm 
UVB compared to 
290nm irradiation 
at 4h or 18h 
(p<0.05) 
Differential 
regulation in 
psoriatic 
epidermis 
following 311nm 
UVB compared to 
un-irradiated 
psoriasis (p<0.05) 
 
 
 
Major functional 
roles* 
CDKN1A/ P21/ 
WAF1 
↑ ↑ Apoptosis 
Cell cycle regulation 
 
MDM2 - ↑ Apoptosis 
Cell cycle regulation 
 
GDF15 ↑ ↑ Apoptosis 
Differentiation 
 
IL24/ MDA7 ↑ ↑ Apoptosis 
Differentiation 
 
PIK3C2G ↓ ↓ Apoptosis 
Cell proliferation 
Cell migration 
IL17 pathway 
JUNB ↑ ↑ Cell proliferation 
Differentiation 
Apoptosis 
FOSL1 ↑ ↑ Cell proliferation 
Differentiation 
Apoptosis 
MAPK10 ↓ ↓ Apoptosis 
IL17 pathway 
 
IRF2 - ↓ Cell proliferation 
Cell cycle regulation 
Apoptosis 
BUB1 - ↓ Cell cycle regulation 
Apoptosis 
 
MMP3 ↑ ↑ Apoptosis 
Wound repair 
Tumour formation 
IL17 pathway 
IL6 ↑ ↑ Inflammation 
Cell proliferation 
Cell cycle regulation 
Apoptosis 
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AURKA - ↓ Cell cycle regulation 
Tumour formation 
 
DLGAP5 - ↓ Cell cycle regulation 
Tumour formation 
 
NEK2 ↓ ↓ Cell cycle regulation 
 
 
DUSP4 ↑ ↑ Cell proliferation 
Differentiation 
 
DUSP6 ↑ ↑ Cell proliferation 
Differentiation 
 
AKT2 - ↑ IL17 pathway 
Tumour formation 
Angiogenesis 
Insulin signalling 
NOS2A ↓ ↓ IL17 pathway 
Antimicrobial peptide 
IL19 ↓ ↓ IL17 pathway 
Apoptosis 
 
IL8 - ↑ IL17 pathway 
Neutrophil activation 
LCE2A ↑ ↑ Precursor of cornified 
envelope of stratum 
corneum 
LCE2C ↑ ↑ Precursor of cornified 
envelope of stratum 
corneum 
LCE3D ↑ ↑ Precursor of cornified 
envelope of stratum 
corneum 
LCE3E ↑ ↑ Precursor of cornified 
envelope of stratum 
corneum 
DEFB103A/ 
 HBD-3 
↑ ↑ Antimicrobial peptide 
 
DEFB4/  
HBD-2 
- ↑ IL17 pathway 
Antimicrobial peptide 
PI3 - ↑ Antimicrobial peptide 
Atherogenesis 
S100A12/  
EN-RAGE 
- ↑ Cell cycle regulation 
Differentiation 
Antimicrobial peptide 
Inflammation 
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PDGF-D - ↓ Angiogenesis 
Cell proliferation 
Differentiation 
Cancer 
CCL21 - ↑ Angiogenesis 
Chemotaxis 
 
KRT77 ↓* ↓* Keratinocyte structure 
 
*Data from Ingenuity pathway analysis 
Table 7-1. Summary of differential gene expression within psoriatic epidermis 
4/18h post irradiation with a single dose of three MEDs of 311nm UVB compared 
to 290nm UVB or un-irradiated psoriasis. The major known functional roles are listed 
for each gene. * see Figure 7-11. 
 
 
7.3.2. Differentially regulated pathways 
    The pathways of interest which were differentially regulated included 
apoptosis, control of cell cycle and the antimicrobial peptides. Of note, 
autophagy genes (such as p63 and Beclin 1) were not differentially regulated at 
the studied time-points.  
    At 4h post 311nm UVB the highest gene expression group compared to un-
irradiated lesional psoriasis was cell death (p=6.33 x 10-7), followed by cell 
cycle (p=9.81 x 10-6) (Figure 7-2).  Although expression profiles in these 
groups were still significantly altered at 18h post 311nm compared to un-
irradiated lesional psoriasis, expression of these groups then ranked 21st 
(p=3.04 x 10-4) and 16th (p=6.01 x 10-5) respectively. Expression of 
antimicrobial peptides ranked 54th at the 4h time-point and 58th at 18h post 
311nm UVB compared to un-irradiated psoriasis, with significance levels of 
p=5.74 x 10-3 and 5.6 x10-3 respectively. 
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Figure 7-2. Ingenuity pathway analysis of functional datasets differentially 
regulated at different time-points post irradiation of 311nm UVB to 
psoriatic plaques in vivo. Expression profiles are shown and values depict log 
mean values compared to un-irradiated lesional psoriasis. a) after 4h (n=9), and 
b) after 18h (n=11). Only the first 23 groups are shown in each case, with the 
yellow threshold line indicating significance at p<0.05 (i.e. all the datasets 
shown are above the significance level). Sixty genes are included in the cell 
death dataset and 34 in the cell cycle dataset at 4h, compared to 59 and 29 
respectively at 18h. 
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7.3.3. Apoptosis and cell cycle regulatory genes 
    Some of the other most significantly differentially regulated genes following 
311nm but not following 290nm UVB or un-irradiated psoriasis, were genes with 
important apoptotic effects. Many pro-apoptotic genes are also important in the 
control of cell cycle and some are described further below including CDKN1A, 
MDM2, DUSP6, IL6, AURKA AND BUB1. All biopsies were analysed in each 
case; i.e. at 4h post 311nm irradiation n=9, 18h post 311nm irradiation n=11, 4h 
post 290nm irradiation UVB n=6 and 18h post 290nm irradiation UVB n=8. 
 
7.3.3.1. Differentially regulated genes at 4h post UVB-
irradiation 
    Ingenuity analysis identified 23 significantly differentially regulated apoptotic 
genes which are directly or indirectly linked to each other in biological pathways 
leading to apoptosis (Figure 7-4).  
    CDKN1A (p21/ WAF1) was the most significantly up-regulated gene 
occurring at 4h post 311nm (with a 23.7 and a 27.5 fold up-regulation following 
irradiation with 311nm compared to un-irradiated or 290nm UVB-irradiated 
psoriasis respectively (p<0.05)) (Figure 7-3). The expression of CDKN1A is 
tightly controlled by p53 (Herbig, Jobling et al. 2004), and is selectively induced 
prior to apoptosis (Gomez-Manzano, Fueyo et al. 1997). CDKN1A is specifically 
cleaved by caspase-3-like enzymes, which in turn activates CDK2 leading to 
apoptosis (Gervais, Seth et al. 1998). This occurs via Bax activation within the 
mitochondrial pathway (Gomez-Manzano, Fueyo et al. 1997). CDKN1A is 
located on chromosome six, and acts as a regulator of cell cycle progression at 
G1 by binding to and inhibiting cyclin-CDK2 or –CDK4 complexes. It also 
regulates DNA replication and damage repair in S phase by interaction with 
proliferating cell nuclear antigen (PCNA). CDKN1A is controlled by MDM2 
expression (see below). CDKN1A also has p53 independent effects on cell 
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cycle and apoptosis through interactions with other proteins (Murphy, Mabruk et 
al. 2002), as shown in Figure 7-4. 
 
 
Figure 7-3. Expression fold change of genes in response to 311nm UVB 
and 290nm UVB at 4h and 18h post irradiation, compared to un-irradiated 
psoriasis for CDKN1A. Median and inter-quartile range shown, with whiskers 
indicating minimum and maximum values. Graphs shows normalised values 
centred around zero. Red plots represent irradiation with 311nm UVB and 
green plots represent irradiation with 290nm UVB. *Significant difference shown 
(p<0.05) (N.B comparison between 311nm at 4h and 290nm at 18h (and vice 
versa) not done). 
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Figure 7-4. Interactions of the apoptotic genes, differentially expressed in 
psoriatic epidermis 4h post 311nm UVB irradiation in vivo compared to 
non-irradiated lesional epidermis. Ingenuity analysis revealed the above 
biological connections. Direct interactions are shown with uninterrupted lines, 
and indirect connections with dashed lines. Inverted triangles represent 
kinases, up-right triangles are phosphatase, squares are cytokines, interrupted 
squares are growth factors, diamonds are peptidases, rectangles are ligand-
dependent nuclear receptors, ovals are transcription regulators and circles are 
other molecules. Red arrows indicate significant up-regulation, and green 
arrows indicate significant down-regulation of the genes compared to un-
irradiated psoriasis. The number and close interactions of expressed genes 
seen in this network is highly suggestive that it will translate into biological 
changes of apoptosis.  
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      Figure 7-5 shows the relationship of p53 (TP53) and caspase 3 (CASP3) to 
some of the key apoptotic genes identified. Interestingly RUNX1 is biologically 
connected to this pathway and has been identified as a psoriasis susceptibility 
locus (PSORS2) (Helms, Cao et al. 2003; Stuart, Nair et al. 2006); this was up-
regulated 5.7 fold compared to un-irradiated psoriasis at the 4h time-point post 
irradiation with 311nm UVB, but not differentially regulated at 18h compared to 
un-irradiated psoriasis, or compared to irradiation with 290nm UVB at either 
time-point.  
    CDKN1A influences cell cycle progression at G1 and S phase, and appears 
to be the central node which directly interacts with the differentially regulated 
genes listed above, with altered expression following 311nm but not 290nm 
UVB (Figure 7-4 and Figure 7-5). Genes involved in checkpoint control at G2M 
were generally down-regulated, while those influencing G1 arrest were up-
regulated. Genes associated with arrest in cell cycle featured prominently in the 
psoriatic epidermis taken 4h post 311nm irradiation with an overall significance 
of p=1.35 x10-4. The following genes had altered expression in response to 
311nm UVB in psoriatic epidermis (see Table 7-1): 
 MDM2 is located on chromosome 12 and encodes a nuclear 
phosphoprotein which acts as a regulator of p53 and induces G1 arrest. 
Traditionally MDM2 was considered a negative regulator of p53, but recent 
evidence suggests that this gene may also promote p53 activity (Naski, 
Gajjar et al. 2009). This was up-regulated by 4.8 fold 4h following 311nm 
UVB compared to un-irradiated psoriasis (p<0.05), but this effect was not 
significantly different to irradiation with 290nm UVB (Figure 7-6). Therefore 
regulation of MDM2 is not specific to the therapeutic wavelength of UVB, 
and may be a bystander effect. 
 IRF2 (interferon regulatory factor 2; a candidate for PSORS3, a previously 
identified psoriasis susceptibility locus) is situated on chromosome 4q. It 
promotes cell cycle proliferation, and is involved in cell cycle regulation by 
binding histone H4 during S phase, and may regulate a critical cell cycle 
checkpoint at G2M (Xie, van Wijnen et al. 2002). IRF2 has been shown to 
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up-regulate the anti-apoptotic protein BCL-2 (Wang, Liu et al. 2007). In this 
experiment IRF2 was down-regulated by 2.8 fold only by 311nm at 4h 
compared to un-irradiated psoriasis (p<0.05) but again was not significantly 
differentially regulated compared to 290nm UVB (Figure 7-6).  
 BUB1: is involved in the spindle-assembly checkpoint, and also binds to 
p53 preventing apoptosis. BUB1 was down-regulated 4-fold at 4h following 
311nm UVB compared to un-irradiated psoriasis (p<0.05) (Figure 7-6), 
consistent with in increased susceptibility to apoptosis (Beeharry and Yen 
2009) but was not significantly differentially regulated compared to 290nm 
UVB.  
 AURKA: encodes a protein required for mitosis, including spindle assembly 
and mitotic check-point control. This was down-regulated by 4.1 fold 4h 
following 311nm UVB compared to un-irradiated psoriasis (p<0.05), but not 
following irradiation with 290nm UVB (Figure 7-6).  
 DLGAP5 (HURP/ DLG7) is important in spindle assembly in mitosis, and is 
down-regulated 2.8 fold 4h post 311nm UVB compared to un-irradiated 
psoriasis (p<0.05) but was not significantly differentially regulated 
compared to 290nm UVB.  
 IL6: is cytokine has been shown to be up-regulated in response to UV 
induced DNA-damage in primary keratinocytes (Petit-Frere, Clingen et al. 
1998). UVC was shown to up-regulate IL6 to a greater extent that UVB in 
the latter study, although the data shown here suggests IL6 is up-regulated 
by 3.6 fold following 311nm UVB compared to un-irradiated psoriasis and 
4.5 fold compared to psoriasis irradiated with 290nm UVB (p<0.05) (Figure 
7-6). IL6 induces cell proliferation and appears to be important for 
progression through G1 (Loyer, Ilyin et al. 1996), prevents apoptosis 
(Tassone, Neri et al. 2005), and augments the Th17 pathway which leads 
to an enhanced inflammatory response; the latter is further discussed in 
section 7.3.4. 
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 NEK2 encodes a protein kinase which forms part of the mitotic spindle-
assembly checkpoint. It is located on chromosome one and is down-
regulated by 4.4 fold 4h following 311nm irradiation compared to un-
irradiated psoriasis (p<0.05), and 6.7 fold compared to psoriasis irradiated 
with 290nm UVB (p<0.05). 
 JUNB (candidate gene for PSORS6) is located on chromosome 19 and is a 
core member of the activator protein-1 (AP-1) transcription complex which 
consists of dimers of the JUN, FOS, activating transcription factor (ATF) 
and musculoaponeurotic fibrosarcoma (MAF) families (Zenz and Wagner 
2006). Enhanced activity (induced by activation of MAPK) regulates cell 
proliferation, differentiation,  attenuates apoptosis via the mitochondrial 
pathway (Son, Heo et al. 2010) but promotes apoptosis via the death 
receptor pathway (Baumann, Hess et al. 2003). Down-regulation of JUNB is 
associated with hyperproliferation in psoriasis (Zenz, Eferl et al. 2005). 
Irradiation with 311nm UVB induced a 3.4 fold up-regulation of this gene at 
4h compared to un-irradiated psoriasis (p<0.05) and 5.7 fold up-regulation 
compared to 290nm UVB-irradiated psoriasis (p<0.05).  
 FOSL1 encodes a leucine zipper protein which can dimerise with proteins 
from the Jun family, forming the transcription factor AP-1, and has a role in 
cell proliferation, differentiation and transformation. It is located on 
chromosome 11 and is up-regulated by 8.5 fold 4h following 311nm 
irradiation compared to un-irradiated psoriasis (p<0.05) and 4.4 fold 
compared to 290nm UVB (p<0.05), and remains up-regulated at 18h (4.5 
fold compared to un-irradiated psoriasis, and 4.4 fold compared to 
irradiated with 290nm UVB (p<0.05)) (Figure 7-6). Up-regulation of FOSL1 
and JUNB are associated with reduced proliferation by targeting cyclin A2 
(Pan, Nakade et al. 2010) which affects both G1/S and G2/M, and may 
promote apoptosis (see JUNB above). 
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Figure 7-5. Canonical apoptotic pathway connecting key identified pro-
apoptotic genes to p53 and caspase 3. Ingenuity analysis revealed the above 
interactions. Direct connections are shown with uninterrupted lines, and indirect 
connections with dashed lines. Squares represent cytokines, interrupted 
squares are growth factors, diamonds are peptidases, ovals are transcription 
regulators and circles are other molecules. Red arrows show genes significantly 
up-regulation compared to un-irradiated psoriasis. Where no arrow exists the 
gene was not differentially regulated in the dataset, although related proteins for 
2 of these (TP53 (p53)-inducible nuclear protein and IGFL1) were both up-
regulated, suggesting that these genes may be activated rather than 
differentially regulated, or differentially regulated at a different time-point. Note 
this also links in with the antimicrobial peptide DEFB103A (HBD-3), insulin-like 
growth factor 1 (IGF-1/ somatomedin-c) and the NFκB complexes. 
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Figure 7-6. Expression fold change of genes in response to 311nm UVB 
and 290nm UVB at 4h and 18h post irradiation, compared to un-irradiated 
psoriasis for a) MDM2, b) IRF2, c) BUB1, d) AURKA, e) IL6 and f) FOSL1. 
Median and inter-quartile range shown, with whiskers indicating minimum and 
maximum values. Graphs shows normalised values centred around zero. Red 
plots represent irradiation with 311nm UVB and green plots represent 
irradiation with 290nm UVB. *Significant difference shown (p<0.05) (N.B 
comparison between 311nm at 4h and 290nm at 18h (and vice versa) not 
done). 
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7.3.3.2. Gene expression maximally differentially regulated 
at 18h post 311nm UVB irradiation 
The following genes were maximally differentially expressed at the 18h time-
point, and are pro-apoptotic. 
 GDF15 (growth differentiation factor 15; also known as MIC-1 or 
macrophage inhibitory cytokine-1) is a member of the Transforming Growth 
Factor beta superfamily and is located on chromosome 19. It is a 
transcriptional target gene for p53, and induces apoptosis via the MAPK 
signalling pathway (Yang, Choi et al. 2009). Interestingly it is thought to be 
a good prognostic marker for coronary artery disease (Schlittenhardt, 
Schober et al. 2004; Sun, Huang et al. 2010). It was persistently up-
regulated between 4h and 18h post 311nm UVB compared to un-irradiated 
psoriasis (5.9-6.4 fold), and 290nm UVB (5.9-6.0 fold) (p<0.05) (Figure 
7-7). 
 MMP3 is expressed by keratinocytes and encodes a protein from the matrix 
metalloproteinase family which are involved in the normal breakdown of 
extracellular matrix. This enzyme plays a central role in apoptosis and is 
thought to interrupt extracellular matrix survival signalling, therefore 
accelerating the apoptotic process (Levkau, Kenagy et al. 2002). It also has 
functions in wound repair and tumour formation, and is located on 
chromosome 11. It was up-regulated following 311nm irradiation at 4h and 
18h compared to un-irradiated psoriasis and 290nm irradiated psoriasis 
(p<0.05), but was maximal at 18h (9.5 and 10.7 fold change respectively). 
 IL24 (MDA7) is a member of the IL10 family of cytokines. It is located on 
chromosome one and over-expression leads to elevated levels of several 
GADD genes, down-regulating the anti-apoptotic BCL-2 proteins resulting 
in apoptosis (Sarkar, Su et al. 2002). IL24 is up-regulated following 311nm 
irradiation at both 4h and 18h compared to un-irradiated and 290nm-
irradiated psoriasis (p<0.05), but maximally at the latter time-point (3.2 and 
5.4 fold respectively). 
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 PIK3C2G encodes a protein belonging to the phosphoinositide 3-kinase 
(PI3K) family. These proteins coordinate a diverse range of cell functions 
including proliferation and cell survival. PI3K activation leads to activation of 
AKT, which in turn phosphorylates BAD enhancing survival, therefore 
acting on the mitochondrial apoptotic pathway. This gene is located on 
chromosome 12 and is down-regulated 4.6 fold 18h post 311nm compared 
to un-irradiated psoriasis and 5.5 fold post 290-irradiated psoriasis 
(p<0.05), therefore promoting apoptosis. 
 DUSP4 and 6 (dual specificity protein phosphatase) encodes a protein 
located on chromosome 8 and 12 respectively and are both up-regulated 
4h following 311nm irradiation 3.1 and 7.5 fold respectively compared to 
un-irradiated psoriasis (p<0.05), and 6.3 and 8.8 fold respectively 
compared to psoriasis irradiated with 290nm UVB (p<0.05). These 
negatively regulate the MAPK (mitogen-activated protein kinase) 
superfamily which are associated with cell proliferation and differentiation 
(e.g. MAPK, SPHK1/ JNK (MAPK8) and p38. MAPK was significantly down-
regulated 18h following 311nm in this experiment). Specifically, both 
inactivate ERK2 (MAPK1), and DUSP4 also inactivates ERK1 (MAPK3) 
and JNK (MAPK8), all of which are key regulators in cell differentiation and 
proliferation. 
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Figure 7-7. Expression fold change of genes in response to 290nm UVB at 
4h and 18h post irradiation, compared to un-irradiated psoriasis for 
GDF15. Median and inter-quartile range shown, with whiskers indicating 
minimum and maximum values. Graph shows normalised values centred 
around zero. Red plots represent irradiation with 311nm UVB and green plots 
represent irradiation with 290nm UVB. *Significant difference shown (p<0.05) 
(N.B comparison between 311nm at 4h and 290nm at 18h (and vice versa) not 
done). 
 
 
7.3.4. Adaptive immune system 
    Cytokines including TNFα, IL17 and IL22 are secreted by Th17 cells and are 
important in the development of psoriasis. At 4h post 311nm UVB four genes 
were differentially regulated from the IL17 canonical pathway compared to un-
irradiated psoriasis: AKT2, IL6 and MMP3 were up-regulated and IL19 was 
down-regulated (IL6 and MMP3 were also significantly differentially regulated 
compared to irradiation with 290nm UVB) (p<0.05). At 18h, eight genes were 
significantly differentially regulated compared to un-irradiated psoriasis, of 
which three genes were up-regulated (DEFB4, IL8 and MMP3) and five genes 
were down-regulated (MAPK10, PIK3C2G, IL19, IL17f and NOS2A) (p<0.05). 
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Of these MMP3, MAPK10, PIK3C2G, IL19 and NOS2A were also significantly 
differentially regulated compared to irradiation with 290nm at 18h. Therefore at 
these early time-points the Th17 pathway appears to be induced. 
 
 
7.3.5. Innate immune system 
    LCE2a, 2c, 3d and 3e were all significantly up-regulated in response to 
311nm UVB (p<0.05); in particular at the 18h time-point (4.2, 3.6, 4.9 and 6.2-
fold respectively compared to un-irradiated psoriasis and 4.1, 4.6, 3.1 and 3.7 
fold respectively compared to 290nm irradiated psoriasis), consistent with 
previous data which showed group up-regulation in response to UVB in NHEKs 
and in skin biopsies from four patients (Jackson, Tilli et al. 2005). It is thought 
that this may occur as a protective mechanism, although further research is 
necessary. de Cid et al recently showed reduced copy number of LCE3C and 
LCE3B in psoriatic skin compared to controls (de Cid, Riveira-Munoz et al. 
2009), suggesting that these genes may influence the psoriasis phenotype. 
    The gene with the largest fold change 18h following irradiation was the 
antimicrobial peptide DEFB103A (up-regulated by 10.8 fold 18h post 311nm 
irradiation compared to un-irradiated psoriasis, and 4.8 fold compared to 
psoriasis irradiated with 290nm UVB (p<0.05)) (Figure 7-8). DEFB103A, also 
known as HBD-3 (human beta defensin 3), is secreted by keratinocytes, and 
contain three disulphide bridges. It has a broad-spectrum antimicrobial activity 
but is preferentially active against gram-positive bacteria (Buchau and Gallo 
2007).  HBD-2 (also known as DEFB4) was up-regulated by 4.6 fold 18h post 
311nm UVB irradiation compared to un-irradiated psoriasis, but not significantly 
differentially regulated compared to 290nm UVB-irradiation. Both human 
defensins are located on chromosome eight, are inducibly expressed by 
keratinocytes, and are strongly expressed in the psoriatic epidermis. Their 
presence has been shown to stimulate release of the proinflammatory cytokines 
IL8, IL18 and IL20 from primary keratinocytes (Niyonsaba, Ushio et al. 2005). 
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Associations of HBD-3 and apoptosis/ cell cycle regulatory genes are shown 
below (Figure 7-9). 
 
 
Figure 7-8. The human beta defensin-3 gene (HBD-3/ DEFB103A) is up-
regulated by 311nm UVB at 18h compared to un-irradiated psoriasis and 
psoriasis irradiated with 290nm UVB. Median and inter-quartile range shown, 
with whiskers indicating minimum and maximum values. Graph shows 
normalised values centred around zero. Red plots represent irradiation with 
311nm UVB and green plots represent irradiation with 290nm UVB. *Significant 
difference shown (p<0.05) (N.B comparison between 311nm at 4h and 290nm 
at 18h (and vice versa) not done). 
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Figure 7-9. Functional network showing interactions between the 
antimicrobial peptide DEFB103A (HBD-3), and genes associated with 
apoptosis and cell cycle control. Red arrows show genes that were 
significantly up-regulated compared to un-irradiated psoriasis. 
 
Other antimicrobial peptides to be differentially regulated by UVB were: 
 PI3 encodes an elastase-specific inhibitor that functions as an antimicrobial 
peptide against Gram-positive and negative bacteria. It is located on 
chromosome 20 and was up-regulated by 4.1 fold 18h post 311nm UVB 
compared to un-irradiated psoriasis (p<0.05), this was not significantly 
differentially regulated compared to 290nm UVB. 
 S100A12 (Calgranulin C/ ENRAGE) is located on chromosome one and 
was up-regulated by 2.3 fold 18h post 311nm UVB compared to un-
irradiated psoriasis (p<0.05), this was not significantly differentially 
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regulated compared to 290nm UVB. It is a proinflammatory cytokine 
expressed by basal and suprabasal keratinocytes (Eckert, Broome et al. 
2004), and is over-expressed in psoriatic skin (Mirmohammadsadegh, 
Tschakarjan et al. 2000). It activates AGER (RAGE) which is located within 
the MHC class three region on chromosome six, which can drive cellular 
dysfunction. It is not known if this affects apoptosis. 
 NOS2A (nitric oxide synthesis 2; iNOS) is located on chromosome 17, and 
is down-regulated 2.1 fold at 18h post irradiation with 311nm UVB 
compared to un-irradiated psoriasis, and 2.1 fold compared to irradiated 
with 290nm UVB (p<0.05).  
 
 
7.3.6. Insulin resistance 
    There has been much interest in the recently discovered association 
between psoriasis and the metabolic syndrome, which leads to an increased 
risk of cardiovascular disease (Prodanovich, Kirsner et al. 2009). This is 
thought to be due to the effects of insulin resistance, and may be regulated by 
genes affecting platelet aggregation such as p-selectin. In particular up-
regulation of Peptidase inhibitor-3 (PI3) has been shown to be anti-atherogenic 
and in contrast to MAPK which is pro-atherogenic (Madonna, Pandolfi et al. 
2004). In this study cardiovascular genes ranked 5th in the functional datasets 
at the 18h time-point following irradiation with 311nm UVB compared to un-
irradiated psoriasis. Of the 149 genes significantly affected, 96 were associated 
with atherosclerosis, and 78 of these were down-regulated. This experiment 
showed that PI3 (anti-atherogenic) is up-regulated by four fold compared to un-
irradiated psoriasis but is not differentially regulated by 290nm UVB, Platelet 
derived growth factor-D (PDGF-D) is down-regulated 2.3 fold and MAPK (pro-
atherogeic) is down-regulated by 1.9 fold in biopsies taken 18h following 311nm 
compared to un-irradiated psoriasis, but not following irradiation with 290nm. 
Figure 7-10 shows interactions between the main genes involved. 
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Figure 7-10. Simplified diagram showing interaction of genes involved in 
cardiovascular risk factors. Squares represent cytokines, ovals are 
transcription regulators and double circles are complexes, and circles are other 
molecules. Uninterrupted lines show direct relationships and broken lines show 
indirect relationships. SELP (P-selectin) was not differentially regulated in the 
analysis. Red arrows show genes significantly up-regulated and green arrows 
show significant down-regulation compared to un-irradiated psoriasis 
 
 
7.3.7. Other genes of interest 
    It has previously been demonstrated that VEGF (which is released by 
keratinocytes) is elevated in psoriasis, and this decreases with treatment 
(Coimbra, Oliveira et al. 2010). In this study, CCL21 (which is an inhibitor of 
VEGF-c) was elevated 18h post treatment with 311nm UVB compared to un-
irradiated psoriasis (p<0.05) but was not significantly differentially regulated 
compared to 290nm UVB. VEGF was not differentially regulated at the time-
points studied. Therefore the data here is consistent with previous studies. 
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7.3.8. Differential regulation of genes by 290nm UVB-irradiation 
compared to 311nm UVB or un-irradiated psoriasis. 
In chapter five the concept of reduced penetration of 290nm UVB with respect 
to 311nm UVB was partly addressed. However, results from this gene array 
study clearly showed that some genes were preferentially affected following in 
vivo irradiation with 290nm rather than 311nm (Figure 7-1) (e.g. the keratin 
gene KRT77 (Figure 7-11) and the ATPase enzyme transporter gene 
ATP6v0A4), indicating that sufficient quantities of 290nm UVB penetrate into 
the epidermis to have significant biological effects. 
 
Figure 7-11. The Keratin 77 gene (Krt77) is down-regulated by both 311nm 
and 290nm UVB at 4h and 18h compared to un-irradiated psoriasis. Down-
regulation is most marked at 4h following 290nm. Median and inter-quartile 
range shown, with whiskers indicating minimum and maximum values. Graph 
shows normalised values centred around zero. Red plots represent irradiation 
with 311nm UVB and green plots represent irradiation with 290nm UVB. 
*Significant difference shown (p<0.05) (N.B comparison between 311nm at 4h 
and 290nm at 18h (and vice versa) not done). 
7-206 
 
7.3.9. Real-time PCR validation of 311nm UVB induced gene 
expression changes 
Five genes were chosen to validate the above arrays using a two-step real-time 
PCR reaction. These were chosen to represent differential regulation of genes 
at 4h and 18h post irradiation and following 311nm, and differential regulation 
between 290nm and 311nm UVB (section 2.6). The majority of DNA would be 
expected to amplify after 20-35 rounds of PCR if present in sufficient quantities, 
and would then reach a plateau with minimal further amplification. PCR which 
significantly amplifies DNA after 35 rounds is difficult to interpret as this 
suggests that very small quantities of the relevant gene were present within the 
DNA sample. As the quantity of each DNA sample has been standardised 
initially against an internal control (GADPH), it was known that the overall 
quantity of DNA was consistent between reactions, but if the gene is expressed 
at very low levels an accurate quantification is not possible unless the sample is 
run with a much larger DNA content (i.e. double the sample is required to 
amplify the DNA by just one Ct). As RNA had been extracted from micro-
dissected epidermis, relatively small quantities were available for PCR. 
Consequentially, the quantity of DNA obtained was insufficient in some samples 
were the gene is expressed at very low levels, and as a result baseline levels 
(i.e. un-irradiated lesional psoriasis) of some genes (such as GDF15 and 
FOSL1) were not quantified. In these cases, the differential regulation of genes 
following irradiation with 311nm and 290nm UVB are directly compared. Overall 
these data correlated well with the above gene array results (Figure 7-12 and 
Table 7-2), although overall significance was not achieved for most of the PCR 
reactions due to small sample numbers. 
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Figure 7-12. PCR results for 5 
differentially regulated genes within 
psoriatic epidermis. Up-regulation of 
a) CDKN1A at 4h post 311nm UVB and 
b) DEFB103A at 18h post 311nm UVB 
respectively compared to un-irradiated 
or 290nm-irradiated psoriasis. c) 
GDF15 up-regulation 18h following 
311nm UVB compared to the 4h time-
point; d) FOSL1 up-regulation at 4h 
following 311nm UVB compared to 18h; 
e) Keratin 77 is up-regulated 4h 
following 311nm UVB compared to 
290nm UVB-irradiation. Median and 
IQR shown with whiskers indicating 
maximum and minimum values. *  
indicates significance at p<0.05 using a 
Mann Whitney-U test. 
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Gene 
name 
Fold change following 
irradiation with 311nm 
measured by gene array  
 
Fold change following 
irradiation with 311nm 
measured by PCR 
CDKN1A ↑ x 4 at 4h compared to 
290nm UVB;   
↑ x 28 compared to un-
irradiated 
↑ x 2.8 at 4h compared to 
290nm UVB;   
↑ x 19 compared to un-
irradiated 
DEFB103A ↑ x 4.8 at 18h compared to 
290nm; 
↑ x 10.9 at 18h compared 
to un-irradiated 
↑ x 5.4 at 18h compared 
to 290nm; 
↑ x 3.8 at 18h compared 
to un-irradiated 
GDF15 ↑ x 1.1 at 18h compared to 
4h post 311nm UVB 
 
 
↑ x 5.5 at 18h compared 
to 4h post 311nm UVB 
FOSL1 ↑ x 3 at 4h compared to 
18h post 311nm UVB 
 
 
↑ x 10 at 4h compared to 
18h post 311nm UVB 
KRT77 ↓ x 3.5 fold at 4h with 
290nm compared to 4h 
post 311nm UVB 
 
↓ x 2.5 fold at 4h  with 
290nm compared to 4h 
post 311nm UVB 
Table 7-2. Comparison of gene expression changes as measured by gene 
array and PCR following irradiation of psoriatic epidermis in vivo. Results 
generally show good concordance, validating the array process. GADPDH was 
used as a control probe for each sample in the real time PCR reactions, and 
standard internal controls were used for the Illumina DASL arrays.  
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7.4. Discussion 
    Analysing the differential effects of a clinically effective and ineffective 
psoriatic treatment provides a novel way to interrogate which changes in the 
transcriptome may be important in clearing psoriasis. This study has focussed 
on early time-points (4h and 18h) after a single irradiation with 290 or 311nm 
UVB in order to discover genes which may have a causal role in clearing 
psoriasis, rather than those whose expression mirrors clinical improvement. 
The major pathways affected were apoptosis and cell cycle regulation, and 
interestingly these pathways overlap considerably at the gene level. The most 
highly differentially up-regulated apoptosis-inducing genes following 311nm 
UVB-irradiation (compared to 290nm UVB-irradiated or un-irradiated psoriasis) 
included CDKN1A (p21/ WAF1), MMP3, GDF15 and IL24. These genes act via 
the mitochondrial route to induce apoptosis. The observed apoptosis induction 
at the gene level is consistent with the detected UVB-induced keratinocyte 
apoptosis seen in vivo following irradiation with 311nm UVB to psoriatic 
plaques, and described in chapter three. 
    DASL arrays (see section 2.5.4) were used in these experiments which are 
specially designed to cope with RNA extracted from processed tissue 
specimens, by using short primers spanning approximately 50 bases. For the 
PCR reactions, specific primers containing approximately 60-100 base pairs 
were used. The results confirm that RNA processing was satisfactory as gene 
levels are reasonably consistent between patients; despite the expected effects 
on gene expression which may be present due to factors such as age, sex and 
previous UV exposure. Real-time PCR was performed using five of the above 
differentially regulated genes and GAPDH as a control. These reactions were 
run using some of the samples processed for the gene arrays, and successfully 
validate the array data.  
    The array data showed that 159 genes are differentially regulated by 
therapeutic UVB (18h) compared to un-irradiated and 290nm-irradiated 
psoriasis, and 46 following effective UVB (4h) compared to un-irradiated and 
290nm-irradiated psoriasis. Therefore over three times as many differentially 
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regulated genes were identified18h post 311nm UVB than at the 4h time-point, 
supporting the observed apoptosis demonstrated in previous chapters. 
    It is well known that UVB induces cell cycle arrest and these results suggest 
that arrest may occur in G1, with reduced checkpoint control in G2M consistent 
with reduced ability to repair damaged cells. Cells which are damaged beyond 
repair will undergo apoptosis in due course. However, it is interesting to note 
that many of the cell cycle regulatory genes were not differentially regulated by 
290nm compared to 311nm UVB, suggesting that they are not wavelength 
specific effects and may not directly contribute to clearance of psoriasis at the 
time-points studied. It would have been interesting to study a further time-point 
around 8-12h, to see whether a significant differential effect is observed 
between the two wavelengths, as the lack of differential effect could be 
explained by sampling the wrong time-point. 
     Other major pathways to be differentially regulated include inflammation, in 
particular the Th17 pathway, which was up-regulated after 311nm UVB. This is 
in-keeping with erythema seen post irradiation, in particular as the peak 
erythemal response seen following 311nm and 290nm UVB follow a similar 
time-course (Farr, Besag et al. 1988), although the difference in slope of the 
dose-response curves means that for a given multiple of the MED, erythema 
induced by 311nm will be of greater intensity than 290nm UVB (Farr and Diffey 
1985). 
    Attention has focused on antimicrobial peptides over the recent years. In 
particular LL37 which is expressed in keratinocytes and has previously been 
shown to be induced by UVB (Mallbris, Edstrom et al. 2005). It was therefore 
surprising that this peptide was not significantly differentially regulated in this 
study. However, in Mallbris study of eight patients (without psoriasis) biopsies 
were taken 24-28h post UVB, perhaps explaining the difference between the 
studies. The above data showed up-regulation of HBD-2, HBD-3, PI3 and 
S100A12 at the 18h time-point post 311nm UVB exposure compared to un-
irradiated psoriasis, consistent with published data which showed up-regulation 
of HBD-2 and HBD-3 24h post 313nm UVB both in normal epidermis in vivo 
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and in cultured keratinocytes (Glaser, Navid et al. 2009). Previous studies have 
confirmed that these anti-microbial peptides are expressed in higher levels in 
psoriatic skin than normal epidermis (Buchau and Gallo 2007), but whether 
further enhancement of expression of these peptides occur with UV exposure 
has not previously been elucidated. Interestingly, enhancing antimicrobial 
peptides further has been shown to induce apoptosis for LL37 (Barlow, Li et al. 
2006; Zasloff 2009) but the effects of high levels of other antimicrobial peptides 
on apoptosis have not yet been examined, and further work is necessary to 
investigate whether or not this may influence the apoptotic response. The 
known interactions between HBD-3, apoptotic genes and cell cycle regulatory 
genes is summarised in Figure 7-9. 
    Notably a few key genes were perhaps surprisingly not differentially 
regulated in this study, in particular NFκB (which is central to activation of the 
apoptotic pathway) and the effecter gene caspase-3. As such a significant level 
of apoptosis was seen within psoriatic epidermis at 18h post 311nm irradiation, 
it was expected that NFκB would be significantly differentially regulated 
compared to irradiation with 290nm UVB and un-irradiated psoriasis. The two 
most likely reasons for this are: firstly these genes were differentially expressed 
at different time-points and could therefore missed be because biopsies were 
only analysed at 4h and 18h post UVB; or secondly, that the gene levels are not 
affected, but may be cleaved/ phosphorylated etc therefore activating the gene 
to cause down-stream effects.  Further analysis of biopsies taken at time-points 
between 8h and 24h are required to study this further, but are beyond the 
scope of this thesis. 
    Finally, it is interesting to note that even at these early time-points, before 
any clinical improvement in psoriasis is observed, pro-atherogenic genes are 
down-regulated and anti-atherogenic genes are up-regulated, consistent with 
previous studies which have linked good control of psoriasis with improved 
cardiovascular risk factors, for example post treatment with methotrexate 
(Prodanovich, Ma et al. 2005). 
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7.5. Conclusions 
 Pro-apoptotic genes are expressed in psoriatic epidermis at early time-
points (4h) following irradiation with 311nm but not 290nm UVB. 
 UVB induces G1 arrest and reduces check-point control at G2M, but this 
effect is not specific to 311nm UVB-irradiation at the time-points studied. 
 Antimicrobial peptides appear to be further up-regulated by UVB at the 18h 
time-point. 
 UVB induces anti-atherogenic genes at the time-points studied. 
 The PCR studies successfully backed up the data obtained by gene arrays. 
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8. Concluding remarks 
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    This thesis unquestionably demonstrated the presence of keratinocyte 
apoptosis following in vivo irradiation of psoriatic plaques with a clinically 
effective dose of UVB (311nm), but not following an ineffective wavelength 
(290nm), using two different methodologys. It has previously been observation 
that irradiation of psoriasis with high doses (up to 28 times the MED) of UVB 
with wavelengths below 300nm did not improve psoriasis (Parrish and Jaenicke 
1981), and this provided a neat and novel way to distinguish which of the many 
effects of UVB may be important in clearing psoriasis. 
    A rigorous in vivo approach demonstrated that the observed differences in 
lesional keratinocyte apoptosis were not due to a differential time-course. The 
apoptotic time-course was also defined here for both wavelengths using 
primary human keratinocyte cultures. This was shown to be similar in both 
wavelengths, although 290nm UVB was actually a more potent inducer of 
apoptosis than 311nm in vitro. A further observation of interest was that 
keratinocyte apoptosis was primarily suprabasal, and apoptotic cells were often 
located within the rete ridges rather than above the dermal papillae. This 
suggested that the chromophore for UVB-induced apoptosis may be within the 
basal/ suprabasal layers (containing proliferating cells). Reduced penetration by 
wavelengths below 300nm may therefore account for the very low numbers of 
apoptotic cells seen following irradiation with these wavelengths in vivo but not 
in vitro.  
    Real-time experiments were designed to track primary keratinocytes in 
culture following exposure to both 311nm and 290nm UVB. This demonstrated 
that actively proliferating keratinocytes were more likely to undergo UVB-
induced apoptosis. Cells did not appear to influence their neighbours, 
suggesting that regulation by keratinocyte induced cytokines etc was unlikely. 
Cultured cells also had a wide range of time-of-onset for apoptosis following the 
initial irradiation, and a wide variation in the time taken for each cell to complete 
the apoptotic process was observed. The latter may be due to the extent of 
DNA damage received by the cell, and therefore the degree of attempted cell 
repair that occurs. These data were used in combination with observed 
numbers of apoptotic cells within the psoriatic plaques to estimate an 
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approximate rate of apoptosis. Flow cytometry experiments demonstrated that 
proliferating cells were indeed more likely to undergo apoptosis, and this 
applied to both stem and transit amplifying cells (although predominantly the 
latter) following irradiation of epidermis ex vivo. Further studies are required to 
confirm this observation in psoriatic epidermis. 
    The wavelength-dependence for UVB-induced apoptosis was examined by 
irradiating psoriatic plaques with equi-erythemogenic doses of UVB using a 
range of wavelengths, from 290nm to 320nm. This showed that significant 
keratinocyte apoptosis was induced using wavelengths between 301nm and 
311nm, but none at 296nm (or below) or at 320nm. Although the numbers of 
patients recruited did not allow demonstration that one of the three apoptosis-
inducing wavelengths (301nm, 306nm and 311nm) was significantly more 
effective than the others, the data suggested that 311nm UVB is likely to be 
equally effective, if not the most effective apoptosis-inducing wavelength tested. 
However there may be inter-patient variation suggesting the possibility of 
tailored UV phototherapy for the future.  
    To assess the overall contribution of UVB-induced keratinocyte apoptosis to 
psoriatic plaque remodelling, a mathematical model was created. A unique 
model of both normal and psoriatic epidermis was developed by combining 
histological observation with published data from the literature. Iterative testing 
of the model using established data ensured its robustness. The model 
predicted that if apoptosis was an important mechanism in clearing psoriasis, 
the majority of affected cells would be proliferating, and that both stem and 
transit amplifying cells would be affected. This was confirmed with experimental 
data. The model was used to dynamically demonstrate that the observed rate of 
apoptosis was sufficient to clear psoriasis following a number of repeated 
irradiations consistent with what is observed in clinical practice. This is the first 
time systems biology has been used to predict the effect of a psoriatic 
treatment, and may be applied to other treatments in the future. 
    The genes which may be important in triggering the apoptotic process were 
investigated at an early time-point (4h) prior to any histological suggestion of 
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apoptosis, and at 18h when apoptosis is just observed in biopsy specimens, but 
no apoptotic/ plaque clearing effect would be clinically apparent in vivo. 
Interestingly a number of important pro-apoptotic genes were found to be 
significantly up-regulated from 4h (such as CDKN1A/ p21/WAF1) following 
311nm but not 290nm to psoriasis in vivo, and several anti-apoptotic genes 
were significantly down-regulated following 311nm but not 290nm compared to 
un-irradiated psoriasis. These genes all induce apoptosis via the mitochondrial 
pathway, consistent with previous work in the lab on dithranol (McGill, Frank et 
al. 2005). Importantly however, 290nm UVB differentially regulated several 
genes compared to un-irradiated psoriasis and 311nm UVB, suggesting that 
sufficient 290nm UVB penetrates into the epidermis to induce a biologically 
significant effect, although this may be predominantly within the upper 
epidermis. Unexpectedly, genes controlling atherosclerosis were also 
significantly differentially regulated, and anti-microbial peptides were also 
significantly differentially up-regulated compared to un-irradiated and 290nm-
irradiated psoriasis. The latter will be further investigated in future work. 
      Finally, monitoring patients‟ weekly PASI scores during their routine 
narrowband phototherapy treatment allowed analysis of the rate of patient 
clearance, irrespective of whether or not they complete the course. This also 
partly deals with patients‟ psoriasis flaring up part way through a treatment 
course, which may confound the end effect of a treatment course. For example, 
a patient may be clearing well, but then have a streptococcal throat infection 
during their phototherapy course, leading to a super-antigen response and 
consequent deterioration in their psoriasis. Measuring a single PASI score at 
the beginning and end of a treatment course does not consider such flares, and 
as such a course of UVB may be deemed to be unsuccessful despite an initially 
good response to treatment. Assessment of weekly PASI scores can highlight 
such a flare, and this can be taken into account when determining patient 
response. This study found that 35% of patients did not achieve a PASI 90 
overall, consistent with previous reports (see sections 1.3.1 and 3.3.10). 
However, further analysis revealed that this reduces to 17% when patients‟ with 
a disease flare-up / had dropped out before at least six weeks of treatment, 
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were excluded. An interesting extension to this work would therefore be to 
monitor weekly PASI scores in a larger number of patients undergoing routine 
therapy, so see if many of the „poor responders‟ are actually patients that 
experience a flare-up of their disease. This would suggest that patients may 
benefit from concurrent therapy aimed at suppressing cytokine production.  
    Overall this thesis demonstrates that keratinocyte apoptosis can directly 
account for clearance of psoriatic plaques, and challenges the previous in vitro 
observations that psoriatic keratinocytes are relatively resistant to apoptosis 
(Wrone-Smith, Mitra et al. 1997). This has important implications in the design 
of future therapeutic options for psoriasis, and suggests that treatments either 
directly targeting apoptosis or acting synergistically with them may be highly 
effective in clearing disease. Importantly, the model predicts that clearance 
induced by keratinocyte apoptosis can induce long term remission, although in 
contrast to T cell/ cytokine therapies, it would not prevent a new trigger (e.g. 
super-antigen exposure) from inducing further psoriasis. 
    Further work which arises from this thesis includes analysis of which part of 
the cell cycle leaves cells most susceptible to apoptosis, and whether or not this 
can be utilised in the clinical situation to enhance the apoptotic effect of 
therapeutic wavelengths of UVB in psoriasis clearance. For example, using a 
topical agent to induce cell cycle arrest in G2M, combined with phototherapy. 
This may lead to shorter treatment courses (and therefore quicker clinical 
response), with an improved safety profile by reducing total UV exposure.  
    Separating patients into good and poor responders (according to PASI 
response) will allow further insight into the mechanism of UVB-induced 
clearance of psoriasis, and indicate which pathways are differentially regulated 
when patients respond well to treatment. Further data-mining of the gene array 
analysis generated here may identify common pathways and potential 
biomarkers which are differentially regulated in the good versus poor 
responders. This will help identify why some patients‟ psoriasis responds better 
to UVB phototherapy, and will provide greater insight into the mechanisms of 
UVB clearance of plaques. Understanding these mechanisms will allow further 
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optimisation of phototherapy and potentially other therapeutic modalities in 
clinical practice. 
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The Newcastle Upon Tyne Hospitals       
       NHS Trust 
           
     Royal Victoria Infirmary 
       Newcastle Upon Tyne 
        NE1 4LP 
        Tel: 0191 2824214 
 
PATIENT  INFORMATION SHEET A
1
 
 
EFFECTS AND MECHANISMS OF ULTRAVIOLET B (UVB) IN PSORIASIS. 
 
We would like to invite you to participate in a research study. Before you decide 
whether you will participate, it is important that you understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully. Talk to others about this study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part 
 Part 2 gives you more detailed information about the conduct of the study 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
 
Part 1 
What is the purpose of this study? 
Light therapy, particularly UVB (ultraviolet B) therapy is an effective method of treating 
psoriasis. Although we know that this can be very effective in many patients, we don‟t 
know exactly how it works, or which wavelengths of light will be most effective. This 
study is designed to address both these issues. We will look at samples of skin before 
and after exposure to different wavelengths of UVB, to see whether special proteins 
                                            
1
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have been altered. We will also look at the effects of different wavelengths of light, as 
described below. The benefit of finding out how light treatments work and which part of 
light is most helpful, is that it may enable us to design new treatment regimes in the 
future, which may work more effectively and have less side effects.  The maximum 
amount of time you could be involved with this study is 6- 8 weeks (i.e. the duration of 
your UVB course). 
This research will form the basis of a thesis for a PhD. 
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Why have I been asked to help? 
Your doctor has prescribed UVB as part of the treatment for your psoriasis. You will 
therefore be given this treatment routinely, and will be required to attend 3 times per 
week for treatment. If you decide to participate in this trial you will have up to 4 small 
areas of psoriasis and 4 areas of uninvolved skin treated with a separate light source, 
as explained below. Following this, treatment to all areas will continue as normal. 
In total we are asking approximately 120 patients to participate in this study (into 1 of 6 
groups). We are now recruiting patients to group A; this is explained below. 
 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you are considering taking 
part you will be given this information sheet to keep, and will be asked to sign a 
consent form if you decide to go ahead (you will be given a copy of this to keep). If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
 
What will happen to me if I decide to take part? (Group A) 
You will be involved in the research for up to 4 days before starting your UVB 
treatment. We are examining the effects of UV light both at wavelengths which are, 
and wavelengths which are not helpful in treating psoriasis. This will help us work out 
why UV clears psoriasis, and may help improve UV treatment in the future. We will fully 
explain to you what will be involved before you decide to participate. Your normal 
treatment will not be affected.  
 
Visit 1  
On day 1 we will test how sensitive your skin is to UV by shining increasing amounts of 
the UV to be tested onto your skin. Skin sensitivity testing is done routinely whether or 
not you participate.  
 
Visit 2 (approximately 45 minutes) 
We then see you as usual on day 2 (24 hours later) to read the results. At this visit, we 
will also shine a specific light on up to 4 small areas (15mm) of normal skin and on up 
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to 4 similar areas of psoriatic skin. Occasionally this may cause a slight redness or 
burning to that area of skin, although this will be temporary.  
 
Visits 3/4 (approximately 15 minutes each) 
You will be asked to attend on 2 further visits for this study. These will be between 12 
hours and 3 days after the UV (you will be informed when this will be before deciding 
whether to participate). This time intervals will have been chosen to give us the most 
helpful results, and will mean that your time and effort in participating in the study will 
be put to the most use. 
 
We need to examine biopsies from normal and involved skin in patients with psoriasis. 
Skin biopsies are small samples of skin (4-6mm across) which are taken following the 
injection of a small amount of local anaesthetic. Local injection is painful for the first 4-5 
seconds but following this the area of skin is not sensitive to pain. We usually insert 1or 
2 stitches after the biopsy has been taken, although on occasions a stitch may not be 
required. If a stitch is required, this will need to be removed two weeks later either by 
the practice nurse at your GP surgery, or by the phototherapy nurses when you attend 
for your treatment. In total we would ask you to have up to 4 skin biopsies during your 
involvement in this study. 
 
You will be asked to provide a blood sample for later analysis, and this will be stored. 
This is entirely voluntary. 
 
We will also examine your skin before treatment and at weekly intervals when you 
attend for your routine UV treatment; this will take approximately 10 minutes on each 
occasion, and will not cause discomfort. Photographs may be taken of selected areas 
of your skin to show clearance of psoriasis, although you will not be identifiable from 
these. 
 
 
 
Expenses and payments 
You will be asked to make 3 extra visits to hospital as part of your involvement in the 
study. Extra visits will be kept to a minimum and every effort will be made to make the 
timing of visits as convenient as possible for participants. We will reimburse expenses 
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for additional visits, e.g. bus fare, petrol, parking etc. However, if you need to take a 
taxi to make the journey please inform us of this in advance. 
 
What do I have to do? 
Your involvement in this study will not affect your day-to-day activities. However, 
following a biopsy we will ask you to keep this area clean and dry for at least 2 days, 
and to contact us on the telephone number below if you have any concerns about the 
wound. 
 
 
What are the side effects of any treatment received when taking part? 
As with your normal light treatment, it is possible that you may get some transient 
reddening of your skin in the areas treated (similar to a mild sunburn). This should not 
require any specific treatment, although we would ask you to let us know if this does 
occur. 
 
Biopsies, just like any small cut in the skin, may bleed a little, although this should stop 
if you apply firm and continuous pressure to the area for 5-10 minutes. The anaesthetic 
used to numb your skin will wear off after a few hours, and it may therefore be helpful 
to take some simple painkillers like paracetamol, when you get back home. The risk of 
infection in the wound is small, however the risk will increase if you leave a wet 
dressing in place. You will therefore be given spare dressings to take home, and asked 
to contact us or your GP if you have any concerns about this. Finally, biopsies will 
leave a small scar; and although this tends to fade with time, there is usually a small 
permanent mark. 
 
 
What are the possible benefits of taking part? 
Although we believe that this work will help us understand and improve the treatment 
of psoriasis, it is important to realise that we do not expect you to benefit directly by 
volunteering for this study.  
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What if there is a problem? 
Any complaint about the way you have been dealt with during this study or side effects 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
 
Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
 
Contact for further information. 
If you require further information about the trial, Dr S Weatherhead, Prof P Farr or Prof 
N Reynolds can be contacted in the Dermatology department on 0191 2824214. If you 
have any concerns during your involvement in the study, 24 hour help can be received 
by calling 0191 2825599. 
 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making a decision. 
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PATIENT  INFORMATION SHEET B 
 
EFFECTS AND MECHANISMS OF ULTRAVIOLET B (UVB) IN PSORIASIS. 
 
We would like to invite you to participate in a research study. Before you decide 
whether you will participate, it is important that you understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully. Talk to others about this study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part 
 Part 2 gives you more detailed information about the conduct of the study 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of this study? 
Light therapy, particularly UVB (ultraviolet B) therapy is an effective method of treating 
psoriasis. Although we know that this can be very effective in many patients, we don‟t 
know exactly how it works, or which wavelengths of light will be most effective. This 
study is designed to address both these issues. We will look at samples of skin before 
and after exposure to different wavelengths of UVB, to see whether special proteins 
have been altered. We will also look at the effects of different wavelengths of light, as 
described below. The benefit of finding out how light treatments work and which part of 
light is most helpful, is that it may enable us to design new treatment regimes in the 
future, which may work more effectively and have less side effects.  The maximum 
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amount of time you could be involved with this study is 6- 8 weeks (i.e. the duration of 
your UVB course). 
This research will form the basis of a thesis for a PhD. 
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Why have I been asked to help? 
Your doctor has prescribed UVB as part of the treatment for your psoriasis. You will 
therefore be given this treatment routinely, and will be required to attend 3 times per 
week for treatment. If you decide to participate in this trial you will have up to 4 small 
areas of psoriasis and 4 areas of uninvolved skin treated with a separate light source, 
as explained below. Following this, treatment to all areas will continue as normal. 
 
In total we are asking approximately 120 patients to participate in this study (into 1 of 6 
groups). We are now recruiting patients to group B; this is explained below. 
 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you are considering taking 
part you will be given this information sheet to keep, and will be asked to sign a 
consent form if you decide to go ahead (you will be given a copy of this to keep). If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
 
What will happen to me if I decide to take part?  
You will be involved in the research for up to 4 days before starting your UVB 
treatment. We are examining which of the many effects of UV light are important  
for psoriasis clearance, and this may help improve UV treatment in the future. We will 
fully explain to you what will be involved before you decide to participate. Your normal 
treatment will not be affected.  
 
Visit 1 
On day 1 we will test how sensitive your skin is to UV by shining increasing amounts of 
the UV to be tested onto your skin (this is done routinely whether or not you 
participate).  
 
Visit 2 (approximately 60 minutes) 
We then see you as usual on day 2 (24 hours later) to read the results. At this visit, we 
will shine different doses of UV onto 4 small areas (15mm) of normal skin and onto 4 
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similar areas of psoriatic skin. Occasionally this may cause a slight redness or burning 
to that area of skin, although this will be temporary.  
 
Visit 3 (approximately 30-40 minutes) 
You will be asked to attend on 1 further occasion for this study. These will be between 
12 hours and 3 days after the UV (you will be informed when this will be before 
deciding whether to participate). This time interval will have been chosen to give us the 
most helpful results, and will mean that your time and effort in participating in the study 
will be put to the most use. 
 
We need to examine biopsies from normal and involved skin in patients with psoriasis. 
Skin biopsies are small samples of skin (4-6mm across) which are taken following the 
injection of a small amount of local anaesthetic. Local injection is painful for the first 4-5 
seconds but following this the area of skin is not sensitive to pain. We usually insert 1or 
2 stitches after the biopsy has been taken, although on occasions a stitch may not be 
required. If a stitch is required, this will need to be removed two weeks later either at 
the practice nurse by your GP surgery, or by the phototherapy nurses when you attend 
for your treatment. In total we would ask you to have up to 4 skin biopsies during your 
involvement in this study. 
 
You will be asked to provide a blood sample for later analysis, and this will be stored. 
This is entirely voluntary. 
 
We will also examine your skin before treatment and at weekly intervals when you 
attend for your routine UV treatment; this will take approximately 10 minutes on each 
occasion, and will not cause discomfort. Photographs may be taken of selected areas 
of your skin to show clearance of psoriasis, although you will not be identifiable from 
these. 
 
 
Expenses and payments 
You will be asked to make at 2 extra visits to hospital as part of your involvement in the 
study. Extra visits will be kept to a minimum and every effort will be made to make the 
timing of visits as convenient as possible for participants. We will reimburse expenses 
for additional visits, e.g. bus fare, petrol, parking etc. However, if you need to take a 
taxi to make the journey please inform us of this in advance. 
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What do I have to do? 
Your involvement in this study will not affect your day-to-day activities. However, 
following a biopsy we will ask you to keep this area clean and dry for at least 2 days, 
and to contact us on the telephone number below if you have any concerns about the 
wound. 
 
 
What are the side effects of any treatment received when taking part? 
As with your normal light treatment, it is possible that you may get some transient 
reddening of your skin in the areas treated (similar to a mild sunburn). This should not 
require any specific treatment, although we would ask you to let us know if this does 
occur. 
 
Biopsies, just like any small cut in the skin, may bleed a little, although this should stop 
if you apply firm and continuous pressure to the area for 5-10 minutes. The anaesthetic 
used to numb your skin will wear off after a few hours, and it may therefore be helpful 
to take some simple painkillers like paracetamol, when you get back home. The risk of 
infection in the wound is small, however the risk will increase if you leave a wet 
dressing in place. You will therefore be given spare dressings to take home, and asked 
to contact us or your GP if you have any concerns about this. Finally, biopsies will 
leave a small scar; and although this tends to fade with time, there is usually a small 
permanent mark. 
 
 
What are the possible benefits of taking part? 
Although we believe that this work will help us understand and improve the treatment 
of psoriasis, it is important to realise that we do not expect you to benefit directly by 
volunteering for this study.  
 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during this study or side effects 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
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Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
 
 
Contact for further information. 
If you require further information about the trial, Dr S Weatherhead, Prof P Farr or Prof 
N Reynolds can be contacted in the Dermatology department on 0191 2824214. If you 
have any concerns during your involvement in the study, 24 hour help can be received 
by calling 0191 2825599. 
 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making a decision. 
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PATIENT  INFORMATION SHEET C 
 
EFFECTS AND MECHANISMS OF ULTRAVIOLET B (UVB) IN PSORIASIS. 
 
We would like to invite you to participate in a research study. Before you decide 
whether you will participate, it is important that you understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully. Talk to others about this study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part 
 Part 2 gives you more detailed information about the conduct of the study 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
 
Part 1 
What is the purpose of this study? 
Light therapy, particularly UVB (ultraviolet B) therapy is an effective method of treating 
psoriasis. Although we know that this can be very effective in many patients, we don‟t 
know exactly how it works, or which wavelengths of light will be most effective. This 
study is designed to address both these issues. We will look at samples of skin before 
and after exposure to different wavelengths of UVB, to see whether special proteins 
have been altered. We will also look at the effects of different wavelengths of light, as 
described below. The benefit of finding out how light treatments work and which part of 
light is most helpful, is that it may enable us to design new treatment regimes in the 
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future, which may work more effectively and have less side effects.  The maximum 
amount of time you could be involved with this study is 6- 8 weeks (i.e. the duration of 
your UVB course). 
 
This research will form the basis of a thesis for a PhD. 
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Why have I been asked to help? 
Your doctor has prescribed UVB as part of the treatment for your psoriasis. You will 
therefore be given this treatment routinely, and will be required to attend 3 times per 
week for treatment. If you decide to participate in this trial you will have up to 4 small 
areas of psoriasis treated with a separate light source, as explained below. Following 
this, treatment to all areas will continue as normal. 
In total we are asking approximately 120 patients to participate in this study (into 1 of 6 
groups). We are now recruiting patients to group C; this is explained below. 
 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you are considering taking 
part you will be given this information sheet to keep, and will be asked to sign a 
consent form if you decide to go ahead (you will be given a copy of this to keep). If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
 
What will happen to me if I decide to take part?  
You will be involved in this research for up to 2 days before starting your UVB 
treatment, and then during the first 2 ½ weeks of routine treatment. We are examining 
which of the many effects of UV light are important for psoriasis clearance, and this 
may help improve UV treatment in the future. We will fully explain to you what will be 
involved before you decide to participate. Your normal treatment will not be affected. 
You will be asked to attend on 1 additional occasion as part of your involvement in this. 
 
Visit 1 
On day 1 we will test how sensitive your skin is to UV by shining increasing amounts of 
the UV to be tested onto your skin (this is done routinely whether or not you 
participate).  
 
Visit 2 
We then see you as usual on day 2 (24 hours later) to read the results. At this visit, you 
will start your routine treatment but with 4 small areas (15mm) of psoriasis on covered 
up. These areas will be treated with UV just before or just after your routine treatment, 
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and are likely to clear much quicker than the rest of your psoriasis. Occasionally this 
may cause a slight redness or burning to that area of skin, although this will be 
temporary.  
 
Visits alongside routine treatment: (approximately 30-60 minutes per visit)  
You will be asked to attend for normal phototherapy 3 times per week. Over the next 7 
occasions we will repeat the extra doses of UV (as for visit 2). On each occasion we 
will treat the same small areas of skin with UV, although we ask that you keep the 
areas we are assessing covered during your standard treatment, until your involvement 
in the study is completed.  
 
Additional visit: (approximately 30 minutes) 
Four skin biopsies (see below) will be taken on 1 occasion between 12 hours and 3 
days after the UV (you will be informed when this will be before deciding whether to 
participate). This time interval will have been chosen to give us the most helpful 
results, and will mean that your time and effort in participating in the study will be put to 
the most use. 
 
Skin biopsies are small samples of skin (4-6mm across) which are taken following the 
injection of a small amount of local anaesthetic. Local injection is painful for the first 4-5 
seconds but following this the area of skin is not sensitive to pain. We usually insert 1or 
2 stitches after the biopsy has been taken, although on occasions a stitch may not be 
required. If a stitch is required, this will need to be removed two weeks later either by 
the practice nurse at your GP surgery, or by the phototherapy nurses when you attend 
for your treatment. In total we would ask you to have up to 4 skin biopsies during your 
involvement in this study. 
 
You will be asked to provide a blood sample for later analysis, and this will be stored. 
This is entirely voluntary. 
 
We will also examine your skin before treatment and at weekly intervals when you 
attend for your routine UV treatment; this will take approximately 10 minutes on each 
occasion, and will not cause discomfort. Photographs may be taken of selected areas 
of your skin to show clearance of psoriasis, although you will not be identifiable from 
these. 
Expenses and payments 
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You will be asked to make at least 1 extra visit to hospital as part of your involvement 
in the study. Extra visits will be kept to a minimum and every effort will be made to 
make the timing of visits as convenient as possible for participants. We will reimburse 
expenses for additional visits, e.g. bus fare, petrol, parking etc. However, if you need to 
take a taxi to make the journey please inform us of this in advance. 
 
 
What do I have to do? 
Your involvement in this study will not affect your day-to-day activities. However, 
following a biopsy we will ask you to keep this area clean and dry for at least 2 days, 
and to contact us on the telephone number below if you have any concerns about the 
wound. 
 
 
What are the side effects of any treatment received when taking part? 
As with your normal light treatment, it is possible that you may get some transient 
reddening of your skin in the areas treated (similar to a mild sunburn). This should not 
require any specific treatment, although we would ask you to let us know if this does 
occur. 
 
Biopsies, just like any small cut in the skin, may bleed a little, although this should stop 
if you apply firm and continuous pressure to the area for 5-10 minutes. The anaesthetic 
used to numb your skin will wear off after a few hours, and it may therefore be helpful 
to take some simple painkillers like paracetamol, when you get back home. The risk of 
infection in the wound is small, however the risk will increase if you leave a wet 
dressing in place. You will therefore be given spare dressings to take home, and asked 
to contact us or your GP if you have any concerns about this. Finally, biopsies will 
leave a small scar; and although this tends to fade with time, there is usually a small 
permanent mark. 
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What are the possible benefits of taking part? 
Although we believe that this work will help us understand and improve the treatment 
of psoriasis, it is important to realise that we do not expect you to benefit directly by 
volunteering for this study.  
 
What if there is a problem? 
Any complaint about the way you have been dealt with during this study or side effects 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
 
Contact for further information. 
If you require further information about the trial, Dr S Weatherhead, Prof P Farr or Prof 
N Reynolds can be contacted in the Dermatology department on 0191 2824214. If you 
have any concerns during your involvement in the study, 24 hour help can be received 
by calling 0191 2825599. 
 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making a decision. 
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PATIENT  INFORMATION SHEET D 
 
EFFECTS AND MECHANISMS OF ULTRAVIOLET B (UVB) IN PSORIASIS. 
 
We would like to invite you to participate in a research study. Before you decide 
whether you will participate, it is important that you understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully. Talk to others about this study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part 
 Part 2 gives you more detailed information about the conduct of the study 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of this study? 
Light therapy, particularly UVB (ultraviolet B) therapy is an effective method of treating 
psoriasis. Although we know that this can be very effective in many patients, we don‟t 
know exactly how it works, or which wavelengths of light will be most effective. This 
study is designed to address both these issues. We will look at samples of skin before 
and after exposure to different wavelengths of UVB, to see whether special proteins 
have been altered. We will also look at the effects of different wavelengths of light, as 
described below. The benefit of finding out how light treatments work and which part of 
light is most helpful, is that it may enable us to design new treatment regimes in the 
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future, which may work more effectively and have less side effects.  The maximum 
amount of time you could be involved with this study is 6- 8 weeks (i.e. the duration of 
your UVB course). 
 
This research will form the basis of a thesis for a PhD. 
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Why have I been asked to help? 
Your doctor has prescribed UVB as part of the treatment for your psoriasis. You will 
therefore be given this treatment routinely, and will be required to attend 3 times per 
week for treatment. If you decide to participate in this trial you will have up to 2 small 
areas of psoriasis treated with a separate light source, as explained below. Following 
this, treatment to all areas will continue as normal. 
In total we are asking approximately 120 patients to participate in this study (into 1 of 6 
groups). We are now recruiting patients to group D; this is explained below. 
 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you are considering taking 
part you will be given this information sheet to keep, and will be asked to sign a 
consent form if you decide to go ahead (you will be given a copy of this to keep). If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
 
What will happen to me if I decide to take part?  
You will be involved in this research for up to 2 days before starting your UVB 
treatment. We are examining the effects of UV light both at wavelengths which are, 
and wavelengths which are not helpful in treating psoriasis. This will help us work out 
why UV clears psoriasis, and may help improve UV treatment in the future. We will fully 
explain to you what will be involved before you decide to participate. Your normal 
treatment will not be affected.  
 
Visit 1 
On day 1 we will test how sensitive your skin is to UV by shining increasing amounts of 
the UV to be tested onto your skin. Skin sensitivity testing is done routinely whether or 
not you participate.  
 
Visit 2 (maximum 3h) 
We then see you as usual on day 2 (24 hours later) to read the results. At this visit, we 
will shine 2 different wavelengths of light onto small areas (15mm) of your psoriasis. In 
total this process takes approximately 45 minutes. Occasionally this may cause a slight 
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redness or burning to that area of skin, although this will be temporary. Four and 18 
hours later, we will need to take 2 skin biopsies from your psoriasis (this will take an 
additional 20 minutes), to work out what effects the different wavelengths of light have 
had on your skin.  
 
Skin biopsies are small samples of skin (4-6mm across) which are taken following the 
injection of a small amount of local anaesthetic. Local injection is painful for the first 4-5 
seconds but following this the area of skin is not sensitive to pain. We usually insert 1or 
2 stitches after the biopsy has been taken, although on occasions a stitch may not be 
required. If a stitch is required, this will need to be removed two weeks later either by 
the practice nurse at your GP surgery, or by the phototherapy nurses when you attend 
for your treatment. In total we would ask you to have up to 2 skin biopsies during your 
involvement in this study. 
 
You will be asked to provide a blood sample for later analysis, and this will be stored. 
This is entirely voluntary. 
 
 
Expenses and payments 
It is possible that you will be asked to make an extra visit to hospital as part of your 
involvement in the study. Extra visits will be kept to a minimum and every effort will be 
made to make the timing of visits as convenient as possible for participants. We will 
reimburse expenses for additional visits, e.g. bus fare, petrol, parking etc. However, if 
you need to take a taxi to make the journey please inform us of this in advance. 
 
 
What do I have to do? 
Your involvement in this study will not affect your day-to-day activities. However, 
following a biopsy we will ask you to keep this area clean and dry for at least 2 days, 
and to contact us on the telephone number below if you have any concerns about the 
wound. 
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What are the side effects of any treatment received when taking part? 
As with your normal light treatment, it is possible that you may get some transient 
reddening of your skin in the areas treated (similar to a mild sunburn). This should not 
require any specific treatment, although we would ask you to let us know if this does 
occur. 
 
Biopsies, just like any small cut in the skin, may bleed a little, although this should stop 
if you apply firm and continuous pressure to the area for 5-10 minutes. The anaesthetic 
used to numb your skin will wear off after a few hours, and it may therefore be helpful 
to take some simple painkillers like paracetamol, when you get back home. The risk of 
infection in the wound is small, however the risk will increase if you leave a wet 
dressing in place. You will therefore be given spare dressings to take home, and asked 
to contact us or your GP if you have any concerns about this. Finally, biopsies will 
leave a small scar; and although this tends to fade with time, there is usually a small 
permanent mark. 
 
 
What are the possible benefits of taking part? 
Although we believe that this work will help us understand and improve the treatment 
of psoriasis, it is important to realise that we do not expect you to benefit directly by 
volunteering for this study.  
 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during this study or side effects 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
 
Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
 
Contact for further information. 
If you require further information about the trial, Dr S Weatherhead, Prof P Farr or Prof 
N Reynolds can be contacted in the Dermatology department on 0191 2824214. If you 
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have any concerns during your involvement in the study, 24 hour help can be received 
by calling 0191 2825599. 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making a decision. 
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PATIENT  INFORMATION SHEET E 
 
EFFECTS AND MECHANISMS OF ULTRAVIOLET B (UVB) IN PSORIASIS. 
 
We would like to invite you to participate in a research study. Before you decide 
whether you will participate, it is important that you understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully. Talk to others about this study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part 
 Part 2 gives you more detailed information about the conduct of the study 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
 
Part 1 
What is the purpose of this study? 
Light therapy, particularly UVB (ultraviolet B) therapy is an effective method of treating 
psoriasis. Although we know that this can be very effective in many patients, we don‟t 
know exactly how it works, or which wavelengths of light will be most effective. This 
study is designed to address both these issues. We will look at samples of skin before 
and after exposure to different wavelengths of UVB, to see whether special proteins 
have been altered. We will also look at the effects of different wavelengths of light, as 
described below. The benefit of finding out how light treatments work and which part of 
light is most helpful, is that it may enable us to design new treatment regimes in the 
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future, which may work more effectively and have less side effects.  The maximum 
amount of time you could be involved with this study is 6- 8 weeks (i.e. the duration of 
your UVB course). 
 
This research will form the basis of a thesis for a PhD. 
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Why have I been asked to help? 
Your doctor has prescribed UVB as part of the treatment for your psoriasis. You will 
therefore be given this treatment routinely, and will be required to attend 3 times per 
week for treatment. If you decide to participate in this trial you will have up to 4 small 
areas of psoriasis and 4 areas of uninvolved skin treated with a separate light source, 
as explained below. Following this, treatment to all areas will continue as normal. 
In total we are asking approximately 120 patients to participate in this study (into 1 of 6 
groups). We are now recruiting patients to group E; this is explained below. 
 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you are considering taking 
part you will be given this information sheet to keep, and will be asked to sign a 
consent form if you decide to go ahead (you will be given a copy of this to keep). If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
 
What will happen to me if I decide to take part?  
You will be involved in this research for up to 4 days before starting your UVB 
treatment. We are examining the effects of UV light both at wavelengths which are, 
and wavelengths which are not helpful in treating psoriasis. This will help us work out 
why UV clears psoriasis, and may help improve UV treatment in the future. We will fully 
explain to you what will be involved before you decide to participate. Your normal 
treatment will not be affected.  
 
Visit 1 
On day 1 we will test how sensitive your skin is to UV by shining increasing amounts of 
the UV to be tested onto your skin.  Skin sensitivity testing is done routinely whether or 
not you participate, but we will also test your sensitivity to the other wavelengths that 
we are using.  
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Visit 2 
We then see you as usual on day 2 (24 hours later) to read the results. At this visit, we 
will shine 4 different wavelengths of light onto 4 small areas (15mm) of your psoriasis, 
and onto your normal skin. In total this process takes approximately 60 minutes. 
Occasionally this may cause a slight redness or burning to that area of skin, although 
this will be temporary.  
 
Visit 3 
You will be asked to attend once more to complete your involvement in the study.  In 
order to make this as convenient as possible, this visit will usually coincide with your 
first routine treatment in the phototherapy department, and will take an additional 30 
minutes. 
 
We will need to examine biopsies from your normal and involved skin, to work out what 
effects the different ranges of light have had on your skin. Skin biopsies are small 
samples of skin (4-6mm across) which are taken following the injection of a small 
amount of local anaesthetic. Local injection is painful for the first 4-5 seconds but 
following this the area of skin is not sensitive to pain. We usually insert 1or 2 stitches 
after the biopsy has been taken, although on occasions a stitch may not be required. If 
a stitch is required, this will need to be removed two weeks later either by the practice 
nurse at your GP surgery, or by the phototherapy nurses when you attend for your 
treatment. In total we would ask you to have up to 4 skin biopsies during your 
involvement in this study. 
 
You will be asked to provide a blood sample for later analysis, and this will be stored. 
This is entirely voluntary. 
 
We will also examine your skin before treatment and at weekly intervals when you 
attend for your routine UV treatment; this will take approximately 10 minutes on each 
occasion, and will not cause discomfort. Photographs may be taken of selected areas 
of your skin to show clearance of psoriasis, although you will not be identifiable from 
these. 
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Expenses and payments 
It is possible that you will be asked to make an extra visit to hospital as part of your 
involvement in the study. Extra visits will be kept to a minimum and every effort will be 
made to make the timing of visits as convenient as possible for participants. We will 
reimburse expenses for additional visits, e.g. bus fare, petrol, parking etc. However, if 
you need to take a taxi to make the journey please inform us of this in advance. 
 
 
What do I have to do? 
Your involvement in this study will not affect your day-to-day activities. However, 
following a biopsy we will ask you to keep this area clean and dry for at least 2 days, 
and to contact us on the telephone number below if you have any concerns about the 
wound. 
 
 
What are the side effects of any treatment received when taking part? 
As with your normal light treatment, it is possible that you may get some transient 
reddening of your skin in the areas treated (similar to a mild sunburn). This should not 
require any specific treatment, although we would ask you to let us know if this does 
occur. 
 
Biopsies, just like any small cut in the skin, may bleed a little, although this should stop 
if you apply firm and continuous pressure to the area for 5-10 minutes. The anaesthetic 
used to numb your skin will wear off after a few hours, and it may therefore be helpful 
to take some simple painkillers like paracetamol, when you get back home. The risk of 
infection in the wound is small, however the risk will increase if you leave a wet 
dressing in place. You will therefore be given spare dressings to take home, and asked 
to contact us or your GP if you have any concerns about this. Finally, biopsies will 
leave a small scar; and although this tends to fade with time, there is usually a small 
permanent mark. 
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What are the possible benefits of taking part? 
Although we believe that this work will help us understand and improve the treatment 
of psoriasis, it is important to realise that we do not expect you to benefit directly by 
volunteering for this study.  
 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during this study or side effects 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
 
Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
 
 
Contact for further information. 
If you require further information about the trial, Dr S Weatherhead, Prof P Farr or Prof 
N Reynolds can be contacted in the Dermatology department on 0191 2824214. If you 
have any concerns during your involvement in the study, 24 hour help can be received 
by calling 0191 2825599. 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making a decision. 
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The Newcastle Upon Tyne Hospitals       
       NHS Trust 
           
     Royal Victoria Infirmary 
       Newcastle Upon Tyne 
        NE1 4LP 
        Tel: 0191 2824214 
 
PATIENT  INFORMATION SHEET F 
 
EFFECTS AND MECHANISMS OF ULTRAVIOLET B (UVB) IN PSORIASIS. 
 
We would like to invite you to participate in a research study. Before you decide 
whether you will participate, it is important that you understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully. Talk to others about this study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part 
 Part 2 gives you more detailed information about the conduct of the study 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
 
Part 1 
What is the purpose of this study? 
Light therapy, particularly UVB (ultraviolet B) therapy is an effective method of treating 
psoriasis. Although we know that this can be very effective in many patients, we don‟t 
know exactly how it works, or which wavelengths of light will be most effective. This 
study is designed to address both these issues. We will look at samples of skin before 
and after exposure to different wavelengths of UVB, to see whether special proteins 
have been altered. We will also look at the effects of different wavelengths of light, as 
described below, and try to work out why some people respond better than others. The 
benefit of finding out how light treatments work and which part of light is most helpful, 
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is that it may enable us to design new treatment regimes in the future, which may work 
more effectively and have less side effects.  The maximum amount of time you could 
be involved with this study is 6- 8 weeks (i.e. the duration of your UVB course). 
This research will form the basis of a thesis for a PhD. 
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Why have I been asked to help? 
Your doctor has prescribed UVB as part of the treatment for your psoriasis. You will 
therefore be given this treatment routinely, and will be required to attend 3 times per 
week for treatment. If you decide to participate in this trial you will be examined before 
treatment and part of the way through your treatment course, to see how you are 
improving. We may take up to 2 small skin biopsies from an area of your psoriasis to 
try to find out what is going on in your skin to clear your psoriasis, or why it is not 
responding.  
In total we are asking approximately 120 patients to participate in this study. We are 
now recruiting the final group of patients to this study, group F; this is explained below. 
 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you are considering taking 
part you will be given this information sheet to keep, and will be asked to sign a 
consent form if you decide to go ahead (you will be given a copy of this to keep). If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
 
What will happen to me if I decide to take part?  
You will be involved in this research for an assessment prior to starting your UVB 
treatment, and will then be seen again after you have attended several routine 
treatments. We are examining why some patients with psoriasis respond well to UV 
light but others don‟t. We will fully explain to you what will be involved before you 
decide to participate. Your normal treatment will not be affected.  
 
Visit 1 (approximately 10 minutes) 
On day 1 we ask you some routine questions about your psoriasis and examine your 
skin. You psoriasis will be graded according to how red, thick, scaly and extensive it is, 
and this will be used later to assess how much better you have got with treatment. This 
visit will coincide with your routine „photo-testing‟ visit. 
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Visit 2 (approximately 20 minutes) 
We then see you during your routine therapy after you have had several treatments, 
but before you have started to respond significantly to the UV. We will ask you have 2 
skin biopsies (see below) from your psoriasis, which may help us work out what has 
happened in your skin to make you respond /not respond to phototherapy.  
 
Skin biopsies are small samples of skin (4-6mm across) which are taken following the 
injection of a small amount of local anaesthetic. Local injection is painful for the first 4-5 
seconds but following this the area of skin is not sensitive to pain. We usually insert 1or 
2 stitches after the biopsy has been taken, although on occasions a stitch may not be 
required. If a stitch is required, this will need to be removed two weeks later either by 
the practice nurse at your GP surgery, or by the phototherapy nurses when you attend 
for your treatment.  
 
You will be asked to provide a blood sample for later analysis, and this will be stored. 
This is entirely voluntary. 
 
We will also examine your skin before treatment and at weekly intervals when you 
attend for your routine UV treatment; this will take approximately 10 minutes on each 
occasion, and will not cause discomfort. Photographs may be taken of selected areas 
of your skin to show clearance of psoriasis, although you will not be identifiable from 
these. 
 
 
Expenses and payments 
It is possible that you will be asked to make an extra visit to hospital as part of your 
involvement in the study. Extra visits will be kept to a minimum and every effort will be 
made to make the timing of visits as convenient as possible for participants. We will 
reimburse expenses for additional visits, e.g. bus fare, petrol, parking etc. However, if 
you need to take a taxi to make the journey please inform us of this in advance. 
 
 
What do I have to do? 
Your involvement in this study will not affect your day-to-day activities. However, 
following a biopsy we will ask you to keep this area clean and dry for at least 2 days, 
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and to contact us on the telephone number below if you have any concerns about the 
wound. 
 
 
What are the side effects of any treatment received when taking part? 
As with your normal light treatment, it is possible that you may get some transient 
reddening of your skin in the areas treated (similar to a mild sunburn). This should not 
require any specific treatment, although we would ask you to let us know if this does 
occur. 
 
Biopsies, just like any small cut in the skin, may bleed a little, although this should stop 
if you apply firm and continuous pressure to the area for 5-10 minutes. The anaesthetic 
used to numb your skin will wear off after a few hours, and it may therefore be helpful 
to take some simple painkillers like paracetamol, when you get back home. The risk of 
infection in the wound is small, however the risk will increase if you leave a wet 
dressing in place. You will therefore be given spare dressings to take home, and asked 
to contact us or your GP if you have any concerns about this. Finally, biopsies will 
leave a small scar; and although this tends to fade with time, there is usually a small 
permanent mark. 
 
 
What are the possible benefits of taking part? 
Although we believe that this work will help us understand and improve the treatment 
of psoriasis, it is important to realise that we do not expect you to benefit directly by 
volunteering for this study.  
 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during this study or side effects 
you might suffer will be addressed. The detailed information on this is given in Part 2. 
 
 
Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. 
The details are included in Part 2. 
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Contact for further information. 
If you require further information about the trial, Dr S Weatherhead, Prof P Farr or Prof 
N Reynolds can be contacted in the Dermatology department on 0191 2824214. If you 
have any concerns during your involvement in the study, 24 hour help can be received 
by calling 0191 2825599. 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making a decision. 
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Part 2 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time. Any stored biopsies or blood may still be 
analysed in the event of you withdrawing but will be coded and only the researchers 
will know that they are yours. Others will not have access to this information. 
 
 
What if there is a problem? 
Complaints. 
If you have a concern about any aspect of this study, you should speak with the 
researchers who will do there best to answer your questions (0191 2824214). If you 
remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital. 
 
 
Will my taking part in this study be kept confidential? 
If you decide to participate we will document this in your medical notes and inform your 
GP. Your confidentiality will be maintained by anonymising your details and keeping 
them on a secured database. The information will be kept for up to 6 years to allow the 
data to be analysed, forming the basis for publication in an appropriate medical journal. 
You will not be personally identified in any publication. 
 
 
What will happen to any samples I give? 
Biopsy samples will be given a unique code known only to be researchers, and will be 
stored in the laboratory in Dermatological Sciences, University of Newcastle-upon-
Tyne. These will be analysed at a later time within the laboratory, and destroyed at the 
end of the study.  Samples will be accessed by the researchers only. 
 
 
Will any genetic tests be done? 
We may use your skin samples to examine how UV therapy affects the proteins 
expressed in your skin as genes are switched on or off due to the UV. This can help us 
to understand what drives psoriasis. Similarly your blood sample will be used to 
analyse any genetic differences which may make you more or less likely to respond 
well to UV treatment. We will only look for genetic changes relevant to the clearing of 
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your psoriasis. You will not be told the results of this, and it will not be recorded in your 
medical records. This part of the study is optional. 
 
 
Who is funding the study? 
This study is funded by the Wellcome Trust. The investigators will not receive any 
financial benefit as a result of your participation in this trial. 
 
 
Who has reviewed this study? 
This study has been given favourable ethical opinion by the Local Research Ethics 
Committee. 
 
 
 
Thank you for your interest and help. 
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      The Newcastle Upon Tyne Hospitals                      
        NHS Trust 
 
        Phototherapy Dept 
        Royal Victoria Infirmary 
       Newcastle Upon Tyne 
        NE1 4LP 
        Consent Form       Tel: 0191 2824214 
       
Effects and Mechanisms of Ultraviolet B (UVB) in Psoriasis 
 
 
Researchers: Dr S Weatherhead, Prof P Farr and Prof N Reynolds 
 
I confirm that I have read and understood the information sheet dated 01/10/06 for 
the above study and have had the opportunity to ask questions 
 
I understand that my participation is voluntary and that I’m free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
I understand that sections of my medical notes may be looked at by responsible 
individuals from the Dermatology department where it is relevant to me taking 
part in research. I give permission for these individual to have access to my 
records. 
 
I understand that photographs will be taken of my skin during the study, and that 
these will be used as part of the assessment of my response to the light. These 
photographs will remain confidential and I will not be recognisable to others from 
the pictures. 
 
12-281 
 
I understand that my blood and skin samples may be stored for further analysis 
including genetic (DNA) testing. However, this will be for research purposes and 
will not affect me personally. 
 
I agree to take part in the above study. 
 
_____________________  ________________   __________________ 
Name of Patient   Date        Signature 
 
 
_____________________  ________________   __________________ 
Name of Person taking consent Date        Signature 
(if different from researcher) 
 
 
_____________________  ________________   __________________ 
Researcher    Date        Signature 
1 for patient; 1 for researcher, 1 to be kept with hospital notes 
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The Effects and Mechanisms of UVB in Psoriatic Clearance 
 
      Patient code: ……………………….. 
 
N      Tel. No: ……………………………… 
 
      Appoint. Times: …………………….. 
 
      Age: ……………. Sex: ………….. 
 
Date of entry into trial: …………… Group: …………..  ST: …….. 
 
Age of onset of psoriasis: ………….. 
 
 
 
Previous psoriasis treatment? 
 
 Recent: ……………………………………………………………………… 
 
 UVR: ………………………………………………………………………... 
 
Other Medications: ………………………………………………………………… 
 
Relevant PMH: …………………………………………………………………….. 
 
Large/ medium/ small plaques  Scalp/ nails/ joint involvement 
 
PASI score:……………….   Target plaque: ………………… 
 
No. MED given: …3……….  Wavelengths: …TL01/290……. 
 
MED for treatment: ……….. 
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TL01      290 
Irradiance:……………   Irradiance: ……………. 
 
 ST 2-4  ST1    ST 2-4  ST1 
    1 1459  1094   1 40  20  
2 1158  868   2 31.7  15.9 
3 919  689   3 25.2  12.6 
4 729  547   4 20  10 
5 579  434   5 15.9  7.9 
6 459  345   6 12.6  6.3 
7 365  273   7 10  5.0 
8 289  217   8 7.9  4.0 
9 230  172   9 6.3  3.1 
10 182  137   10 5  2.5 
 
  
 
 
 
Biopsy date and times: ………………………Sample Codes: ………………… 
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13. Appendix C: PASI scoring 
sheet 
Erythema/ thickness/ scale 
0= none,   1= slight,   2= moderate,   3= striking,   4= exceptional 
 
Area 
0= none,   1=<10%;   2=10- <30%;   3=30-<50%;   4= 50-<70%;  5=70-<90%; 
6=>90%  
 
HEAD 
 
E   + T    + S     =    
         = 
A    x  0.1       =   
 
 
 
TRUNK 
 
E   + T    + S     =    
         =   
A    x  0.3       =   
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UPPER LIMBS 
E   + T    +    + S     =    
         =   
A    x  0.2       =   
 
 
 
LOWER LIMBS 
 
E   + T    + S     =    
         =   
A    x  0.4       =   
            
 
 
          = 
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14. Appendix D: Fixation 
methods 
Examples of differential antibody staining with different fixation methods.  
 
 
Anti-active caspase-3 detection in tissue sections with different fixation 
techniques. Serial sections of psoriatic epidermis, taken from a patient 24h 
post a single 3 MED irradiation of 311nm UVB. Cryosections were fixed in 
either 100% methanol, 100% acetone or 4% paraformaldehyde, and prepared 
as in section 2.1.4. Double labelled was performed with anti-active-caspase-3 
(Oregon green secondary antibody) and Toto-3 (blue). It can be seen that 
fixation with paraformaldehyde gives a more intense background, and it can be 
difficult to determine which cells are positive. Methanol and or acetone (or 
indeed both together in a 1:1 ratio- not shown here) are therefore the preferred 
fixation method for this antibody. 
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T cell detection in tissue sections with different fixation techniques. Serial 
sections of psoriatic epidermis. Cryosections were fixed in either 100% 
methanol, 100% acetone or 4% paraformaldehyde, and prepared as in section 
2.1.4. Double labelled was performed with anti-CD3 (Oregon green secondary 
antibody) and Toto-3 (blue). It can be seen that fixation with acetone gives a 
significantly reduced staining pattern. 
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15. Appendix E: Protocols 
 
Mowiol 
 To a 100ml beaker add 3.84g Mowiol 40-88 and 12g glycerol 
 Mix with a stir bar for 2h 
 Add 12ml ddH20 and stir overnight 
 Add 20ml Tris-HCL (pH 8.5), and continue stirring. Heat occasionally to 500C 
(maximum) in a water-bath for 10 mins. Continue to stir until all dissolved 
 Centrifuge at 5000x g for 15 mins to clarify the solution 
 Remove supernatant 
 Optional: add 2.5% 1,4 diazabicyclo [2,2,2] octane (DABCO) to reduce fading 
 Aliquot and store at -200C for up to 6 months or -800C for longer term storage 
 Apply around edge of air-dried immuno-stained tissue sections and press cover 
firmly in place; removing any small air bubbles 
 Keep in fridge overnight, then store in dark area at RTP 
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Protocol for Immunohistochemistry: Sequential Method  
1. Fix for 10 mins with either: 
a. Acetone (dry) 
b. Methanol 
c. Acetone: Methanol (1:1) 
d. Paraformaldehyde (0.4g in 10ml PBS +2ul 5mmol NaOH) 
 
2. Wash with PBS and Tween 
 
3. Triton x 0.2% 10 min 
 
4. Wash 3x 1 min 
 
5. Block with goat serum  in 2% BSA 1:60. Incubate for 30 mins at rtp 
 
6. Tip off 
 
7. Primary antibody: e.g. caspase-3 in 2% BSA 1:500. Incubate for 60 mins at 
rtp 
 
8. Wash x3 
 
9. Goat anti-rabbit (488) in 2% BSA 1:300. Incubate for 45 mins 
 
10. Wash x3 
 
11. Goat serum 1:60. Incubate for 20 mins 
 
12. 2nd Antibody in 2% BSA. Incubate for 45mins 
 
13. Wash x3 
 
14. Goat anti-mouse (568) in BSA 1:300. Incubate for 30 mins 
 
15. Wash x3 
 
16. Toto-3 1:7000 12 mins 
 
17. Wash x3 
 
18. Wash x1 with distilled water 
 
19. Wash x1 with 100% ethanol 
 
20. Dry at rtp 
 
21. Mowicol around edges of section then press coverslip firmly in place 
 
22. Leave overnight in fridge, then store in dark area 
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16. Appendix F: Netlogo 
modelling code 
 
turtles-own 
[ 
  stem?         ;; true for stem cells, false for TA or diff 
  TA?             ;; true for TA cells, false for others 
  diff?             ;; true for differentiating cells, false for others 
  arrest?         ;; cells that arrest but don't die after UV 
  dermis?       ;; turtle to draw the dermis 
  stem-factor ;;level of factor x within cell, determining whether the cell can divide or not 
  time-as-differentiated ;; no. hours since cell derived  TA as a differentiated cell 
  stem-clock    ;;hours for stem cell division 
  TA-clock       ;;hours for a TA to divide  
  time-since-stem ;; hours since stem for TA 
  age-of-cell     ;; turover time for the cell 
  m                   ;; turtle to move 
  divide            ;; number of divisions for each TA cell 
  add                ;; for increasing bm 
  minus            ;; for decreasing bm  
  grey-clock     ;; time from apoptosis for stem cell 
  dying?           ;; cells undergoing apoptosis 
] 
 
patches-own 
[ 
  gradient         ;; cytokine gradient from the basal layer/ top of the epidermis 
  ?                    ;; altering variable in epidermis set-up 
] 
 
globals 
[  
  TA-count        ;; count of TA cells 
  diff-count        ;; count of diff cells 
  stem-count     ;; count of stem cells 
  total-count      ;; count of all cells 
  treatments      ;; number of UVB epidsodes 
  UV-gap           ;; hours between UV irradiations 
  positions         ;; position of the basement membrane 
  psos                ;; psoriasis phenotype 
  clock               ;; count (hrs) since last change in position of the basement membrane 
  change            ;; indicates that the basement membrane will need to shift up or down 
  shift-up            ;; basement membrane reduces in size 
  add-                ;; adds the number of actively dividing TA cells which are not close  
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    enough to the basement membrane (may need to expand bm) 
  minus-                ;; adds the number of non-dividing cells near the bm (may need to  
reduce the bm) 
  active-TA            ;; a TA cell which is still in the dividing phase of its life 
  adding                ;; number of dividing TAs present/ total number of places in the  
dividing zone 
  reducing             ;; extra number of non-dividing cells in the dividing zone/ total  
number of places in the dividing zone 
  percent-stem      ;; percentage of stem cells actively dividing at any time 
  turn-clock            ;; count down (hrs) since irradiation 
] 
 
 
to setup 
;; setup the basement membrane and create a gradient 
  clear-all 
  ask patches 
    [ 
    set pcolor black 
    ] 
  setup-epidermis 
  set-default-shape turtles "circle" 
  set-stem 
  ask patches with [pcolor = yellow] 
     [ 
     set gradient 10000 
     ] 
  ask patches with [pycor = max-pycor]  
     [ 
     set gradient 0 
     ] 
  repeat 80  
     [ 
     diffuse gradient 0.25 
     ]    
   ask patches with [pycor = -2] 
     [ 
       set gradient 100 
     ]    
   ask patches with [pycor = -1] 
     [ 
       set gradient 50 
     ]     
   ask patches with [pycor >= 0] 
     [ 
       set gradient 0 
     ]    
  setup-plot 
  evaluate-params 
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  set treatments 0 
  set UV-gap 0   
  set clock 0 
  set turn-clock 0 
;;movie-start "psoriasis-movie1.mov" 
;;movie-set-frame-rate 10 
 end 
 
 
to setup-epidermis 
;; create the epidermis as either the normal or psoriatic morphology 
  clear-all 
  let normal    [0 0 1 1 2 2 2 1 0 1 0 -1 0 -1 -2 -2 -2  -1 -1  0 ] 
  let pso        [0 1 2 3 8 8 2 1 0 1 0 -1 0 -1 -2 -8 -8 -3 -2 -1 ] 
  ifelse Start-with-psoriasis-phenotype   
      [ 
      set percent-stem 80 
      set positions 7 
      crt 1 
      let newx -1 
      let newy -5 
      ask patches with [pxcor = 80]  
         [if pycor <= -5 
             [ 
             set pcolor yellow 
             ] 
         ] 
      ask turtles 
           [ 
           let q 0 
           loop 
               [ 
               foreach pso 
                   [ 
                   set newx newx + 1 
                   set newy newy - ? 
                   setxy newx newy 
                   facexy newx min-pycor 
                   let r 1 
                   set pcolor yellow 
                   while [r <= world-height]      
                       [ 
                       fd 1 
                       set pcolor yellow 
                       set r r + 1  
                       ] 
                   ] 
               set q q + 1 
               if (q > 3) [stop] 
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              ] 
           ] 
       ] 
       [ 
       set percent-stem 20 
       set positions 1 
       crt 1 
       let newx -1 
       let newy -5 
       ask patches with [pxcor = 80]  
         [if pycor <= -5 
             [ 
             set pcolor yellow 
             ] 
         ] 
 ask turtles 
           [ 
           let q 0 
           loop 
               [ 
               foreach normal 
                   [ 
                   set newx newx + 1 
                   set newy newy - ? 
                   setxy newx newy 
                   facexy newx min-pycor 
                   let r 1 
                   set pcolor yellow 
                   while [r <= world-height]      
                       [ 
                       fd 1 
                       set pcolor yellow 
                       set r r + 1  
                       ] 
                   ] 
               set q q + 1 
               if (q > 3) [stop] 
              ] 
           ] 
       ] 
 
end 
 
 
to set-stem   
;;create stem cells 
   crt 50 
   ifelse Start-with-psoriasis-phenotype      
      [ 
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      set positions 7  
      ask turtles  
         [  
        if (who = 3)  [setxy 1 -5] 
        if (who = 4) [setxy 2 -7] 
        if (who = 5) [setxy 3 -10] 
        if (who = 6)or (who = 43) [setxy 4 -18] 
        if (who = 7) [setxy 5 -26] 
        if (who = 8) [setxy 14 -26] 
        if (who = 9)or (who = 44) [setxy 15 -18] 
        if (who = 10) [setxy 16 -10] 
        if (who = 11)  [setxy 17 -7] 
        if (who = 12) [setxy 22 -7] 
        if (who = 13) [setxy 23 -10] 
        if (who = 14)or (who = 45) [setxy 24 -18] 
        if (who = 15) [setxy 25 -26] 
        if (who = 16) [setxy 34 -26] 
        if (who = 17)or (who = 46) [setxy 35 -18] 
        if (who = 18) [setxy 36 -10] 
        if (who = 19)[setxy 37 -7] 
        if (who = 20) [setxy 38 -5] 
        if (who = 21) [setxy 18 -5] 
        if (who = 22) [setxy 21 -5] 
        if (who = 23) [setxy 41 -5] 
        if (who = 24) [setxy 42 -7] 
        if (who = 25) [setxy 43 -10] 
        if (who = 26)or (who = 47) [setxy 44 -18] 
        if (who = 27) [setxy 45 -26] 
        if (who = 28) [setxy 54 -26] 
        if (who = 29)or (who = 48) [setxy 55 -18]       
        if (who = 30) [setxy 56 -10]       
        if (who = 31) [setxy 57 -7]       
        if (who = 32) [setxy 58 -5]       
        if (who = 33) [setxy 61 -5]   
        if (who = 34) [setxy 62 -7]   
        if (who = 35) [setxy 63 -10]   
        if (who = 36)or (who = 49) [setxy 64 -18]       
        if (who = 37) [setxy 65 -26]       
        if (who = 38) [setxy 74 -26]       
        if (who = 39)or (who = 50) [setxy 75 -18]   
        if (who = 40) [setxy 76 -10]   
        if (who = 41) [setxy 77 -7]       
        if (who = 42) [setxy 78 -5]  
        set size 1 
        set stem-clock random 150 
        set stem? true 
        set TA? false 
        set diff? false 
        set dermis? false 
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        set color 85 
        set dying? false 
        if (who = 1)[die] 
        if (who = 2) [die] 
        if (who = 0) [die] 
        ] 
   ] 
   [set positions 1  
    ask turtles  
        [ 
        if (who = 3) [setxy 1 -4] 
        if (who = 4) [setxy 2 -5] 
        if (who = 5) [setxy 3 -6] 
        if (who = 6)or (who = 43) [setxy 4 -8] 
        if (who = 7) [setxy 5 -10] 
        if (who = 8) [setxy 14 -10] 
        if (who = 9)or (who = 44) [setxy 15 -8] 
        if (who = 10) [setxy 16 -6] 
        if (who = 11) [setxy 17 -5] 
        if (who = 12)[setxy 22 -5] 
        if (who = 13) [setxy 23 -6] 
        if (who = 14)or (who = 45) [setxy 24 -8] 
        if (who = 15)[setxy 25 -10] 
        if (who = 16) [setxy 34 -10] 
        if (who = 17)or (who = 46) [setxy 35 -8] 
        if (who = 18) [setxy 36 -6] 
        if (who = 19) [setxy 37 -5] 
        if (who = 20) [setxy 38 -4] 
        if (who = 21) [setxy 18 -4] 
        if (who = 22) [setxy 21 -4] 
        if (who = 23) [setxy 41 -4] 
        if (who = 24) [setxy 42 -5] 
        if (who = 25)[setxy 43 -6] 
        if (who = 26)or (who = 47) [setxy 44 -8] 
        if (who = 27) [setxy 45 -10] 
        if (who = 28) [setxy 54 -10] 
        if (who = 29)or (who = 48) [setxy 55 -8]       
        if (who = 30) [setxy 56 -6]       
        if (who = 31) [setxy 57 -5]       
        if (who = 32) [setxy 58 -4]       
        if (who = 33) [setxy 61 -4]   
        if (who = 34) [setxy 62 -5]   
        if (who = 35) [setxy 63 -6]   
        if (who = 36)or (who = 49) [setxy 64 -8]       
        if (who = 37) [setxy 65 -10]       
        if (who = 38) [setxy 74 -10]       
        if (who = 39)or (who = 50) [setxy 75 -8]   
        if (who = 40) [setxy 76 -6]   
        if (who = 41) [setxy 77 -5]       
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        if (who = 42) [setxy 78 -4] 
        set size 1 
        set stem-clock random 150 
        set stem? true 
        set TA? false 
        set diff? false 
        set arrest? false 
        set dermis? false 
        set color 85 
        set dying? false 
       if (who = 1)[die] 
       if (who = 2) [die] 
       if (who = 0) [die] 
       ] 
    ] 
 end 
  
  
to go 
;; run the model 
;; Rechecks the number of dividing  cells adjacent to the basal layer, and expands / 
contracts the epidermis accordingly. 
no-display 
if  (count turtles with [pycor = -4] > 75) and (ticks > 400) and 
     ((count patches with [(pycor < -1 and pcolor = black) and count turtles-here > 0] / 
count patches with [pycor < -1 and pcolor = black]) >= 0.98)  
      [ 
      bm 
      ask-concurrent (turtles with [stem?]) 
         [ 
         ;;ask stem cells to move down if a space has been created below them by a shift 
in the basement membrane 
            ask patch-at-heading-and-distance 180 1 
                [ 
                if pcolor = black 
                   [ 
                   ask turtles-on patch-at-heading-and-distance 0 1 
                      [ 
                      shift-down 
                       
                      ] 
                   ] 
                ] 
                 
             ] 
 
      ] 
ask turtles 
   [ 
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   if any? neighbors with [(count turtles-here = 0) and ([pycor] of self < [pycor] of myself)] 
       [ 
       check-position 
       ] 
   ] 
 
ask turtles 
  [ 
   ;; allow normal cell division to occur, with cells differentiating when they reach a 
threshold gradient 
   set-stem-division 
   set-TA-division 
   set-diff 
   let nb5 max-one-of neighbors with [pcolor = black][gradient]  
   if (TA? or diff?) and (count turtles-on nb5 = 0)  
       [ 
       move-to nb5 
       ] 
   if stem?  
      [ 
      set stem-clock stem-clock + 1 
      set grey-clock grey-clock + 1 
      ] 
   if TA?  
      [ 
      set TA-clock TA-clock + 1  
      set time-since-stem time-since-stem + 1 
      set age-of-cell age-of-cell + 1 
      ]  
   if diff?  
      [ 
      set time-as-differentiated time-as-differentiated + 1 
      set age-of-cell age-of-cell + 1 
      ]              
   if TA? and (divide > TA-cell-cycle) and ([gradient] of patch-here < 1800)  
      [ 
      set TA? false  
      set diff? true  
      set color 65  
      set time-as-differentiated 0 
      ] 
   if color = pink  
        [ 
          check-position 
        ] 
  ] 
 ;; irradiate the epidermis at the specified frequency and time interval 
 if (irradiation-frequency > 0) and (UV-gap >= irradiation-frequency) and (Number-of-
treatments > treatments) 
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  [ 
  uv 
  ask turtles 
    [ 
    ;; check that the youngest most actively dividing cells have not been displaced from 
the basal and suprabasal layers by cells with less proliferative ability 
     check-position 
    ] 
  ] 
 ;; close any gaps that appear in the epidermis, especially after irradiation 
 repeat 5 
  [ask-concurrent turtles  
     [ 
     if (TA? or diff?)  
        [ 
        let shifting turtles-here  
        ask patch-at-heading-and-distance 180 1  
            [ 
            if (pcolor = black) and (count turtles-here = 0) 
                [ 
                ask shifting  
                    [ 
                    shift-down  
                    ] 
                 ] 
            ] 
        ]          
      ] 
    ] 
;; stop cells piling-up on top of each other     
ask turtles with [stem?] 
              [ 
               if count turtles-here with [TA?] > 0 
                   [ 
                     ask turtles-here with [TA?] 
                       [ 
                        relocate 
                       ] 
                   ] 
              ] 
ask turtles with [TA?] 
  [ 
  if count turtles-here > 2 
    [ 
    relocate 
    ] 
  ] 
set clock clock + 1 
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;;set the counter for when to give the next irradiation 
set uv-gap uv-gap + 1 
 
if turn-clock = 1 [if any? turtles with [dying?]  
                     [ 
                      ask turtles with [dying?] 
                          [  
                            die 
                          ] 
                       ]               
                    ]  
if (turn-clock > 0)  
     [ 
       set turn-clock turn-clock - 1 
     ] 
if (turn-clock > 0) and (turn-clock <= 24) 
     [ 
                   ask turtles with [dying?]  
                      [ 
                        let s random 24 
                        if s < 2 
                          [ 
                            die 
                          ] 
                      ]                  
       ] 
ask turtles with [(diff?) and (pycor > -4)] 
  [ 
    if count turtles-on patch-at-heading-and-distance 180 1 = 0 
       [ 
         ask turtles-on patch-at-heading-and-distance 0 1 
            [ 
              set heading 180 
              fd 1 
            ] 
        ] 
  ] 
;; adjust the cytokine level according to the total keratinocyte number 
divide-change 
;; turtles die as they fall off the top of the epidermis 
surface 
display 
evaluate-params   
tick 
if ((ticks >= 1200) and (ticks mod 2 = 0)) [movie-grab-interface] 
;;if ticks >= 2300 [set cytokine-stimulus "off"] 
if ticks >= 3200 [movie-close stop] 
end 
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to surface 
;; if lowest level is top of the epidermis, don't go higher 
if any? turtles with [pycor > -1] 
       
         [ 
          ask turtles-on patches with [pycor > -1] 
             [ 
               set heading 180 
               fd 1  
               if pycor > -1 [fd 1] 
             ] 
         ] 
  if count turtles-on patches with [pycor = -1] > 80 
              [ 
                ask turtles-on patches with [(count turtles-here > 1) and (pycor = -1)]  
                   [ 
                     ask min-one-of turtles-here [time-since-stem] 
                        [ 
                         stop 
                        ] 
                         
                    roll                         
                   ] 
              ] 
 if count patches with [(pycor = -1) and (count turtles-here > 0)] < 80 
              [ 
                ask patches with [(count turtles-here > 1) and (pycor = -1)] 
                    [ 
                      ask max-one-of turtles [time-since-stem] 
                         [ 
                           roll 
                         ] 
                    ] 
              ] 
end 
 
 
to roll 
let x (count turtles-on patches with [pycor = -1]) - 81 
if x >= 1 
  [ 
   ask n-of x turtles-on patches with [(pycor = -1) and (count turtles-here > 1)] [die] 
  ] 
if ((count turtles-here > 1) and (pycor = -1)) 
   [ 
     ask max-one-of turtles-here [time-since-stem] 
         [ 
           set heading 90 
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           fd 1 
           roll 
           if count turtles-here <= 1 [stop] 
         ] 
   ] 
end 
 
 
to check-position 
;; check the most proliferative cells are closest to the basal layer 
if stem? 
         [ 
         stop 
         ] 
 
if ((TA?) or (diff?))  
    [ 
    repeat 25 
            [ 
            let friends-patch max-one-of neighbors with [(pcolor = black) and ((count turtles-
here = 0) or ( [time-since-stem] of min-one-of turtles-here [time-since-stem] > 
[time-since-stem] of myself))] [gradient]  
            ifelse friends-patch = nobody  
                [ 
                ask patch-at-heading-and-distance 180 1  
                      [ 
                        if (pcolor = black) and ((count turtles-here = 0) or ( [time-since-stem] of 
min-one-of turtles-here [time-since-stem] > [time-since-stem] of myself)) 
                           [ 
                             ask turtles-on patch-at-heading-and-distance 0 1 
                                [ 
                                  set heading 180 
                                  fd 1 
                                  relocate 
                                ] 
                           ] 
                      ]            
                ] 
                [ 
                if turtles-on friends-patch != stem? 
                  [ 
                  move-to friends-patch 
                  relocate                 
                  ] 
                ] 
            ] 
      ] 
end 
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to divide-change 
;; if cytokine-stimulus is on, the maximum cytokine production occurs in keeping with 
psoriasis,  
;; if not the amount of cytokines produced is relative to the total keratinocyte load 
;; and this affects the proportion of TA cells whicvh divide 5 times instead of 4 
ifelse cytokine-stimulus 
  [ 
  ask turtles with [color = pink] 
       [ 
            let s random 99 
            ifelse s < 50 
               [ 
                 set Number-of-TA-divisions 5 
               ] 
               [ 
                 set Number-of-TA-divisions 4 
               ] 
            ] 
  ask turtles with [color = 85] 
     [ 
     set percent-stem 80 
     ] 
    ] 
    [ 
  ask turtles  
      [ 
   if (count turtles with [color = pink] >= 200) 
         [ 
         ask turtles with [(color = pink) ] 
            [ 
            let s random 99 
            ifelse s < 50 
               [ 
                 set Number-of-TA-divisions 5 
               ] 
               [ 
                 set Number-of-TA-divisions 4 
               ] 
            ] 
         ]   
      
     if (count turtles with [color = pink] < 200) and (count turtles with [color = pink] >= 150) 
         [ 
         ask turtles with [(color = pink) ] 
            [ 
            let s random 99 
            ifelse s < 37.5 
               [ 
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                 set Number-of-TA-divisions 5 
               ] 
               [ 
                 set Number-of-TA-divisions 4 
               ] 
            ] 
         ] 
     if (count turtles with [color = pink] < 150) and (count turtles with [color = pink] >= 100) 
         [ 
         ask turtles with [(color = pink) ] 
            [ 
            let s random 99 
            ifelse s < 25 
               [ 
                 set Number-of-TA-divisions 5 
               ] 
               [ 
                 set Number-of-TA-divisions 4 
               ] 
            ] 
         ] 
     if (count turtles with [color = pink] < 100) and (count turtles with [color = pink] >= 75) 
         [ 
         ask turtles with [(color = pink) ] 
            [ 
          let s random 99 
            ifelse s < 12.5 
               [ 
                 set Number-of-TA-divisions 5 
               ] 
               [ 
                 set Number-of-TA-divisions 4 
               ] 
            ] 
         ] 
  if (count turtles with [color = pink] < 75) 
         [ 
         set percent-stem 20 
         ask turtles with [(color = pink)] 
            [ 
            set Number-of-TA-divisions 4 
            ] 
         ] 
       ] 
  ] 
end 
 
 
 
16-304 
 
to bm 
;; changes size of basement membrane according to the number of actively dividing 
cells 
 ask turtles 
    [ 
    set add 0 
    set minus 0 
    if (TA?)  and (color = pink)  
     [ 
     if ([gradient] of patch-here <= 4000) 
             [ 
              set add 1 
              set minus 0 
             ]   
       ] 
     ask patches with [gradient > 4000] 
          [ 
          ask turtles-here with [(color = 134) or diff?] 
             [ 
             set minus 1 
             set add 0 
             ]    
        ]     
     ]  
set change 0 
set shift-up 0 
if count turtles with [add  = 1] = 0 
  [ 
  stop 
  ] 
let k (active-TA - (count turtles with [add = 1]) + (count turtles with [minus = 1])) 
set adding (active-TA / (k)) 
set reducing (((count turtles with [minus = 1]) - (count turtles with [add = 1])) / k) 
if  adding > 1.20 
       [ 
       set positions positions + 1 
       set shift-up 1 
       set change 1 
       if positions > 7  
           [ 
           set positions 7 
           set change 0 
          ] 
      ] 
if  reducing > 0.4 
       [ 
        set positions positions - 1 
         set change 1 
         if positions < 1  
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           [ 
           set positions 1 
           set change 0 
           ] 
       ] 
       
 if change = 0      
      [ 
      stop 
      ] 
 cp 
 crt 1  
      [ 
      set TA? false  
      set diff? false  
      set stem? false  
      set dermis? true  
      ] 
 let newx -1 
 let newy -5 
 ask patches with [pxcor = 80]  
         [if pycor <= -5 
             [ 
             set pcolor yellow 
             ] 
         ]     
 if positions = 7 
      [ 
 set psos    [0 1 2 3 8 8 2 1 0 1 0 -1 0 -1 -2 -8 -8 -3 -2 -1 ] 
 ask turtles 
     [ 
     if dermis? 
         [ 
         let q 0 
         loop 
            [  
            foreach psos 
                [ 
                set newx newx + 1 
                set newy newy - ? 
                setxy newx newy 
                facexy newx min-pycor 
                let r 1 
                set pcolor yellow 
                while [r <= world-height]      
                    [ 
                    fd 1 
                    set pcolor yellow 
                    set r r + 1  
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                    ask patches with [pcolor = yellow and pxcor = newx] 
                         [ 
                          if any? turtles-here with [TA? or stem? or diff?] 
                               [ 
                             ifelse (shift-up = 1) 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift-down 
                                       ] 
                                  ] 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift 
                                       ] 
                                  ] 
                              ] 
                          ]  
                      ]  
                 ] 
           set q q + 1 
           if (q > 3) 
                   [  
                    stop 
                   ] 
              ]    
          ] 
      ] 
    ask turtles  
        [  
        if dermis?  
           [ 
           die 
           ]  
        ] 
             ]   
 if positions = 6 
      [ 
 set psos     [0 1 2 3 7 7 2 1 0 1 0 -1 0 -1 -2 -7 -7 -3 -2 -1 ] 
 ask turtles 
     [ 
     if dermis? 
         [ 
         let q 0 
         loop 
            [  
            foreach psos 
                [ 
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                set newx newx + 1 
                set newy newy - ? 
                setxy newx newy 
                facexy newx min-pycor 
                let r 1 
                set pcolor yellow 
                while [r <= world-height]      
                    [ 
                    fd 1 
                    set pcolor yellow 
                    set r r + 1  
                    ask patches with [pcolor = yellow and pxcor = newx] 
                         [ 
                          if any? turtles-here with [TA? or stem? or diff?] 
                               [ 
                             ifelse (shift-up = 1) 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift-down 
                                       ] 
                                  ] 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift 
                                       ] 
                                  ] 
                              ] 
                          ]  
                      ]  
                 ] 
           set q q + 1 
           if (q > 3) 
                   [  
                    stop 
                   ] 
              ]    
          ] 
      ] 
    ask turtles  
        [  
        if dermis?  
           [ 
           die 
           ]  
        ] 
     ]   
 if positions = 5 
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     [ 
     set psos [0 1 2 2 6 6 2 1 0 1 0 -1 0 -1 -2 -6 -6 -2 -2 -1 ] 
     ask turtles 
         [ 
         if dermis? 
            [ 
            let q 0 
            loop 
               [  
               foreach psos 
                  [ 
                  set newx newx + 1 
                  set newy newy - ? 
                  setxy newx newy 
                  facexy newx min-pycor 
                  let r 1 
                  set pcolor yellow 
                  while [r <= world-height]      
                     [ 
                     fd 1 
                     set pcolor yellow 
                     set r r + 1  
                     ask patches with [pcolor = yellow and pxcor = newx] 
                         [ 
                          if any? turtles-here with [TA? or stem? or diff?] 
                               [ 
                             ifelse (shift-up = 1) 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift-down 
                                       ] 
                                  ] 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift 
                                       ] 
                                  ] 
                              ] 
                          ]  
                     ]  
                ] 
           set q q + 1 
           if (q > 3) 
                   [  
                    stop 
                   ] 
               ]   
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         ] 
     ] 
    ask turtles  
        [  
        if dermis?  
            [ 
            die 
            ]  
         ] 
     ]   
 if positions = 4 
  [ 
  set psos  [0 1 2 2 5 5 2 1 0 1 0 -1 0 -1 -2 -5 -5 -2 -2 -1 ] 
   ask turtles 
     [ 
     if dermis? 
         [ 
          let q 0 
          loop 
            [  
             foreach psos 
                [ 
                 set newx newx + 1 
                 set newy newy - ? 
                 setxy newx newy 
                 facexy newx min-pycor 
                 let r 1 
                 set pcolor yellow 
                 while [r <= world-height]      
                    [ 
                     fd 1 
                     set pcolor yellow 
                     set r r + 1  
                     ask patches with [pcolor = yellow and pxcor = newx] 
                         [ 
                          if any? turtles-here with [TA? or stem? or diff?] 
                               [ 
                             ifelse (shift-up = 1) 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift-down 
                                       ] 
                                  ] 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift 
                                       ] 
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                                  ] 
                              ] 
                          ]  
                     ]  
                ] 
           set q q + 1 
           if (q > 3) 
                   [  
                    stop 
                   ] 
              ]   
         ] 
      ] 
  ask turtles  
      [  
      if dermis?  
      [ 
      die 
      ]  
    ] 
  ]   
 if positions = 3 
  [ 
  set psos  [0 0 1 2 4 4 2 1 0 1 0 -1 0 -1 -2 -4 -4 -1 -2  0 ] 
  ask turtles 
     [ 
     if dermis? 
         [ 
          let q 0 
          loop 
            [  
             foreach psos 
                [ 
                 set newx newx + 1 
                 set newy newy - ? 
                 setxy newx newy 
                 facexy newx min-pycor 
                 let r 1 
                 set pcolor yellow 
                 while [r <= world-height]      
                    [ 
                     fd 1 
                     set pcolor yellow 
                     set r r + 1  
                     ask patches with [pcolor = yellow and pxcor = newx] 
                         [ 
                          if any? turtles-here with [TA? or stem? or diff?] 
                               [ 
                             ifelse (shift-up = 1) 
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                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift-down 
                                       ] 
                                  ] 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift 
                                       ] 
                                  ] 
                              ] 
                          ]  
                     ]  
                ] 
           set q q + 1 
           if (q > 3) 
                   [  
                    stop 
                   ] 
              ]   
         ] 
      ] 
        ask turtles  
            [  
            if dermis?  
               [ 
               die 
               ]  
            ] 
  ]   
 if positions = 2 
  [ 
  set psos [0 0 1 1 3 3 2 1 0 1 0 -1 0 -1 -2 -3 -3 -1 -1  0 ] 
  ask turtles 
     [ 
     if dermis?  
         [ 
          let q 0 
          loop 
            [  
             foreach psos 
                [ 
                 set newx newx + 1 
                 set newy newy - ? 
                 setxy newx newy 
                 facexy newx min-pycor 
                 let r 1 
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                 set pcolor yellow 
                 while [r <= world-height]      
                    [ 
                     fd 1 
                     set pcolor yellow 
                     set r r + 1  
                     ask patches with [pcolor = yellow and pxcor = newx] 
                         [ 
                          if any? turtles-here with [TA? or stem? or diff?] 
                               [ 
                             ifelse (shift-up = 1) 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift-down 
                                       ] 
                                  ] 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift 
                                       ] 
                                  ] 
                              ] 
                          ]  
                     ]  
                ] 
           set q q + 1 
           if (q > 3) 
                   [  
                    stop 
                   ] 
             ]   
         ] 
    ] 
    ask turtles  
        [  
         if dermis? 
            [ 
              die 
             ] 
        ] 
   ]   
if positions = 1 
  [     
  set psos  [0 0 1 1 2 2 2 1 0 1 0 -1 0 -1 -2 -2 -2  -1 -1  0 ] 
   ask turtles 
     [ 
     if dermis? 
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          [ 
          let q 0 
          loop 
            [  
            foreach psos 
                 [ 
                 set newx newx + 1 
                 set newy newy - ? 
                 setxy newx newy 
                 facexy newx min-pycor 
                 let r 1 
                 set pcolor yellow 
                 while [r <= world-height]      
                     [ 
                     fd 1 
                     set pcolor yellow 
                     set r r + 1  
                     ask patches with [pcolor = yellow and pxcor = newx] 
                         [ 
                          if any? turtles-here with [TA? or stem? or diff?] 
                               [ 
                             ifelse (shift-up = 1) 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift-down 
                                       ] 
                                  ] 
                                  [ 
                                  ask turtles-here with [TA? or stem? or diff?] 
                                       [ 
                                       shift 
                                       ] 
                                  ] 
                              ] 
                          ]  
                     ]  
                ] 
           set q q + 1 
           if (q > 3) 
                   [  
                    stop 
                   ] 
             ]   
         ] 
      ] 
      ask turtles  
          [  
          if dermis?  
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              [ 
              die 
              ]  
           ] 
   ]   
 ;;reset the gradient 
 ask turtles  
   [ 
   set add 0 
   set minus 0 
   ] 
 ask patches with [pcolor = black] 
     [ 
     set gradient 0 
     ]  
  ask patches with [pcolor = yellow] 
     [ 
     set gradient 10000 
     ] 
 
  repeat 80  
     [ 
     diffuse gradient 0.25 
     ]   
   ask patches with [pycor = -2] 
     [ 
       set gradient 100 
     ]    
   ask patches with [pycor = -1] 
     [ 
       set gradient 50 
     ]     
   ask patches with [pycor >= 0] 
     [ 
       set gradient 0 
     ]    
surface                   
end 
 
   
to shift-down 
;; if there is a gap in the epidermis, close it 
set heading 180  
fd 1 
ask patch-at-heading-and-distance 180 1  
   [ 
   if (pcolor = black) and (count turtles-here = 0) 
        [ 
         ask turtles-on patch-at-heading-and-distance 0 1  
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                [ 
                shift-down 
                ]       
        ] 
    ] 
end 
 
 
to shift 
;; change the cell position if basement membrane changes shape (called by BM) 
if stem? or TA? or diff? or arrest? 
    [ 
    set heading 0  
    fd 1 
    if any? other turtles-here 
       [ 
       ask other turtles-here 
          [ 
          shift 
          ] 
       ]  
    ] 
end 
 
 
to set-stem-division 
;; stem cells each have a % probability of dividing according to the user defined setting 
on the interface  
if (color = 85) and (stem-clock > stem-cell-cycle)  
      [ 
      let s random 99 
      if s < percent-stem 
          [     
          hatch 1  
             [  
            show "" 
            set stem? false 
            set TA? true  
            set diff? false 
            set dermis? false 
            set color pink 
            set TA-clock -10 + random 15 
            set time-since-stem 1 
            set age-of-cell 0 
            set divide 0 
            relocate              
            ]                    
         ] 
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         set stem-clock 0 
      ] 
;; grey cells are stem cells which have undergone UV-induced apoptosis and have later 
been replaced by symmetrical stem cell division 
  if (color = grey) and (stem-clock > stem-cell-cycle) and (percent-stem = 20) 
      [ 
      let s random 99 
       if s < 20 
          [     
          hatch 1  
             [  
            show "" 
            set stem? false 
            set TA? true  
            set diff? false 
            set dermis? false 
            set color pink 
            set TA-clock -10 + random 15 
            set time-since-stem 1 
            set age-of-cell 0 
            set divide 0 
            relocate              
            ]                    
         ] 
         set stem-clock 0 
   
      ]  
 end 
  
 
to set-TA-division 
;; cell divides specified number of times then rests (turns dark pink)       
if TA? and color = 134 
  [ 
    stop 
  ]         
 if (TA?) and (divide >= Number-of-TA-divisions)  
             [  
             set color 134 
             set time-since-stem time-since-stem + 1000 
             ]   
 if (TA?) and (((TA-clock >= TA-cell-cycle) and (divide < Number-of-TA-divisions)) and 
not (dying?)) 
      [ 
      set divide divide + 1  
      set age-of-cell 0 
      set TA-clock -10 + random 15 
      hatch 1 
                 [ 
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                 show "" 
                 set TA? true 
                 set TA-clock -10 + random 15 
                 set stem? false 
                 set diff? false 
                 set dermis? false 
                 set color pink 
                 set age-of-cell 0 
                 relocate 
                 stop 
                 ]     
          stop 
       ] 
end 
         
 
to set-diff 
;; cells differentiate when they reach a defined threshold in the gradient of the 
underlying patches 
  if (color = 134) and ([gradient] of patch-here < 1900) 
    [ 
    set TA? false 
    set stem? false 
    set diff? true 
    set dermis? false 
    set color 65 
    set time-as-differentiated 0  
    set time-since-stem time-since-stem + 5000 
    set add 0 
    set minus 0 
    stop 
    ] 
end 
 
 
to relocate 
;; only allows 1 turtle per patch, moving cells away from a single patch after division 
;; don't do anything if you've reached the top of the world 
if pycor = max-pycor  
   [ 
   stop 
   ] 
if count turtles-on patch-here < 2  
   [ 
   stop 
   ] 
 ;; to assign each turtle a different moving priority 
 ifelse (max-one-of turtles-here([time-since-stem]) = (min-one-of turtles-here [time-
since-stem]))  
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   [ 
   set m (min-one-of turtles-here [who])  
   if m = stem? 
      [ 
      set m (max-one-of turtles-here [time-since-stem]) 
      ] 
   ] 
   [ 
   set m max-one-of turtles-here [time-since-stem] 
   ]       
  if count turtles-on patch-here < 2  
   [ 
   stop 
   ] 
 ;; move to neighbour with highest gradient and not occupied 
 let nb max-one-of neighbors with [(pcolor = black) and (count turtles-here = 0)] 
[gradient] 
 if nb != nobody 
 ;;get the correct turtle to move 
    [ 
    ifelse [gradient] of nb < [gradient] of patch-here 
        [ 
        ask m 
           [ 
           move-to nb 
           check-position 
           stop 
           ] 
        ] 
        [ 
        ifelse turtles-on patch-here = stem? 
           [ 
          set m min-one-of turtles-here [time-since-stem] 
           ask m 
              [ 
              move-to nb     
              ] 
            ] 
            [ 
            move-to nb 
            ] 
         ] 
         if count turtles-here < 1 
            [ 
            stop 
            ] 
         if any? turtles-here = stem? 
            [ 
            if count turtles-here = 2 
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               [ 
               stop 
               ] 
            ] 
            relocate 
       ] 
  if count turtles-here < 2 
     [ 
     stop 
     ] 
  ;; turtle to move to patch with highest gradient, black and older than myself    
  let aged [time-since-stem] of m 
  if any? neighbors with [(pcolor = black) and ([time-since-stem] of min-one-of turtles-
here [time-since-stem] > aged) ] 
     [ 
     let nb2 max-one-of neighbors with [(pcolor = black) and ([time-since-stem] of min-
one-of turtles-here [time-since-stem] > aged)] [gradient] 
     if nb2 != nobody  
         [ 
          if ([gradient] of patch-here > [gradient] of nb2) and (turtles-on nb2 != stem?)  
            [ 
            ask m  
                [ 
                 move-to nb2 
                 ask other turtles-here 
                      [ 
                      relocate 
                       ] 
                   stop 
                   ] 
              ] 
          ] 
          check-position 
      ]     
  if count turtles-here < 2  
       [ 
        check-position 
       stop 
       ]   
  ;; otherwise look at lowest gradient patch and move here     
  let nb3 min-one-of neighbors with [pcolor = black] [gradient]  
  if m != nobody 
    [  
    ask m  
       [ 
       if stem?  
          [ 
          stop 
          ] 
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       if [gradient] of patch-here > [gradient] of nb3 
           [ 
            move-to nb3 
            relocate 
            stop 
           ] 
       ] 
      check-position 
   ] 
end 
           
 
to uv 
;; irradiate the epidermis 
  set UV-gap 0 
  set treatments treatments + 1 
  set turn-clock 36 
   ask turtles with [(color = pink) or (color = 134) ] 
      [ 
      let s random 99 
      if s < 20 
         [ 
          set dying? true 
         ] 
      ] 
  ask turtles with [color = 85] 
      [ 
      let t random 99 
      if t < 13 
             [ 
            set color grey 
            set grey-clock 0 
             ] 
       ] 
end 
 
    
 
to setup-plot 
 set-current-plot "Populations" 
end 
   
 
to evaluate-params 
  set TA-count count turtles with [color = pink or color = 134 or color = white] 
  set diff-count count turtles with [color = 65] 
  set stem-count count turtles with [color = 85] 
  set add- count turtles with [add = 1] 
  set minus- count turtles with [minus = 1] 
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  set total-count count turtles 
  set active-TA count turtles with [color = pink] 
  set-current-plot-pen "TA cells" 
  plot count turtles with [color = pink or color = 134 or color = white] 
  set-current-plot-pen "Differentiated" 
  plot count turtles with [color = 65] 
  let file "ps-80 params" 
  file-open file 
  file-print "" 
  file-write ticks 
  file-write stem-count 
  file-write TA-count 
  file-write diff-count 
  file-write treatments 
  file-write total-count 
  file-write add- 
  file-write minus- 
  file-close 
end 
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17. Appendix G: Differentially 
regulated genes  
The following lists contain the genes whose expression was significantly 
differentially regulated following irradiation with 311nm UVB compared to 
290nm UVB or un-irradiated psoriatic epidermis, at 4h (46 genes) and 18h (159 
genes). 
At 4h:   At 18h 
 
AMPD1 
 
ALAS2 
 
HBEGF 
 
PSORS1C2 
 
AOC2 
 
ANXA2 
 
HIST1H2BD PYDC1 
 
AOC2 
 
ANXA9 
 
HIST1H3B 
 
RAD51L1 
 
ATF3 
 
APOBEC3A HMCN1 
 
RGS20 
 
C10orf113 APOL3 
 
HOMER2 
 
RGS22 
 
C19orf48 
 
BAT2 
 
HOXA9 
 
RHOD 
 
C6orf122 
 
BCAS3 
 
IGFL2 
 
RIMBP2 
 
CDKN1A 
 
BIRC5 
 
IL19 
 
RPL29 
 
CDKN2A 
 
C16orf74 
 
IL1F10 
 
RPS7 
 
CYP8B1 
 
C1orf56 
 
IL24 
 
RUNDC3A 
 
DUSP4 
 
C6orf142 
 
IMMP2L 
 
SAA2 
 
DUSP6 
 
C7orf10 
 
JUP 
 
SCN2A 
 
EGR3 
 
C9orf93 
 
KEL 
 
SDS 
 
EGR3 
 
CADPS2 
 
KIAA1328 
 
SEMA7A 
 
EPHB2 
 
CATSPERB KLK12 
 
SERPINA1 
 
FLJ45139 
 
CCDC46 
 
KLK6 
 
SERPINA12 
 
FOSB 
 
CCNB3 
 
KLK9 
 
SERPINB7 
 
FOSL1 
 
CD68 
 
KRT75 
 
SERPINE1 
 
GDF15 
 
CD8A 
 
LCE1B 
 
SHANK2 
 
GGT1 
 
CDH16 
 
LCE1D 
 
SLC25A21 
 
HAS1 
 
CHRNA9 
 
LCE2A 
 
SLC35E4 
 
HAS3 
 
CLDN8 
 
LCE2C 
 
SLC5A10 
 
HEXIM1 
 
CLYBL 
 
LCE3C 
 
SLC6A1 
 
IL6 
 
CNTNAP3 
 
LCE3D 
 
SLCO4A1 
 
JUNB 
 
COL4A6 
 
LCE3E 
 
SMOX 
 
KIAA1967 
 
CST6 
 
LNX1 
 
SMTN 
 
LOC131149 CST6 
 
LOC284751 SMYD3 
 
MRPL27 
 
CXCR5 
 
LY6H 
 
SORCS1 
 
MT1A 
 
CYP4F2 
 
LY6H 
 
SOX6 
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NAT5 
 
DBC1 
 
MAPK10 
 
SPINK6 
 
NEK2 
 
DEFB103A MBD5 
 
SPINK7 
 
NEU4 
 
DEGS2 
 
MED24 
 
SPRR1B 
 
NOL6 
 
DMBT1 
 
METRNL 
 
SPRR3 
 
NR4A1 
 
DNASE1L2 MMP1 
 
SPRR4 
 
OSR2 
 
DOCK3 
 
MMP10 
 
SULT2B1 
 
PHC2 
 
DPP6 
 
MMP3 
 
SUPT3H 
 
PIM3 
 
EDA2R 
 
MSRA 
 
SYT17 
 
PREI3 
 
EFCAB2 
 
MYBPHL 
 
TAGLN3 
 
PSPN 
 
ELF3 
 
NEFH 
 
TBC1D5 
 
TFAP2A 
 
EPHA5 
 
NLGN1 
 
TF 
 
TSSK4 
 
ETV3L 
 
NME1-NME2 TH 
 
USMG5 
 
EXOC4 
 
NODAL 
 
THRSP 
 
USP2 
 
FAM155B 
 
NOS2A 
 
TLN2 
 
WTAP 
 
FHIT 
 
NPTX1 
 
TM4SF19 
 
ZHX2 
 
FHOD3 
 
NRG4 
 
TM4SF19 
 
ZSWIM3 
 
FOSL1 
 
ODZ3 
 
TMEM93 
   
GABRB1 
 
PACRG 
 
TPSAB1 
   
GAL 
 
PCDH11Y 
 
TREX2 
   
GCGR 
 
PGM5 
 
TSPO 
   
GDF15 
 
PIK3C2G 
 
VGF 
   
GPHN 
 
PNMA3 
 
VWCE 
   
GPRC5A 
 
PROM1 
 
WFDC12 
   
HAP1 
 
PRSS3 
 
ZHX2 
 
 
 
